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Abstract 
Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system (CNS) 
which causes demyelination and damage to the neuronal axons.  MS is a significant health 
problem in New Zealand, affecting 1 in 1400 people.  One of the major cell types involved in 
MS and its animal model, experimental autoimmune encephalomyelitis (EAE), are the 
proinflammatory subsets of T helper (Th) cells.  However, many other cell types are also 
involved, including macrophages (MΦ) and microglia (MG).  MΦ and MG are considered to 
be important drivers of inflammation during MS; however there is also evidence that indicates 
these cells can also play a protective role.  In the periphery, MΦ can be induced into several 
activation states.  One of these activation states, type II activation, is a regulatory phenotype, 
producing increased IL-10 and decreased IL-12 compared to classical activation.  In vitro type 
II activation is induced by ligating FcγR with immune complexes (IC) with concurrent 
stimulation with lipopolysaccharide.  Previous research has shown that type II activated MΦ 
and type II-inducing treatments are protective in EAE. 
 
MΦ activation state affects the way the Th response develops, with classically activated MΦ 
promoting a Th1 response and type II MΦ promoting a Th2 response.  In the current study, 
the role of MΦ in T cell biasing is investigated further.  Type II activated MΦ altered the 
Th1/Th2 dichotomy away from a Th1 response and towards a Th2 response, as demonstrated 
by decreased production of IFN-γ and increased levels of CD124.  Also, in a novel finding, 
type II activated MΦ also increased the production of IL-17A from T cells.  This study also 
aimed to elucidate the pathways involved in biasing of the T cell response by classical and 
type II MΦ by blocking or enhancing specific pathways.  It was found that, while the level of 
IFN-γ (the prototypical Th1 cytokine) was largely dependent on the levels of IL-10 and IL-12, 
IL-17A and CD124 expression appeared to be independent of these two cytokines.  Type II 
MΦ have decreased expression of CD40 and PD-L1, it was found that these pathways are not 
strongly involved in T cell biasing by type II MΦ. 
 
While it is acknowledged that MG can be pathogenic and protective, the direct effect type II 
activating treatments have on MG is unknown.  In order to investigate whether MG can also 
be type II activated, MG were isolated from the CNS of adult mice their phenotype under 
different activating condition was assessed.  Under type II activating conditions MG produced 
less IL-12 and more IL-10, suggesting type II activation is occurring.  In addition, in 
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MG:T cell co-cultures, T cells cultured with classical or type II activated MG have similar, 
but not identical, profiles to T cells cultured with MΦ.  Type II activated MΦ induced 
increases in CD124 and IL-17A from T cells, however, all MG activation states induced 
similar levels of IFN-γ. 
 
To determine the effect of type II activating treatments in vivo bone marrow chimeric mice 
were created using mice congenic for CD45, which allow MG to be distinguished from 
invading cells.  Treatment of mice with the IC before and during EAE results in decrease the 
incidence and severity of disease.  IC treatments altered both the peripheral and the CNS 
immune environments.  Despite inducing protection, IC treatments induced an increase in 
IL-17A in the peripheral immune system.  In the brain, a population of resident cells that are 
CD45intCD11b positive, and are likely to be CNS associated MΦ express decreased levels of 
MHC class II, suggesting a decreased ability to interact with T cells.  Furthermore, 
parenchymal MG from the brains of IC treated animals have different levels of Iba1 compared 
to those from untreated animals, suggesting differential activation.  Overall the data suggests 
that IC treatment induces a change in the activation state of CNS resident immune cells, that 
is likely to be protective in EAE. 
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1.1 The Immune System 
The mammalian immune system consists of two main branches, known as the innate and the 
adaptive immune systems.  These two different branches co-operate and complement each 
other to produce a whole system which is very effective at the major goal of an immune 
system, protecting the host from invasion of pathogenic microbial organisms.  The innate 
immune system consists of several cell types including neutrophils, macrophages (MΦ), 
monocytes, dendritic cells (DC), basophils and eosinophils.  In terms of host protection, the 
innate immune system serves as the first line of defence against invading pathogens.  These 
cells are able to respond quickly and many express receptors that allow them to recognise a 
broad range of pathogens.  In addition, the innate immune system communicates the presence 
of a threat to the adaptive immune system, allowing the immune response to be propagated. 
 
The adaptive immune system consists of lymphocytes (B and T cells).  The adaptive immune 
system has two characteristics that make it functionally different from the innate immune 
system, specificity and memory.  Lymphocytes form immune responses that are specific for 
the individual pathogens.  During the generation of B and T cells in the bone marrow and the 
thymus, respectively, an extremely vast repertoire of receptors is formed.  Each receptor 
recognises a specific antigen (a molecule against which an immune response is generated).  
Due to the large number of receptors, there are very few lymphocytes expressing each type of 
receptor.  Thus, at the beginning of the adaptive immune response proliferation of the original 
cell must occur in a process known as clonal expansion.  For this reason, the response of the 
adaptive immune system is much slower than that of the innate immune system.  However, 
this is only the case with primary exposure to an antigen; upon secondary exposure to an 
antigen, memory cells which were generated during the first exposure are able to rapidly 
expand to fight infections more efficiently.  Memory cells are thus key for providing 
immunity to reinfection. 
 
In dealing with pathogens, it is essential that the immune system be able to distinguish self 
from non-self.  The immune system has developed many ways to do this, including central 
and peripheral tolerance mechanisms; however, these methods are not absolute and self 
reactive immune responses can occur.  Such self reactive responses can lead to autoimmune 
diseases such as multiple sclerosis (MS), which is an inflammatory disease of the central 
nervous system (CNS) that is mediated by the immune system.  This general introduction will 
provide an overview of the immune system as well as discussing MS and one of its major 
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animal models, experimental autoimmune encephalomyelitis (EAE), and the immunological 
components of this disease.   
1.2 Innate Immune System 
The innate immune system consists of a variety of components; these include the cells of the 
innate immune system, the complement system, and mucosal barriers.  Together these work to 
fight infection and aid the adaptive immune system, as well as performing a variety of 
housekeeping functions. 
 
1.2.1 Pattern recognition receptors 
Unlike the cells of the adaptive immune system that have receptors specific for antigens, the 
cells of the innate immune system express a range of germline encoded receptors, known 
collectively as pathogen recognition receptors (PRR).  PRR are constitutively expressed and 
allow innate immune cells to recognise motifs that are common to pathogens (Akira, 
Uematsu, & Takeuchi, 2006; Mukhopadhyay, Plüddemann, & Gordon, 2009).  These motifs 
are known as pathogen associated molecular patterns (PAMPs) and tend to be molecules that 
are essential for the survival of the pathogen, making it more difficult for pathogens to avoid 
identification by PRR, as the essential nature of the PAMPs makes them difficult to alter 
(Akira et al., 2006).  Examples include lipopolysaccharide (LPS), a component of the gram 
negative bacterial cell wall, and viral and bacterial nucleic acids.  There are several groups of 
PRRs including the toll-like receptors (TLR), nucleotide binding and oligomerisation domain 
(NOD)-like receptors and scavenger receptors (Akira et al., 2006; Jeannin, Jaillon, & 
Delneste, 2008; Mukhopadhyay et al., 2009).  In addition to recognising pathogens, PRR can 
also recognise apoptotic and necrotic cells and facilitate their clearance (Jeannin et al., 2008).   
 
1.2.2 Cells of the innate immune system 
 
1.2.2.1 Monocytes 
Monocytes, an innate immune cell type, are found in the blood and are derived from bone 
marrow precursor cells of the myeloid lineage (Mosser & Edwards, 2008).  Monocytes can 
migrate into tissue where they differentiate into MΦ or DC.  Migration of monocytes into 
tissue can be due to inflammatory signals or as a normal process to replenish the resident MΦ 
(Mosser & Edwards, 2008).  In both mice and humans, there are two different subsets of 
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monocytes which are often thought of as having pro or anti-inflammatory properties.  In 
humans, these cells are separated into different subsets based on their expression of CD16 and 
CD14 (Ingersoll et al., 2010).  In mice monocytes are separated into subsets based on the 
expression of two chemokine receptors; the fractalkine receptor (CX3CR1) and CCR2, and the 
expression of Ly6C (Geissmann, Jung, & Littman, 2003; Ingersoll et al., 2010).  The 
CX3CR1+Ly6C- cells migrate into tissues under steady state while CCR2+Ly6C+ cells migrate 
in response to inflammatory conditions (Geissmann et al., 2003). 
 
1.2.2.2 Macrophages 
MΦ are a cell type of the innate immune system found in tissues throughout the body (Mosser 
& Edwards, 2008).  MΦ have two main functions, acting as part of the immune response and 
also as a housekeeping cell.  The housekeeping functions of MΦ are related to homeostatic 
maintenance and do not elicit an immune response.  Examples of housekeeping functions 
include the clearance of debris and apoptotic cells, and tissue remodelling (Mosser & 
Edwards, 2008).  Immune functions of MΦ include antigen presentation, and the phagocytosis 
and destruction of pathogens.  Traditionally, MΦ have been viewed as proinflammatory cells 
in the context of disease and infection.  MΦ in this “proinflammatory” state are known as 
classically activated MΦ, and they secrete proinflammatory cytokines such as interleukin 
(IL)-12, IL-23 and tumour necrosis factor (TNF)-α (Mosser & Edwards, 2008; Sutterwala, 
Noel, Salgame, & Mosser, 1998).  While MΦ are found in almost every organ of the body, 
not all MΦ are exactly the same; their function is slightly different in different organs, based 
on the milieu they are in.  Some examples of different MΦ subsets include the kupffer cells of 
the liver, osteoclasts found in the bone, alveolar MΦ of the lung, and the microglia (MG) 
from the central nervous system (CNS) (Gordon & Taylor, 2005; Stout & Suttles, 2004).   
 
1.2.2.3 Dendritic cells 
The major role of DC in the immune system is phagocytosis and presentation of antigens.  By 
presenting antigens to T cells, DC (and other antigen presenting cells; APC) link the adaptive 
and innate arms of the immune system, initiating an adaptive immune response.  DCs have a 
small cell body and a large number of processes which extend from them, these processes to 
survey their environment, looking for antigens and signs of infection (R. M. Steinman, 2007).  
DC have been shown to be capable of driving different T cell response pathways under 
different conditions (Anderson, Lucas, Gutiérrez-Kobeh, Field, & Mosser, 2004).   
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1.2.2.4 Neutrophils 
Neutrophils are an extremely short lived cell type, having a life span of 6-8 hours in humans 
(Amulic, Cazalet, Hayes, Metzler, & Zychlinsky, 2012).  Despite this, neutrophils have very 
important roles in both host defence and autoimmune diseases, and are often the first immune 
cells to reach a site of infection.  Neutrophils are primarily classified as a granulocyte; 
however, they are also capable of phagocytosis (Amulic et al., 2012).  Chemokines released at 
the site of inflammation can result in the recruitment of neutrophils to help fight infection.  
Neutrophils are capable of producing an oxidative burst, which involves the release of 
reactive oxygen species, which can be damaging to pathogens (Remer, Brcic, & Jungi, 2003).  
In addition to the oxidative burst, neutrophilic granules contain a variety of antimicrobial 
peptides which, when released into the phagosome or external environment, create an 
inhospitable environment for pathogens (Amulic et al., 2012).  Furthermore, neutrophils are 
also important in the recruitment of other immune cells to inflammatory sites (Amulic et al., 
2012). 
 
1.2.2.5 Basophils and eosinophils 
Both basophils and eosinophils are associated with parasitic infections and allergic disease 
(Min, 2008; Min et al., 2004; Shamri, Xenakis, & Spencer, 2011).  In parasitic infections, 
eosinophils help to fight parasites through the release of granules which contain a variety of 
cytotoxic proteins, as well as cytokines and chemokines.  However, the cytotoxic granules can 
also cause collateral damage to host cells, as seen in allergic disease (Shamri et al., 2011).  
Basophils produce cytokines and release granules which contain proteins such as histamine.  
In addition, basophils have also been implicated in the initiation of Th2 responses (Min, 2008; 
Sokol & Medzhitov, 2010). 
 
1.2.2.6 Natural killer cells 
Natural killer (NK) cells are considered part of the innate immune system, due to the fact that 
they do not have the antigen specificity associated with the adaptive immune system (Vivier 
et al., 2011).  However, during haematopoiesis NK cells develop from the common 
lymphocyte progenitor, not from the common myeloid progenitor (Janeway, Travers, 
Walport, & Shlomchik, 2004).  NK cells are cytotoxic, and are capable of killing tumour cells 
and virus infected cells by the release of perforin and granzymes which lyse the target cell 
(Moretta, Marcenaro, Parolini, Ferlazzo, & Moretta, 2008; Vivier et al., 2011).  
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1.3 Adaptive immune system 
The adaptive immune system consists of two major types of cells, the B and T cells.  These 
cells are collectively known as lymphocytes and provide antigen specific and memory 
responses important in host defence. 
 
1.3.1 B cells 
B cells are part of the adaptive immune system that develops in the bone marrow and reside 
mainly in secondary lymphoid tissues, such as the spleen and lymph nodes.  The major role of 
B cells is the production of antibodies (immunoglobulin; Ig), which are central to humoral 
immunity.  The B cell population of an individual contains an extremely vast array of B cell 
receptors.  This variation is generated by rearrangement of immunoglobulin gene sequences, 
resulting in a B cell population that can identify an immense amount of different antigens 
(approximately 5x1013) (Pieper, Grimbacher, & Eibel, 2013).  The B cell receptor consists of 
a cell surface bound antibody.  Following activation and recognition of an antigen, B cells 
undergo somatic hyper maturation, which allows the B cell receptor to achieve a higher 
affinity for its antigen, and thus produce a stronger response (Janeway et al., 2004; Pieper et 
al., 2013).  B cells can produce several different classes of antibody including IgG1, IgG2a, 
IgM, IgA, and IgE, which each have roles in different types of immune responses (e.g. 
bacterial vs. parasitic infections).  Class switching to produce different antibodies is 
dependent on interactions with T cells; in the absence of these interactions B cells only 
produce IgM (Uronen & Callard, 2000).  B cells are important in a wide range of conditions 
including infection, autoimmunity and allergy (Pieper et al., 2013).   
1.3.2 Antigen presenting cells 
B cells are capable of recognising antigens and can propagate an immune response in the 
absence of other cells, although interactions with T cells help to make the B cell response 
more efficient.  In contrast, T cells can only respond to an antigen that is presented to it by 
another cell, known as an APC.  APC are therefore essential for the development of T cell 
responses.  Antigen is presented to T cells on major histocompatibility complex (MHC) 
molecules.  There are two classes of MHC molecules; MHC class I, which is expressed by all 
cell types, and MHC class II, which is limited to DC, MΦ and B cells (Janeway et al., 2004);  
the term APC generally refers to these 3 cell types.  Antigen presented on MHC class I 
molecules are generally endogenous or cytostolic proteins, that is proteins from inside the 
cell, such as viral proteins from an infected cell (Harty, Tvinnereim, & White, 2000).  
Chapter 1- General Introduction   7   
 
However, APC can also express exogenous proteins on MHC class I; this is known as cross-
presentation (Shen & Rock, 2006).  Antigen presented on MHC II is exogenous, meaning the 
antigen has been taken up by the cell, for example by phagocytosis or endocytosis, and has 
then been processed for presentation to the T cells (Robinson & Delvig, 2002).  APC also 
express co-stimulatory molecules that interact with receptors on T cells, and these interactions 
are essential for initiating the appropriate T cell responses (Smith-Garvin, Koretzky, & 
Jordan, 2009).   
 
1.3.3 T cells 
The term T cell represents a varied population of cells which are derived from the bone 
marrow but mature in the thymus.  Broadly, these cell types can be divided into two separate 
groups based on their expression of αβ or γδ T cell receptors (TCR).  γδ T cells represent a 
small number of the total T cell population.  They are mainly found in epithelial and mucosal 
tissue and have both innate and adaptive characteristics.  For example they express both TCR 
and other receptors, such as TLR, that can recognise molecules produced by stressed cells 
(Bonneville, O’Brien, & Born, 2010; Ciofani & Zúñiga-Pflücker, 2010).  The αβ T cells can 
be further divided into two groups based on the expression of the CD8 or CD4 co-receptor, 
which recognises the conserved regions of MHC class I or class II, respectively.  The T cell 
repertoire of an organism is generated in the thymus, where recombination of the VDJ gene 
segments generates the variable regions in the α and β chains of the TCR, leading to an 
incredibly vast array of TCRs that are specific for different antigens.  This rearrangement of 
genes is responsible for the ability of T cells to responed to specific antigens (Janeway et al., 
2004). 
 
1.3.3.1 CD8+ T cells 
CD8+ T cells (also known as cytotoxic T lymphocytes) are cytotoxic cells that recognise 
endogenous (or cytostolic) antigens presented on MHC class I molecules; however, they are 
also capable of recognising exogenous antigens presented on MHC I in a process known as 
cross presentation (Harty et al., 2000; Shen & Rock, 2006).  The major role of CD8+ T cells is 
to kill abnormal cells, such as damaged or virus infected cells (Hoves, Trapani, & 
Voskoboinik, 2010).  CD8+ T cells mediate cell death in several ways, including through the 
release of perforin and granzyme molecules, and stimulation of the FAS-FAS ligand 
(CD95-CD95L) pathway, which induces apoptosis (Hoves et al., 2010; Krammer, 2000).  In 
Chapter 1- General Introduction   8   
 
addition, CD8+ T cells produce cytokines such as TNF-α and interferon (IFN)-γ, which are 
also capable of inducing apoptosis (Harty et al., 2000). 
 
1.3.3.2 CD4+ T cells 
CD4+ T cells (also known as T helper cells, Th) function to activate and direct other immune 
cells.  CD4+ T cells recognise antigen presented on MHC class II molecules (Robinson & 
Delvig, 2002) and their responses are essential for many immunological processes, such as 
class switching of antibodies by B cells.  CD4+ cells were originally thought to be activated to 
two distinct subsets, Th1 cells and Th2 cells (Mosmann, Cherwinski, Bond, Giedlin, & 
Coffman, 1986); however, more recently the Th1/Th2 dichotomy has been reviewed after the 
discovery of other Th lineages.  The Th paradigm has been expanded to recognise at least 4 
different Th cell types, Th1, Th2, Th17 and Tregs (Zhu & Paul, 2009). 
 
Th1 
Th1 cells produce several cytokines including IFN-γ, IL-2, and TNF-α.  In addition to the 
cytokine profile, Th1 cells can be distinguished from other T cells by the expression of T-box 
transcription factor (T-bet) considered the master regulator of the Th1 lineage (Zhu & Paul, 
2009).  Th1 cells are induced through interaction with APCs presenting antigen and 
expressing IL-12.  IL-12 acts through a transcription factor, signal transducer and activator of 
transcription (STAT)4, which can induce IFN-γ expression (Kaplan, Sun, Hoey, & Grusby, 
1996).  STAT1 is also important in Th1 differentiation; STAT1 is activated in response to 
IFN-γ and is essential for Th1 differentiation in vitro.  It is thought that IFN-γ acts in an 
autocrine feedback loop through STAT1 to upregulate the IL-12 receptor (IL-12R) and T-bet 
expression (Lighvani et al., 2001); however, in vivo Th1 responses can develop in the absence 
of STAT1.  STAT1 deficient mice produce IFN-γ in response to EAE induction or 
Toxoplasma gondii infection (Bettelli et al., 2004; Lieberman, Banica, Reiner, & Hunter, 
2004).  T-bet is also upregulated in these mice, but not to the same extent as wild type mice, 
suggesting that STAT1 and responsiveness to IFN-γ are important for optimal Th1 activation, 
but not necessarily differentiation.   
 
Th1 cells are important in host defence against intracellular pathogens, and are primarily 
involved in cell mediated immune responses and induce isotype switching in B cells to 
produce IgG isotypes (Abbas, Murphy, & Sher, 1996).  IFN-γ is the major cytokine secreted 
by Th1 cells and acts on MΦ to increase their microbicidal activity.  The effects of IFN-γ on 
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MΦ include increased expression of MHC class I and II, and increased production of IL-12, 
nitric oxide (NO) and superoxide (Szabo, Sullivan, Peng, & Glimcher, 2003).  In addition to 
roles in host defence, Th1 cells are often implicated in autoimmune conditions, such as MS 
and EAE.   
 
Th2 
Th2 cells can produce many cytokines including IL-4, IL-5, IL-10 and IL-13 (Zhu, Yamane, 
& Paul, 2010).  The master regulator of the Th2 lineage is GATA-3, which can be used to 
identify this cell type; without expression of GATA3, Th2 differentiation does not occur (Zhu 
& Paul, 2008).  It has been shown in vitro that both IL-2 and IL-4 are important for Th2 
differentiation (Le Gros, Ben-Sasson, Seder, Finkelman, & Paul, 1990).  IL-2 can induce 
upregulation of the IL-4 receptor alpha (IL-4Rα, CD124) chain, which is not expressed or is 
expressed only at low levels on resting T cells (Liao et al., 2008).  IL-4 drives Th2 responses 
through the IL-4 receptor via STAT6 signalling (Le Gros et al., 1990; Zhu & Paul, 2008).  
However, the role of cytokines in Th2 differentiation in vivo remains controversial as mice 
that lack either IL-4 or STAT6 are still capable of developing Th2 immune responses to 
classic Th2 inducing stimuli such as Nippostrongylus brasiliensis and Schistosoma mansoni 
(Jankovic et al., 2000; van Panhuys et al., 2008).  Th2 cells are important for defence against 
extracellular parasites, have roles in allergy and asthma, and play a key role in humoral 
immunity by inducing class switching of B cells to produce specific classes of antibodies 
including IgE and some IgG1 isotypes (Abbas et al., 1996; Zhu & Paul, 2008).  In EAE, Th2 
responses are associated with protection from disease (Chitnis et al., 2001).   
 
Th17 
Th17 cells are a relatively recently identified subset of T cells and are named after their ability 
to express IL-17A, the prototypical cytokine of this subset.  In addition to IL-17A, Th17 cells 
can produce several other cytokines including IL-17F, IL-22 and IL-21 (Zhu & Paul, 2008).  
Murine Th17 cells differentiate in the presence of IL-6 and TGF-β (Bettelli et al., 2006).  
IL-23 is also important for the Th17 response, but unlike IL-6 and transforming growth factor 
(TGF)-β, IL-23 is important in the stabilisation and pathogenic function of the Th17 
responses, and not for differentiation (Bettelli et al., 2006; McGeachy et al., 2007, 2009).  The 
master regulator of the Th17 response is retinoic acid-related orphan receptor (ROR)γt, which 
is necessary for cells to respond to IL-6 and TGF-β (Ivanov et al., 2006).  STAT3 is also very 
important in Th17 differentiation and stabilisation, being activated by IL-6 and IL-23 (Yang 
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et al., 2007).  Th17 cells are associated with protection from extracellular bacteria (e.g. 
Klebsiella pneumonia) and fungi (e.g. Candida albicans).  An important component of the 
protection from these pathogens is the promotion of neutrophil mediated inflammation by 
IL-17A (Louten, Boniface, & de Waal Malefyt, 2009).  In addition to roles in host defence, 
Th17 cells can also be pathogenic and are associated with several autoimmune conditions 
including EAE (Bettelli et al., 2006). 
 
Tregs 
T regulatory cells or Tregs are a suppressive subset of Th cells.  Tregs express high levels of 
the IL-2 receptor, CD25; however, as this marker is also upregulated on activated T cells from 
other lineages, it cannot be used on its own as a marker for the Treg lineage.  In addition to 
CD25, Forkhead box P3 (FOXP3) is highly expressed in Treg cells and is considered to be the 
master regulator of this lineage (Bettelli et al., 2006; Zhu & Paul, 2008).  TGF-β is important 
for the formation of Treg cells and the expression of FOXP3.  TGF-β is also important in 
Th17 differentiation and the absence of IL-6 is necessary for Treg development, suggesting 
these cell types are mutually exclusive (Bettelli et al., 2006).  Tregs are thought to be able to 
regulate other cells in both cell-cell contact dependent and independent methods.  For 
example, Treg cells produce immunosuppressive cytokines such as IL-10 and TGF-β, and the 
high level of CD25 expressed by Tregs can act to sequester IL-2 and prevent it from 
stimulating other T cell lineages (Campbell & Koch, 2011; Sakaguchi, Wing, Onishi, Prieto-
Martin, & Yamaguchi, 2009).  In vivo, 2 types of Tregs exist; natural Tregs differentiate in the 
thymus, and inducible Tregs are induced in the periphery (Zhu & Paul, 2009).  The balance 
between Treg cells and pathogenic subsets of other Th lineages is considered important in the 
regulation of autoimmune inflammation and maintenance of self tolerance.  In EAE, Tregs are 
important regulators of disease, and their in vivo deletion leads to exacerbation of disease 
(Zhang et al., 2004).   
 
1.3.4 Plasticity in the T cell response 
It has long been considered that the different subsets of Th cells represent terminal 
differentiation of lineages, meaning that once a commitment has been made to a lineage the 
cell cannot be changed into a different Th lineage.  Current evidence suggest that, for at least 
some Th subsets, terminal differentiation does not occur and the cells can differentiate further 
or “switch” phenotypes; a particularly good example of this is the Th17 lineage.  In the 
absence of continual TGF-β signalling in vitro differentiated Th17 cells upregulate the 
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expression of IFN-γ in response to IL-23 stimulation, producing both IFN-γ positive and 
IFN-γ/IL-17A double positive cells (Lee et al., 2009).  These cells also responded in a similar 
way to IL-12, although IL-12 could induce IFN-γ up regulation even in the presence of TGF-β 
(Lee et al., 2009).  In vivo differentiated Th17 cells have also been shown to have a plastic 
phenotype (Kurschus et al., 2010).  In transfer models of both colitis and EAE, transfer of 
in vitro polarised Th17 cell induces disease; however, the transferred cells alter their cytokine 
expression after transfer, showing increased number of IFN-γ producing cells and decreased 
numbers of IL-17A producing cells (Kurschus et al., 2010; Lee et al., 2009). 
 
1.3.5 T cell activation 
There are two signals necessary for T cell activation, stimulation of the TCR and activation of 
co-stimulatory pathways.  In addition, a third signal involving soluble factors (e.g. cytokines) 
drives the differentiation of the T cells (Janeway et al., 2004).  The first signal required for 
T cell activation is the stimulation of the TCR and for this to happen several requirements 
must be met.  The TCR must recognise the antigen being presented to it and this is determined 
by the variable regions of the αβ chain that are expressed by the individual T cell (Smith-
Garvin et al., 2009).  A second requirement is that the antigen is being presented on an MHC 
molecule that is recognised by the CD4 or CD8 co-receptors (Janeway et al., 2004).  The αβ 
chains of the TCR and the CD4 or CD8 co-receptors are important for the recognition of the 
antigen, but for activation, signalling through the CD3, which is co-expressed with the αβ 
chains of the TCR, must occur.  The CD3 signalling pathways necessary for T cell activation, 
which does not transpire in the absence of CD3 signalling (Smith-Garvin et al., 2009).   
 
The second signal required for T cell activation is the activation of co-stimulatory pathways.  
There are several known co-stimulatory pathways, which provide a stimulatory signal to the 
T cell, thus aiding the activation of the T cell.  Other pathways provide an inhibitory signal, 
which can serve to suppress the T cell response and prevent damage to the host caused by an 
overzealous immune response.  In the absence of adequate excitatory co-stimulation, T cells 
can undergo anergy and become unresponsive (Saibil, Deenick, & Ohashi, 2007).  Several of 
these co-stimulatory and co-inhibitory pathways will be discussed in more detail below.  In 
addition to the first two signals, there is a third signal for T cell activation which is involved 
in directing the T cell response and consists of the production of soluble factors, such as 
cytokines, by the APC (Janeway et al., 2004; Kaliński, Hilkens, Wierenga, & Kapsenberg, 
1999).  Indeed, DC that have been activated to express cell surface markers necessary for 
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T cell activation such as MHC, CD40 and CD86, but do not express biasing cytokines such as 
IL-12, can stimulate proliferation but are ineffective at directing the T cell to develop into an 
effector cell (Spörri & Reis e Sousa, 2005).  Some of the cytokines involved in T cell 
differentiation have been described above. 
 
1.3.5.1 CD28-CTLA-4/CD80-CD86 
One of the first co-stimulatory molecules to be identified on T cells was CD28.  CD28 is 
expressed on naïve T cells and interacts with CD80 (B7.1) and CD86 (B7.2) on APC to 
provide a stimulatory signal to T cells (Krummel & Allison, 1995).  The difference in 
function between CD80 and CD86 is not well understood, and Manzotti et al. (2006) 
suggested this is likely in part due to different levels of expression of these markers (CD86 is 
often more highly expressed), making the interpretation of data obtained from CD80 and 
CD86 deficient animals difficult to interpret.  There is some evidence to suggest that CD80 
may be a more potent activator of CD28, inducing more rapid proliferation compared to 
CD86 (Manzotti et al., 2006).  CD28 is an important molecule in EAE.  CD28 deficient mice 
are protected from disease; however, disease can be induced following a second immunisation 
in a pathway that appears to rely on CD40/CD40L interactions (Girvin, Dal Canto, & Miller, 
2002).  This suggests that co-stimulation through other pathways can induce T cell activation; 
however, it appears to be less efficient than CD28 stimulation. 
 
In addition to CD28, CD80 and CD86 also interact with the related molecule, cytotoxic 
T lymphocyte-associated antigen (CTLA)-4, which provides an inhibitory signal to the T cell.  
CTLA-4 is not expressed on naïve T cells but is upregulated following activation, and can 
then bind to CD80 and CD86, which it does with a much higher affinity than CD28, to inhibit 
the T cell response (Krummel & Allison, 1995).  Stimulating T cells via CTLA-4 causes a 
decrease in their proliferation and IL-2 production (Walunas, Bakker, & Bluestone, 1996).  
This interaction is thought to be very important in the regulation of T cell responses, as 
CTLA-4 deficient mice suffer from a severe lymphoproliferative disorder that results in early 
death due to uncontrolled T cell responses (Waterhouse et al., 1995).  In addition CTLA-4 is 
highly expressed by Tregs and is important in their ability to control immune responses (Jain, 
Nguyen, Chambers, & Kang, 2010). 
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1.3.5.2 CD40/CD40L 
CD40L (CD154) is expressed on the surface of T cells and is upregulated following TCR 
stimulation.  Interactions between CD40L and CD40 on APC are important for both the T cell 
and the APC.  CD40L deficient mice have a deficiency in T cell priming, as seen by lower 
levels of proliferation and cytokine production in these T cells (Grewal & Flavell, 1998; 
Grewal, Xu, & Flavell, 1995).  CD40L binding to CD40 on APC activates the APC to 
produce cytokines such as IL-12 and TNF-α (Grewal & Flavell, 1998).  The CD40/CD40L 
interactions of B and T cells are essential for isotype switching by B cells and germinal 
vesicle formation (Grewal & Flavell, 1998).  In people with hyper IgM syndrome, mutations 
in the CD40L gene prevent interactions between CD40 on B cells and CD40L on T cells, 
leading to an inhibition of isotype switching and an increased susceptibility to infection 
(Uronen & Callard, 2000).  The interaction between CD40L and CD40 is very important in a 
wide range of conditions including infections, such as Leishmania major and EAE (Campbell 
et al., 1996; Grewal et al., 1996).   
 
CD40L deficient mice on normally resistant backgrounds are susceptible to L. major and 
succumb to infection in a manner similar to that seen in susceptible strains.  The susceptibility 
to infection in CD40L deficient mice is associated with decreased production of IFN-γ by 
T cells and IL-12 by MΦ (Campbell et al., 1996).  CD40L deficient mice succumb to a 
standard dose of L. major but are capable of mounting an effective response against low level 
infection (associated with increased IFN-γ and IL-12 production), and are protected from a 
second high level infection (Padigel & Farrell, 2003).  This suggests that anti-L. major 
responses can be mounted in the absence of CD40/CD40L interaction, but that they are less 
efficiently produced.  In EAE, CD40L deficiency is associated with resistance to disease.  
This protection correlates with low IFN-γ production and little CD80/CD86 expression on 
APC in the lymph nodes; transfer of APC that transgenically express CD80 restores the 
susceptibility to disease (Grewal et al., 1996).  This suggests that resistance to disease may be 
due to failure of APC to be activated and co-stimulate T cells in the absence of CD40/CD40L 
interactions.  CD40/CD40L appear to be important in the induction of EAE in CD28 deficient 
mice following a second priming of myelin peptide (Girvin et al., 2002). 
 
CD40/CD40L interactions not only have roles in driving the Th1 responses involved in 
L. major infection and EAE, but are also important in Th2 responses.  Mice deficient in 
CD40L have exacerbated disease in S. mansoni infection, which is associated with an inability 
to mount a Th2 response (MacDonald et al., 2002).  In addition, deficiency in CD40/CD40L 
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interactions decreases the production of IFN-γ and IL-4 by T cells, supporting the role of this 
pathway for both Th1 and Th2 responses (Poudrier et al., 1998).  Studies suggest that 
CD40/CD40L interactions have dichotomous roles in directing APC and T cell activation.  
Different levels of CD40 stimulation have been shown to affect the activation of APC.  
Mathur et al. (2004) demonstrated that low level CD40 stimulation of MΦ induced the 
production of regulatory IL-10, while high level stimulation induced the production of 
proinflammatory IL-12 (Mathur, Awasthi, Wadhone, Ramanamurthy, & Saha, 2004).  A 
similar result was seen in DC, where low level CD40 stimulation resulted in increased IL-10, 
and high level CD40 stimulation resulted in increased IL-12 (Murugaiyan, Agrawal, Mishra, 
Mitra, & Saha, 2006).  This same pattern of responses is also seen in DC from CD40+/+ or 
CD40+/- mice.  CD40+/+ DCs express higher CD40 and when stimulated with an anti-CD40 
antibody, produce high levels of IL-12.  In contrast, the CD40+/- DC express lower levels of 
CD40 and produce high levels of IL-10 upon stimulation.  CD40+/+ DC stimulate T cells to 
produce IFN-γ (prototypic Th1 cytokine), whereas CD40+/- DCs drive T cells to produce 
IL-10 and TGF-β (Treg associated cytokines), and CD40-/- DC promote production of IL-4 
(prototypic Th2 cytokine) in T cells (Martin, Agarwal, Murugaiyan, & Saha, 2010).  These 
data support the role of CD40 signalling in directing the T cell response.   
 
1.3.5.3 PD-1/PD-L1-PD-L2 
Programmed death (PD)-1 and it’s ligands, programmed death ligand (PD-L)1 and PD-L2, 
form an important regulatory pathway with a significant role in peripheral tolerance 
(Francisco, Sage, & Sharpe, 2010; Probst, McCoy, Okazaki, Honjo, & van den Broek, 2005).  
In mice, deficiencies in PD-1 lead to spontaneous strain specific autoimmune diseases.  PD-1 
deficiency in BALB/c mice results in autoimmune dilated cardiomyopathy (Nishimura et al., 
2001), whereas PD-1 deficient C57BL/6 mice develop a lupus like syndrome characterised by 
glomerulonephritis and arthritis (Nishimura, Nose, Hiai, Minato, & Honjo, 1999).  In support 
of the inhibitory role of this pathway, studies have shown that PD-L1 and PD-L2 can inhibit 
T cell proliferation in vitro and in vivo (Carter et al., 2002; Konkel et al., 2010), and induce 
anergy (Tsushima et al., 2007).  Furthermore, PD-1 and PD-L1 deficient mice develop 
exacerbated EAE (Carter et al., 2007), whilst over expression of PD-L1 on DC is protective in 
EAE (Hirata et al., 2005).   
 
PD-L1 and PD-L2 have vastly different expression profiles.  PD-L1 is expressed on a wide 
range of both haematopoietic and non-haematopoietic cells, while PD-L2 is largely restricted 
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to MΦ and DC (Francisco et al., 2010).  The exact role PD-L1 and PD-L2 is not known; 
however, studies using mice deficient in PD-L1 or PD-L2 suggest that they have different 
roles in controlling disease.  For example, PD-L1 deficient mice have exacerbated disease in 
EAE, while PD-L2 deficient mice do not (Carter et al., 2007).  The opposite response is seen 
in Leishmania mexicana, where PD-L1 deficient mice are protected but PD-L2 mice have 
exacerbated disease (Liang et al., 2006).  Different T cell responses can regulate the 
expression of PD-L1 and PD-L2 on MΦ, with IFN-γ and LPS inducing PD-L1 activation and 
IL-4 inducing PD-L2 activation.  This suggests that PD-L1 and PD-L2 could potentially have 
roles in regulating specific immune responses (Loke & Allison, 2003).  In addition to the 
effects on T cells, PD-L1 and PD-L2 ligation likely affects the APC in a process known as 
“reverse signalling”.  DC treated with a soluble PD-1 protein take on a suppressive 
phenotype, expressing lower levels of CD40, CD80 and CD86 and increased IL-10 (Kuipers 
et al., 2006).  This suggests that the role of The PD-1/PD-L1-PD-L2 pathway may have 
important roles in regulating immune responses on both sides of the immunological synapse.   
 
1.4 Tolerance 
The aim of an immune response is to fight infections to protect the host from pathogens; 
however, many of the processes involved can cause collateral damage to the host, therefore it 
is essential that immune responses are tightly regulated.  In addition, the ability to distinguish 
self from non-self is paramount to protecting the host from damaging autoreactive immune 
responses.  Several mechanisms have evolved to regulate the ability of the immune system to 
recognise and propagate responses against host proteins.  These mechanisms are split into two 
groups known as central and peripheral tolerance.  Failure of tolerance mechanisms can result 
in autoimmune disease which may manifest as organ specific (e.g. MS) or systemic (e.g. 
systemic lupus erythematosus) diseases. 
 
1.4.1 Central tolerance 
Lymphocyte receptors are randomly generated through the rearrangement of gene segments 
and are thus not created for specific antigens.  For this reason, TCR can be generated that 
strongly recognise self peptides, and are therefore a risk factor for initiating autoimmune 
disease.  Conversely, TCR can be generated that have little affinity for MHC-antigen 
complexes.  Central tolerance occurs in primary lymphoid organs during development.  In the 
thymus, processes of positive and negative selection remove both auto-reactive and 
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unresponsive T cells through interactions with antigen presenting cells such as thymic 
epithelial cells (TEC) and thymic DC (Kyewski & Klein, 2006).  TEC express a large array of 
proteins, including proteins that are usually organ specific, with a repertoire that spans most if 
not all organs (Kyewski & Klein, 2006).  Positive selection removes T cells that do not have a 
high enough affinity for the MHC-antigen complex.  These cells do not receive survival 
signals and undergo “death by neglect” (Sprent & Kishimoto, 2001).  The process of negative 
selection removes cells that have a high affinity for self antigens.  Strong recognition of a self 
antigen during negative selection often leads to clonal deletion, whereby the reactive T cell 
undergoes apoptosis; however, some of these cells develop into Tregs (Hogquist, Baldwin, & 
Jameson, 2005; Kyewski & Klein, 2006).  Despite the rigorous mechanisms of central 
tolerance, some self reactive immune cells escape into the periphery. 
 
1.4.2 Peripheral tolerance 
Peripheral tolerance regulates immune responses outside of the primary lymphoid organs.  
There are several mechanisms of peripheral tolerance.  Inhibitory signals to the T cell, such as 
CTLA-4 and PD-L1/2, are involved in regulating T cell responses in the periphery (Francisco 
et al., 2010; Waterhouse et al., 1995).  Indeed, disruption of these pathways leads to 
autoimmune and lymphoproliferative pathologies due to dysregulation of immune responses 
(Nishimura et al., 2001, 1999; Waterhouse et al., 1995).  Treg cells are also important in the 
maintenance of peripheral tolerance due to their inhibitory effects on other immune cells 
(Sakaguchi et al., 2009).  In addition, there are certain subsets of myeloid cells that are 
capable of mediating suppressive effects, including myeloid derived suppressor cells (MDCS) 
and certain subsets of MΦ and monocytes, such as type II MΦ (Anderson, Gerber, & Mosser, 
2002; Gabrilovich & Nagaraj, 2009; Tierney, Kharkrang, & La Flamme, 2009).   
 
The induction of anergy, a state of long-term hyporesponsiveness, is also a mechanism of 
tolerance.  The induction of T cell activation requires at least two signals when antigen is 
presented to naïve T cells, and in the absence of these necessary signals, the T cell takes on an 
anergic state and becomes unresponsive to stimuli (Chappert & Schwartz, 2010; Saibil et al., 
2007).  Specific cell surface interactions, such as the PD-1/PD-L1 pathway can be important 
in the maintenance of anergy in the periphery (Saibil et al., 2007).  Anergy most likely 
happens under non-inflammatory conditions in vivo, as inflammatory signals, such as PAMP, 
induce antigen presenting cells to up regulate co-stimulatory molecules (Mosser, 2003; Saibil 
et al., 2007). 
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1.5 Macrophages 
Whilst MΦ have traditionally been associated with inflammatory responses, they exhibit 
remarkable plasticity in their activation state.  It is now considered that MΦ activation 
represents a spectrum in which different but potentially overlapping responses are induced by 
different stimuli.  Even though MΦ activation is thought of as a spectrum, several specific 
activation states have been identified.  MΦ can be activated to take on proinflammatory 
(classical MΦ), regulatory (type II MΦ), wound healing (alternatively activated (aa)MΦ), and 
acquired deactivating phenotypes under certain conditions (Mosser & Edwards, 2008).   
 
MΦ are often separated into 2 different subsets in the literature M1 and M2, with M1 MΦ 
being classically activated MΦ.  M2 was originally used to describe the alternatively activated 
MΦ, but has since been used to broadly refer to any MΦ that is not a classically activated 
MΦ.  This system of naming is therefore very limited and can become confusing, with MΦ 
subsets that are not truly alternatively activated being referred to as M2 MΦ.  The M2 subset 
is often broken down into M2a (alternative), M2b (type II/regulatory) and M2c (acquired 
deactivating) (Martinez, Sica, Mantovani, & Locati, 2008).  This can also be misleading, as it 
implies that there is a stronger relationship between all of the MΦ subsets classed as M2 than 
any of these subsets have with the classically activated or M1 MΦ, which is not necessarily 
true.  For example, both classically activated MΦ and type II can drive T cell responses by 
presenting antigen; however, aaMΦ cannot (Anderson & Mosser, 2002; Edwards et al., 2006).  
Furthermore, classically and type II activated MΦ have high levels of inducible nitric oxide 
synthase (iNOS) and produce NO, whereas aaMΦ do not and have increased arginase which 
shunts arginine towards the production of extracellular matrix (ECM) components instead of 
NO (Edwards et al., 2006).  Due to the confusing and inappropriate nature of the M1 and M2 
naming system, it will not be used in this thesis.  Instead, MΦ will be referred to as 
classically, type II, or alternatively activated. 
 
1.5.1 Classical activation 
Classically activated MΦ are a proinflammatory subset of MΦ that are typically associated 
with cell mediated immunity (Mosser & Edwards, 2008).  Classical activation requires two 
signals.  Initially both IFN-γ, which primes MΦ to become microbicidal, and TNF-α, were 
identified as being essential for MΦ activation.  However, TLR stimulation can also induce a 
classical activation state due to the production of endogenous TNF-α that feeds back on the 
MΦ.  Therefore, TLR stimuli can induce classical activation of MΦ in conjunction with IFN-γ 
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(Martinez et al., 2008; Mosser & Edwards, 2008).  MΦ activated with TLR stimuli in the 
absence of IFN-γ are often termed innately activated MΦ.  These MΦ are similar, but not 
identical, to classically activated MΦ, supporting the idea that MΦ activation occurs on a 
spectrum (Martinez et al., 2008).  Certain pathogens (such as Mycobacterium tuberculosis) 
can inhibit MΦ ability to respond to IFN-γ and therefore prevent the MΦ from taking on a 
classical activation state, resulting in inefficient pathogen clearance (Kincaid & Ernst, 2003).  
MΦ have important roles in host defence against pathogens.  When activated by classical 
stimuli, MΦ have an increased ability to kill intracellular pathogens.  Killing of pathogens by 
classically activated MΦ is mediated by several pathways including, starvation by restriction 
of nutrients (such as iron), production of reactive oxygen species and NO, and acidification of 
the phagosome (Martinez et al., 2008; Mosser, 2003).  Classically activated MΦ are often 
identified based on the production of high levels of proinflammatory cytokines such as IL-12, 
but also have increased expression levels of co-stimulatory molecules and produce high levels 
of NO.  In the context of this thesis, classically activated MΦ will be identified mainly on the 
basis of high IL-12 and low IL-10 production (Edwards et al., 2006). 
 
1.5.2 Alternative activation 
Alternative activation occurs when MΦ are exposed to Th2 cytokines, namely IL-4 or IL-13.  
Production of these cytokines in vivo, in response to parasitic infection for example, can result 
in the activation of MΦ to aaMΦ (Mosser & Edwards, 2008).  aaMΦ upregulate expression of 
the mannose receptor and arginase (Edwards et al., 2006; Stein, Keshav, Harris, & Gordon, 
1992; Varin & Gordon, 2009).  Arginase converts arginine to ornithine, which is used in the 
formation of components the ECM, such as collagen, that are secreted by aaMΦ and may 
function in resolving immune responses and promoting wound healing (Mosser & Edwards, 
2008; Varin & Gordon, 2009).  Unlike other MΦ activation states, aaMΦ do not promote 
T cell responses, suggesting they do not drive adaptive immune responses (Edwards et al., 
2006).  As aaMΦ do not express iNOS, they do not produce NO and thus have an impaired 
ability to kill intracellular pathogens, suggesting inappropriate activation of MΦ (e.g. in 
infections such as L. major) to an aaMΦ could be detrimental (Edwards et al., 2006; Martinez 
et al., 2008; Mosser & Edwards, 2008). 
 
1.5.3 Type II activation 
Type II activated MΦ were first described by Sutterwala et al., (1998).  This MΦ activation 
state was induced through the binding of antibody receptors (FcγR) with concurrent 
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stimulation of TLR-4 by LPS (Anderson & Mosser, 2002).  However, several other stimuli 
have been shown to induce similar, but not identical, activation states, supporting the idea that 
MΦ activation exists on a continuum (Mosser & Edwards, 2008).  For example, monocytes 
treated with glatiramer acetate (GA), a commonly used treatment for MS, have a similar 
activation state to type II MΦ (Kim et al., 2004; Weber et al., 2007).  Similarly to classically 
activated MΦ, type II activation of MΦ requires 2 signals.  Binding the FcγR with immune 
complexes (IC) alone has little observable effect on the MΦ, but modifies the MΦ response 
when a second inflammatory signal, such as LPS, is present (Tierney et al., 2009). 
 
The effect of type II activating conditions in vitro has been shown to alter the activation state 
of MΦ to an immunoregulatory phenotype.  These MΦ produce increased levels of IL-10 (an 
immunosuppressive cytokine) and decreased levels of IL-12 (a proinflammatory cytokine), 
thus promoting an anti-inflammatory environment (Sutterwala et al., 1998).  In addition, 
type II MΦ can present antigen to T cells; however, they have been shown to support a Th2 
activation state, unlike classical activation which support a Th1 state (Anderson & Mosser, 
2002).  Several studies have documented the in vivo effect of type II MΦ.  These studies show 
type II activated MΦ can affect T cell responses (promoting a Th2 response) and were found 
to be protective in a model of sepsis (Anderson, Gerber, & Mosser, 2002; Anderson & 
Mosser, 2002; Gerber & Mosser, 2001).  In addition, in studies of EAE, both activating 
type II MΦ in vivo via treatment with IC, and adoptive transfer of type II MΦ were protective 
and showed an enhanced Th2 response (La Flamme et al., 2006; Tierney et al., 2009). 
 
In addition to altered cytokine expression, type II MΦ also show altered expression of many 
proteins.  Some examples include reduced expression of CD40, PD-L1, and CD80 (Tierney et 
al., 2009).  Type II MΦ have also been shown to upregulate sphingosine kinase (SPHK), 
MHC class II, LIGHT, and activation of the PKB (AKT) pathway (Edwards et al., 2006; 
Polumuri, Toshchakov, & Vogel, 2007).  As described above, the PD-1/PD-L1 pathway is 
inhibitory and ligation of PD-1 results in reduced proliferation and reduced expression of IL-2 
by T cells (Carter et al., 2002).  SPHK is an enzyme which metabolises the sphingosine 
derived from a membrane sphingolipid, into sphingosine-1-phosphate (S1P).  S1P can act as 
an extracellular ligand or as an intracellular second messenger.  S1P and SPHK are active in a 
wide array of immune cells.  They have been implicated in assisting T cell egress from 
lymphoid organs, neutrophil activation and chemotaxis, and may aid wound healing when 
expressed in MΦ (Melendez, 2008).  LIGHT is a member of the TNF super family that can 
act as a costimulatory molecule and promote T cell proliferation (Tamada et al., 2000).  The 
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PKB pathway is thought to be involved in IL-12 downregulation in response to concurrent 
FcγR and toll-like receptor ligation (Polumuri et al., 2007). 
1.6 Microglia 
MG are the resident MΦ like cells of the CNS.  MG are, as their name suggests, one of the 
glial cells, which are cells in the nervous system that function to support the neurons and the 
neuronal environment.  MG are generally considered to be the only cell type in the CNS that 
is part of the immune system and for this reason it is believed that they have a strong 
influence on the way that immune responses develop in the CNS. 
 
Although the origin of MG has long been debated, it is now widely accepted that MG are of 
haematopoietic origin.  While MG are of haematopoietic origin, the majority of MG arise 
from the primitive MΦ which differentiate in the yolk sac (during primitive haematopoiesis) 
and migrate in to the brain, not from the definitive haematopoiesis through which the 
peripheral leukocytes develop (Ginhoux et al., 2010).  MG have been observed in the brain of 
mouse embryos as early as 8 days post-fertilisation (Alliot, Godin, & Pessac, 1999).  The 
adult pool of MG has been shown to be maintained by local self renewal, as opposed to 
migration of new cells into the tissue from the blood such as is seen in most other organs 
(Ajami, Bennett, Krieger, Tetzlaff, & Rossi, 2007).   
 
There are two forms morphological of MG, the amoeboid and ramified forms.  Neonatal MG 
have an amoeboid shape and are motile.  In contrast, ramified MG are only found in the brains 
of older animals and are non-motile, with the exception of their processes which move to 
survey their environment (Schell, Crane, Smith, & Roberts, 2007).  In mice, all MG have 
switched their phenotype from amoeboid to ramified by 14 days postpartum (Hirasawa et al., 
2005), and the different morphologies likely reflect the function of microglia at different life 
stages.  In the adult brain, ramified MG are often referred to as resting MG; however, these 
cells are actually continuously monitoring their micro-environment and are capable of 
eliciting immune responses and clearing cellular debris (Nimmerjahn, Kirchhoff, & 
Helmchen, 2005; Schlegelmilch, Henke, & Peri, 2011).  The main role of the amoeboid MG 
of neonatal mice is believed to be the phagocytosis of neurons that are produced in surplus in 
the developing brain.  Previous work has shown that many of these new neurons die and are 
phagocytised by microglia (Schlegelmilch et al., 2011).  Amoeboid microglia also have 
important roles in synaptic pruning during development (Paolicelli et al., 2011).   
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MG are the resident MΦ like cells of the CNS (Mosser & Edwards, 2008); however, they are 
not the same as MΦ found in other areas of the body.  MG are not continually renewed from 
the blood, unlike other populations of MΦ which are constantly being replenished by 
monocytes (Ajami et al., 2007; Mosser & Edwards, 2008; Ponomarev, Shriver, & Dittel, 
2006; Schmid et al., 2009).  In addition, the microenvironment of the CNS, which is 
considered an “immune privileged” environment, likely affects the response of MG.  For 
example, the presence of neurons in glial cultures from neonatal rats decreased the reaction of 
the glial cultures to LPS, based on TNF-α and NO production, suggesting neurons may have 
an inhibitory effect on MG function (Chang et al., 2001).  Thus, the CNS microenvironment 
may have a role in inhibiting MG to prevent overzealous immune responses initiated by MG.  
Due to the conditions in the CNS, it is important to consider that MG may react differently to 
other MΦ subsets found in other tissues and therefore need to be treated as a separate cell type 
from MΦ.   
 
When MG are unactivated they have a ramified structure and express lower levels of CD45, 
but upregulate this marker on activation to a level similar as MΦ (Sedgwick et al., 1991).  
Therefore, under inflammatory conditions, MG and MΦ cannot be distinguished from each 
other as activated MG and MΦ are morphologically similar (amoeboid) and express the same 
surface markers, such as CD45, F4/80, MHC class II, and CD11b (Melchior, Puntambekar, & 
Carson, 2006; Ponomarev et al., 2006).  It is thought that unactivated MG may have 
housekeeping functions, similar to those seen in MΦ populations in other tissues 
(Nimmerjahn et al., 2005).   
 
1.7 Multiple Sclerosis 
MS is an inflammatory disease of the central nervous system which is mediated by the 
immune system.  MS most commonly presents itself in the third and forth decades of life and 
is around 2 times as common in women as it is in men (Kumar, Abbas, Fausto, & Mitchell, 
2007; Lins, 2005).  Clinical manifestations of MS include fatigue, decreased motor control, 
ataxia, optical neuritis, cognitive impairment and paralysis (Kumar et al., 2007; Lins, 2005).  
Three main forms of MS have been characterised based on the pattern of disease progression.  
The most common form of MS (85-90% of cases) is relapsing-remitting (RR-MS), where 
patients experience periods in which their symptoms are worsened which are intervened by 
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periods of reduced disease severity.  Many patients with RR-MS will eventually develop a 
secondary progressive form.  10-15% of patients present with a primary progressive form.  
These progressive forms demonstrate a gradual worsening of symptoms, as opposed to the 
distinct attacks seen in RR-MS (Sospedra & Martin, 2005).  
 
Multiple sclerosis literally means “multiple scars”, which refers to the lesions that develop in 
the CNS (Weiner, 2009).  MS lesions in the CNS are characterised by demyelination of 
neuronal axons and subsequent damage to the axons themselves (Compston, 2004; Frohman, 
Racke, & Raine, 2006).  The axons can be damaged by inflammatory mediators such as NO, 
and it has also been suggested that NO may be able to block the transmission of signals down 
axons, thus increasing the impairments associated with active lesions (Compston, 2004).  
Remyelination can occur; however, over the course of the disease progressive loss of axons 
and myelin results in loss of function of neurons and scaring of the CNS (Bjartmar, Wujek, & 
Trapp, 2003; Frohman et al., 2006; Patrikios et al., 2006).  It is believed that this axonal loss 
is involved in the transition of MS from relapsing remitting to progressive disease 
(Greenstein, 2007).   
 
1.7.1 Aetiology 
While the aetiology of MS is not known, it is believed to be caused by a combination of both 
environmental and genetic factors (Goodin, 2009; Hoffjan & Akkad, 2010; Lins, 2005).  
Several genes have been identified as having a role in MS.  Many studies have consistently 
identified human leukocyte antigen (HLA) alleles as a risk factor for MS, with the 
DRB1*1501 allele consistently showing a strong association; however, other genes including 
cytokines and cytokine receptors (e.g. IL-2Rα and IL-7) and co-stimulatory molecules (e.g. 
CD40 and CD80) have been suggested to also have roles (Goodin, 2009; Hoffjan & Akkad, 
2010; International Multiple Sclerosis Genetics Consortium et al., 2011).  Studies in twins 
show a concordance rate of approximately 25% for monozygotic twins and 3-5% for 
dizygotic twins (Hawkes & Macgregor, 2009).  While showing a genetic link, these 
concordance rates are relatively low, suggesting a strong role for other factors (such as 
environmental factors) in the aetiology of MS. 
 
Many environmental factors have been attributed to increased risk of developing MS 
including geographical location, vitamin D3 and exposure to sunlight, stress, and certain 
infections such as Epstein-barr virus (EBV) (Goodin, 2009; Haahr, Plesner, Vestergaard, & 
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Höllsberg, 2004; Munger, Levin, Hollis, Howard, & Ascherio, 2006).  In support of the role 
of environmental factors, it has been observed that people who live in geographical locations 
where there is a low or high rate of MS, that then move to an area with opposing MS rates 
when they are older than 15, maintain the relative risk of developing MS of the area they grew 
up in.  However, if they are younger than 15, their risk of developing MS will be that of the 
area they moved to, suggesting environmental effects are particularly important in childhood 
(Goodin, 2009; Kumar et al., 2007).  Geographic location has a strong relationship with MS, 
which has higher incidences further away from the equator (Kumar et al., 2007; Lins, 2005).  
This effect can be seen not only globally but also locally.  New Zealand has an overall 
incidence of around 1:1400, however, the rate is higher in the southern parts of the country 
compared to northern areas (Taylor et al., 2010).   
 
1.7.2 Immunology 
The role for the immune system as central mediators of disease is supported by several 
findings, including the presence of inflammatory infiltrates in demyelinating lesions in MS 
patients, and the efficacy of immunomodulatory and immunosuppressive drugs in the 
treatment of MS (Frohman et al., 2006; Morris & Yiannikas, 2012).  In addition, several large 
genetic studies have found associations between genes involved in the immune system, such 
as certain HLA alleles, and MS (Goodin, 2009; Hoffjan & Akkad, 2010; International 
Multiple Sclerosis Genetics Consortium et al., 2011).  However, many of the treatments that 
are effective in relapsing-remitting MS are not effective or are less effective in treating the 
progressive forms, which also show differing histopathological patterns in the CNS (Bradl & 
Lassmann, 2009).  Therefore, it is important to remember that MS is a heterogeneous disease 
and that relapsing-remitting and progressive forms may be regulated by different, but possibly 
overlapping, processes.   
 
MS is considered an immune mediated disease in which myelin specific T cells become 
activated and invade the CNS where they mediate disease processes.  However, as studies 
have found that T cells specific for myelin antigens can be found in both the MS patients and 
healthy controls, the presence of myelin specific T cells is not sufficient for the development 
of MS (Martin et al., 1990; Pender, Csurhes, Houghten, McCombe, & Good, 1996).  It has 
been shown that myelin reactive T cells in MS patients are phenotypically different from 
healthy controls, showing an activated or memory phenotype, whereas myelin reactive T cells 
from healthy controls appear naïve (Frohman et al., 2006; Lovett-Racke et al., 1998).  
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Traditionally MS has been viewed as being mediated by CD4+ T cells, nevertheless, many 
other immune cells have been shown to have important roles in disease pathogenesis, 
including CD8+ T cells, MΦ, MG, and B cells.   
 
The event that triggers the initiation of MS is unknown.  It has been proposed that the initial 
step in MS may be related to viral or bacterial infections (such as EBV), potentially by 
molecular mimicry in which lymphocytes are cross reactive, recognising both self and 
pathogen peptide, thus a response against a pathogen could potentially trigger the autoimmune 
disease.  A second theory is that initiation occurs by bystander activation, in which an 
inflammatory environment can either enhance the co-stimulatory properties of APC, or 
enhance the activation of T cells by cytokines and other proinflammatory molecules, 
independently of TCR interaction (Sospedra & Martin, 2005).  However, neither of these 
processes has been proven, and the initial step in MS pathogenesis remains elusive.  It is 
thought that the initial activation of T cells occurs in the periphery.  For disease to occur, the 
pathogenic T cell subsets then need to migrate into the CNS.  In MS patients, breakdown of 
the blood brain barrier (BBB), a physical barrier that limits the access of cells and blood borne 
molecules into the brain, is apparent in magnetic resonance imaging scans (Carson, Doose, 
Melchior, Schmid, & Ploix, 2006).  It is not known whether this breakdown occurs before 
CNS invasion or is a result of CNS inflammation; however, following CNS inflammation, 
movement across the BBB is considered important to disease pathogenesis as blocking this 
movement with the drug natalizumab (see 1.7.3) reduces disease severity (Polman et al., 
2006).  It has been postulated that the site of initial invasion into the CNS may be the choroid 
plexus or the subarachnoid space, although direct movement across the BBB is possible 
(Kivisäkk et al., 2009; Ransohoff, Kivisäkk, & Kidd, 2003).   
 
Following T cell infiltration and recognition of antigen in the CNS, inflammatory lesions 
develop.  This process is thought to involve recruitment of further peripheral cells, activation 
of the resident MG, and production of proinflammatory molecules (Sospedra & Martin, 
2005).  This process results in demyelination and loss of oligodendrocytes, with additional 
axonal damage (Frohman et al., 2006).  While CD4+ T cells are considered important to 
disease pathogenesis, they tend to be situated on the edge of inflammatory lesions (McFarland 
& Martin, 2007).  It is thought that the majority of tissue damage is mediated by CD8+ T cells, 
MΦ, and MG.  MΦ and MG are capable of producing various toxic components, such as NO, 
glutamate, and proinflammatory cytokines, that are likely to be involved in CNS damage, and 
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can also present antigens to T cells (Lassmann, 2008; McQualter & Bernard, 2007; Raivich & 
Banati, 2004).   
 
1.7.3 Current treatments 
There are several treatments available for MS.  The first treatment to be introduced 
specifically for MS was the cytokine IFN-β.  IFN-β is a first line drug and is effective at 
reducing the relapse rate in patients with RR-MS by 30% (Khan et al., 2001).  However 
3-30% of patients taking IFN-β therapies develop neutralising antibodies to the drug, 
rendering the treatment ineffective (Bertolotto et al., 2002).  GA is also considered a first line 
drug and has similar efficacy to IFN-β therapies (Khan et al., 2001).  The low efficacy of 
these treatments demonstrates a need for more effective therapies. 
 
There are other treatments for MS but these are often considered second line and only used if 
IFN-β and GA are ineffective.  These drugs include immunosuppressive drugs such as 
mitoxantrone, which can only be used for a limited amount of time due to the negative effects 
of long term immunosuppressive drugs on the patient’s health (Morris & Yiannikas, 2012).  
Another second line drug is natalizumab, which is a monoclonal antibody that binds to an 
important molecule for the migration of lymphocytes into the CNS in MS, alpha-4 integrin, 
and thus reduces the invasion of inflammatory cells into the CNS (Polman et al., 2006; Yadav 
& Bourdette, 2012).  Natalizumab is more effective than GA or IFN-β, and has been shown to 
reduce relapse rates by up to 68% (Hutchinson, 2007; Polman et al., 2006).  However, 
natalizumab was briefly taken off the market as it was found that it caused an increased risk of 
progressive multifocal leukoencephalopathy (PML) due to the reactivation of the JC (John 
Cunningham) virus in the CNS.  The risk of developing PML whilst on natalizumab is around 
1-2:1000; however, this varies depending on whether the patient is seropositive for the JC 
virus.  Due to the increased risk of PML, natalizumab is only used if other treatments are 
ineffective (Yadav & Bourdette, 2012). 
 
Fingolimod (Gilenya) is a more recent drug for the treatment of MS and is the first drug for 
MS to be taken orally.  Fingolimod modulates the function of a S1P receptor which is 
important for the egress of lymphocytes from the lymph nodes.  It is thought that fingolimod 
mediates its effects by preventing egress of lymphocytes from the lymph nodes and thus 
reducing the number of lymphocytes that invade the CNS.  It appears that fingolimod is more 
effective at reducing relapse rates than IFN-β, showing decreases in relapse rate of 52-60% 
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(Cohen et al., 2010; Kappos et al., 2010); however, fingolimod treatment does have several 
safety concerns.  Most notably, fingolimod can alter cardiac function, with cardiac side effects 
seen relatively frequently in patients on fingolimod due to the expression of S1P on cardiac 
tissues (Cohen et al., 2010; Yadav & Bourdette, 2012).  In conclusion, there is a lack of 
highly effective drugs with good safety profiles for the treatment of MS, therefore it is 
imperative that new therapies are developed to help treat this disease. 
 
1.8 Experimental autoimmune encephalomyelitis 
EAE is one of the most studied models of inflammatory disease and has been used for 
decades as a model for MS.  EAE is the most commonly used animal model for MS although 
other models do exist, including virally mediated models and models in which demyelination 
in induced by chemicals.  EAE was used to develop several drugs including GA, 
mitoxantrone, and natalizumab for the treatment of MS (Baxter, 2007).  EAE is induced by 
introducing myelin peptides or proteins to the peripheral immune system of animals in the 
presence of complete Freund’s adjuvant (CFA), which boosts the immune response against 
the myelin components including myelin oligodendrocyte glycoprotein (MOG), proteolipid 
protein (PLP) and myelin basic protein (MBP) (Baxter, 2007; Merrill et al., 1992).  This 
exposure activates myelin specific T cells, which then proceed to infiltrate the CNS and 
mediate destruction of the myelin sheath in a manner that is believed to be similar to MS (Mor 
& Cohen, 1992).  EAE can also be induced by adoptive transfer in which transferring 
encephalitogenic T cells from an animal immunised with myelin peptide or protein to a naïve 
animal results in disease (Ponomarev et al., 2006).   
 
EAE has been induced in a wide variety of species since its original induction in rhesus 
monkeys and rabbits, including rats, mice, guinea pigs, goats, hamsters, and sheep.  Each of 
these species displays different symptoms and different patterns of disease (Baxter, 2007).  
Physically, in most mouse strains, EAE manifests as progressive paralysis starting in the tail 
and moving up the body (Baxter, 2007; Janeway et al., 2004).  Mice are the most commonly 
used model for studying EAE.  Different strains of mice have different patterns of disease, for 
example C57BL/6 mice display a progressive form of disease following MOG immunisation, 
while SJL/J mice have a relapsing remitting disease.  In addition, different mouse strains with 
different genetic backgrounds have differing susceptibilities to the myelin peptides that induce 
disease (Baxter, 2007; Gold, Linington, & Lassmann, 2006).   
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There are many common features between EAE and MS such as demyelination, the 
perivascular location of lesions, and myelin as the major target of the immune response.  
However, there are also several differences, such as the fact that EAE is an induced disease 
while MS occurs spontaneously (Gold et al., 2006).  There has been much criticism of EAE as 
a model for MS in recent years.  Several treatments that showed promise in EAE failed to 
have a protective effect in MS.  In some cases treatments caused detrimental effects in 
patients that could not be picked up in animal models, such as the reactivation of the JC virus 
causing PML in a subset of patients on nataluzimab (Baxter, 2007; Gold et al., 2006).  
However, EAE has successfully been used to model other drugs, such as GA, for treatment in 
MS.  In addition, the lack of other suitable models for the development of treatments for MS 
necessitates the continued use of animal models in MS drug development. 
 
1.8.1 Immunological components 
EAE studies have shown proinflammatory autoreactive CD4+ T cells are essential for the 
development of EAE.  Although self-reactive T cells direct damage in the CNS and are 
believed to be the major cell type involved in the pathogenesis of disease, T cells are not the 
only cell type involved in EAE/MS.  B cells, MΦ, MG, and DC are all believed to play 
important roles in disease pathogenesis. 
 
Early studies into the immune response involved in EAE implicated Th1 cells in the 
pathogenesis of EAE.  Th1 cells express the cytokines IFN-γ and IL-2.  The implication of 
Th1 cells was in part due to the high number of CD4+ cells in the brain and spinal cord of 
mice with EAE, which were found to express Th1 related cytokines such as IFN-γ (Merrill et 
al., 1992).  In addition, mice lacking the p40 subunit of IL-12 are resistant to EAE (Cua et al., 
2003).  Given that IL-12 is essential for the formation of Th1 cells (Kaplan et al., 1996), this 
was a reasonable conclusion; however, several pieces of evidence contradicted the role of Th1 
cells as primary mediators of disease.  For example, deletion of IFN-γ, the prototypical Th1 
cytokine results in more severe disease, as does deletion of STAT1 through which it signals 
(Bettelli et al., 2004; M. Krakowski & Owens, 1996).  Also, it was found that the IL-12p40 
subunit was shared by IL-23, and that it was this cytokine that was essential to the 
pathogenesis of EAE, not the IL-12 (Cua et al., 2003).  It was later found that IL-23 is 
important in the maintenance of Th17 cells, which are now considered an important cell 
population in EAE (Bettelli et al., 2006; McGeachy et al., 2007, 2009). 
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The discovery of Th17 cells suggested that it may only be the Th17 cells and not the Th1 cells 
that are pathogenic in EAE.  However, further studies suggested a role for both cell types.  
For example, in an adoptive transfer model, Th17 cells were unable to efficiently induce 
disease in the absence of Th1 cells, which were pathogenic alone.  In the presence of Th1 cell, 
Th17 cells were able to induce a more severe disease than Th1 alone, suggesting that in the 
absence of Th1 cells, Th17 cannot enter the CNS (O’Connor et al., 2008).  However it has 
also been shown that Th17 cells alone produce an atypical disease characterised by ataxia, as 
opposed to paralysis, and the presence of both Th1 and Th17 cells produced a more severe 
form of classical EAE (Domingues, Mues, Lassmann, Wekerle, & Krishnamoorthy, 2010).  
Thus, the data suggests both Th1 and Th17 are important cell types in EAE. 
 
In addition to proinflammatory T cell subsets there are also T cells types that are associated 
with protection from EAE.  One such T cell population are the Th2 cells.  Th2 cells are not 
generally associated with the induction of EAE, but instead, Th2 responses are associated 
with protection from EAE (Chitnis et al., 2001; Gimsa, Wolf, Haas, Bechmann, & Nitsch, 
2001; La Flamme et al., 2006).  IL-4, the prototypical Th2 cytokine, signals via STAT6 and 
deletion of STAT6 results in more severe EAE and a decrease in Th2 responses (Chitnis et al., 
2001).  In addition to Th2 cells, Tregs have also been shown to be important in EAE.  
Protection from EAE by Tregs involves the production of IL-10, and the deletion of these 
cells has been shown to exacerbate disease (Zhang et al., 2004). 
 
Despite the well documented role of T cells in EAE, they are not the only immune cell subset 
involved in the disease process.  Studies have shown that both DC and MΦ are important for 
the induction of EAE.  Both of these cell types are capable of presenting antigen to T cells and 
initiating an adaptive response.  While MΦ can present antigens, the role of initiating adaptive 
immune responses in EAE is thought to be primarily performed by DC.  It has been 
demonstrated that DC that have been loaded with MOG in vitro are able to induce EAE when 
introduced to naïve animals (Weir, Nicolson, & Bäckström, 2002).  MΦ/monocytes have been 
shown to be essential for EAE, and MG have also been shown to have an important role.  The 
role of MΦ and MG in EAE will be discussed in more detail below. 
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1.8.2 Role of MΦ and MG in EAE 
MΦ have been shown to be essential to disease pathogenesis in EAE.  The deletion of 
MΦ/monocytes from the periphery markedly reduced disease severity.  In these MΦ depleted 
mice, leukocytes were not able to invade the CNS parenchyma, instead accumulating in the 
leptomeninges, suggesting MΦ are essential for entry to the CNS (Tran, Hoekstra, Rooijen, 
Dijkstra, & Owens, 1998).  In addition, infiltrates of MΦ correlate with disease severity, 
regardless of the number of lymphocytes present (Gold et al., 2006). 
 
MΦ and MG have many potential roles in tissue damage in EAE.  MΦ/MG may act in 
inflammatory lesions to recruit immune cells into the CNS by secreting chemokines (Gold et 
al., 2006).  In addition, they are capable of secreting compounds that can cause tissue damage, 
such as NO, which interferes with mitochondria and axonal transmission.  MΦ/MG can also 
produce proinflammatory cytokines, such as IFN-γ and TNF-α, and are capable of antigen 
presentation (Gold et al., 2006; Lassmann, 2008; Melchior et al., 2006; Raivich & Banati, 
2004).  These proinflammatory functions likely contribute to the damage done to the CNS and 
to neurological impairment.   
 
MΦ/MG may also have beneficial roles in EAE, such as the clearance of debris after 
resolution of the immune response.  Both MΦ and MG are involved in phagocytosis of 
apoptotic T cells in lesions, and in the phagocytosis of myelin sheath components (Jack, 
Ruffini, Bar-Or, & Antel, 2005).  MΦ have also been shown to be important in remyelination. 
In a study using lysolecithin, an oligodendrocyte toxin which causes demyelination, the 
depletion of MΦ severely impeded the remeylination of neurons.  This study suggests that 
MΦ may be important in remyelination, possibly by removing myelin debris (Kotter, Setzu, 
Sim, Van Rooijen, & Franklin, 2001).   
 
There is evidence that MG may have the ability to be either pathological or protective in EAE.  
There is a lot in vitro of data to suggest that MG are capable of a proinflammatory activation 
state that has the potential to be neurotoxic (Melchior et al., 2006).  Many in vivo studies also 
support the pathogenic role of MG in EAE.  Importantly, inhibition of MG activation in vivo 
of MG in EAE resulted in decreased disease severity, supporting a pathogenic role for MG in 
EAE (Heppner et al., 2005).  As there is evidence for both pathological and protective roles 
for MG in EAE, it may be that the MG play different roles depending on the stage of disease. 
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Evidence to support the proinflammatory role of MG in EAE can be found in studies of bone 
marrow chimeric mice in which IL-23/IL-12 were not present in the CNS, but were in the 
peripheral immune system (Becher, Durell, & Noelle, 2003).  These studies allow the 
proinflammatory effects of MG in vivo to be observed, albeit in an altered state.  MG which 
are able to produce IL-23 and/or IL-12 are important in the maintenance of EAE.  It was 
shown that mice in which the p40 subunit common to both IL-12 and IL-23 had been 
specifically deleted from the CNS, but not from the systemic immune system, reduced disease 
but not the degree of CNS inflammation.  In the CNS, higher levels of Th2 cytokines (IL-4) 
and lower levels of Th1 cytokines (IFN-γ) were found.  This suggests that the p40 subunit 
expression by CNS cells is important for maintenance of a Th1 response in the CNS (Becher 
et al., 2003).  In addition, specific deletion of CD40 from the CNS but not the periphery also 
protected from disease, suggesting that activation of MG via CD40/CD40L interactions are 
important in EAE pathogenesis (Becher, Durell, Miga, Hickey, & Noelle, 2001).  
Interestingly, Th1 cells have been shown to induce a higher level of MG activation compared 
to Th2 cells, which could contribute to the limited disease seen in the absence of IL-12/IL-23, 
in which Th2 infiltrates are detected in the CNS (Gimsa et al., 2001). 
 
In contrary to the evidence to suggest MG have a proinflammatory role in EAE, there is some 
evidence that MG may be activated to a protective activation state.  In vitro, MG exposed to 
IL-4 or low levels of IFN-γ promoted neuronal survival, compared to unstimulated MG, 
suggesting that under controlled conditions MG may be able to promote repair and cell 
renewal.  Repair is usually impaired by inflammatory immune responses, but a well controlled 
immune response may be protective.  While the activation state of MG was not addressed in 
this study, it is possible that treatment with IL-4 induces an alternatively activated phenotype 
which may aid in the recovery from CNS insult (Butovsky et al., 2006). 
 
The production of Ym1 (a marker of aaMΦ activation) mRNA by MG in vivo suggests that 
they can become alternatively activated.  Some evidence for alternative activation is that IL-4 
deficient mice show more severe disease, but when IL-4 is delivered to the CNS directly, the 
disease is lessened.  IL-4 and Ym1 were not found at high levels in the MG of the normal 
CNS, but were increased in activated MG in the diseased CNS.  This study suggests that the 
majority of MG in active EAE at peak disease are aaMG, as they express Ym1 protein.  IL-4 
appears to be especially important in the CNS, as IL-4-/- mice that express IL-4 in the 
periphery have exacerbated disease.  In these mice the MG do not express Ym1, suggesting 
that they are not alternatively activated (Ponomarev, Maresz, Tan, & Dittel, 2007).  
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1.9 Aims and objectives 
Broadly, this thesis has several aims which centre around investigating the type II activation 
of MΦ and MG.  Type II MΦ have an immunoregulatory phenotype and have been shown to 
provide protection in EAE (Tierney et al., 2009).  It has been shown that MG are important 
for regulating immune responses in the CNS.  As MG are located at the site of inflammation 
in EAE and MS, it is likely that type II activated MG will be capable of regulating CNS 
immune responses and reducing disease severity.  To date, there has been no conclusive 
evidence to show if MG are capable of achieving a type II activation state.  This thesis aimed 
to determine if MG are capable of achieving type II activation in vitro.  In addition, the 
interaction between type II MΦ and MG with T cells were assessed, and pathways involved in 
the biasing of the T cell response were investigated.  Finally, this thesis aimed to determine if 
MG can be type II activated in vivo and the mechanisms involved in protection from EAE by 
type II inducing treatments. 
 
1.9.1 Specific aims 
1. To investigate in further detail the phenotype of the T cell response induced by 
activation of T cells by type II MΦ. 
2. To elucidate the pathways involved in the biasing of the T cell response by type II 
MΦ. 
3. To optimise a protocol for the isolation and culture of adult murine MG in vitro. 
4. To determine the ability of MG to achieve a type II activation state in vitro. 
5. To establish the ability of type II activated MG to bias the T cell response and to 
investigate possible pathways involved. 
6. To investigate the role of type II activating treatments on the regulation of EAE, and 
the activation state of MG in mice treated with type II inducing treatments in vivo. 
 
 
 
 
 
  
 
 
 
 
Chapter 2: 
General Methods 
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2.1 Mice strains 
All mice were housed at the Vertebrate Containment Facility of Victoria University of 
Wellington (VUW), Wellington, New Zealand, and in the Biomedical research unit (BRU) at 
the Malaghan Institute of Medical Research (MIMR), Wellington, New Zealand.  In both 
locations, mice were housed in filter-topped cages in a temperature regulated environment 
with a 12 hour light/dark cycle, and supplied with food and water ad libitum (unless 
experiment required temporary food removal).  All experimental work was approved by the 
Animal Ethics Committee of VUW (ethics approval numbers 2011R21 and 2011R30). 
 
C57BL/6 mice were bred at the BRU at the MIMR (Wellington New Zealand).  The breeding 
stock was originally obtained from Jackson Laboratory (Bar Harbour, ME, USA). 
 
B6.SJL-ptprcamice were bred at the BRU at the MIMR (Wellington, New Zealand).  These 
are congenic mice on the C57/BL/6 background, expressing CD45.1 as opposed to the 
CD45.2 expressed by C57BL/6 and 2D2 mice.  The breeding stock was originally obtained 
from the Animal Resource Centre (Canning Vale, WA, Australia). 
 
2D2 mice were bred at the Vertebrate Containment Facility of VUW (Wellington, New 
Zealand).  2D2 mice are on the C57BL/6 background and are transgenic, expressing a TCR 
specific for the MOG35-55 peptide (Bettelli et al., 2003).  The breeding stock was from the 
MIMR (Wellington, New Zealand) and was originally obtained from Prof. Vijay K. Kuchroo 
(Harvard Medical School, Boston, MA, USA). 
 
BALB/c mice were bred at the Vertebrate Containment Facility of VUW (Wellington, New 
Zealand).  The breeding stock was originally obtained from Frank Brombacher (University of 
Cape Town, Cape Town, South Africa). 
 
IL-4Rα-/- mice were bred at the Vertebrate Containment Facility of VUW (Wellington, New 
Zealand).  The breeding stock was originally obtained from Frank Brombacher (University of 
Cape Town, Cape Town, South Africa). 
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2.2 Peptides 
MOG35-55 peptides (MEVGWYRSPFSRVVHLYRNGK) and PLP180-199 peptides 
(WTTCQSIAFPSKTSASIGSL) were purchased from GenScript Corporation (Piscataway, 
NJ, USA) 
 
Ovalbumin (OVA)323-339 peptide (ISQAVHAAHAEINEAGR) was purchased from 
Mimotopes (Clayton, VIC, Australia). 
 
2.3 In vivo techniques 
 
2.3.1 EAE induction 
 
2.3.1.1 BALB/c 
8-16 week old mice were immunised by subcutaneous (s.c.) injection in the hind flanks with 
an emulsion containing PLP180-199 (100 µg per mouse; GenScript Corporation, USA) and 
complete Freunds adjuvant (500 µg heat-inactivated M. tuberculosis per mouse, Difco 
Laboratories, Michigan, USA; in incomplete Freund’s adjuvant, Sigma St. Louis, MO, USA; 
Keating et al., 2009).  The emulsion was created by passing the mixture through an 18 gauge 
needle until a thick consistency had been obtained.  The mice also received intraperitoneal 
(i.p.) injections of pertussis toxin (400 ng per mouse; Sapphire Bioscience, Redfern, NSW, 
Australia) in 200 µl pertussis buffer (see appendix A) on days 0 and 2.   
 
2.3.1.2 C57BL/6 
16-22 week old bone marrow chimeric mice (C57BL/6C57BL/6 or 
B6.SJL-ptprcaC57BL/6) were immunised by s.c. injection in the hind flanks (100 µl/hind 
flank) with an emulsion containing MOG35-55 (50 µg per mouse; GenScript Corporation, 
USA) and complete Freunds adjuvant (500 µg heat-inactivated M. tuberculosis per mouse, 
Difco Laboratories, USA; in incomplete Freund’s adjuvant, Sigma, USA).  The emulsion was 
created by passing the mixture through an 18 gauge needle until a thick consistency had been 
obtained.  The mice also received i.p. injections of pertussis toxin (200 ng per mouse; 
Sapphire Bioscience, Australia) in 200 µl pertussis buffer on days 0 and 2 (La Flamme et al., 
2006; Tierney et al., 2009).   
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2.3.1.3 Scoring of diseased mice 
Mice were weighed (using a Mettler PB6000 balance; Mettler Tolodo; Columbus, OH, USA) 
and scored daily after day 7 post-immunisation.  The disease score was assigned using the 
following criteria; 0=unaffected, 1=tail tone lost, 2=flaccid tail, 3=flaccid tail and affected 
hind limbs, 4=paralysis of hind limbs, 5=moribund.  Mice were euthanised if their disease 
score reached 5. 
 
2.3.2 Immune complex (IC) treatment 
IC were prepared as described below (2.5.1).  Mice were treated by i.p. injection with 2x105, 
2x106, or 2x107 IC in 1x phosphate buffered saline (PBS, see appendix A) 7 days prior to 
immunisation, on the day of immunisation, and every 7th day for the duration of the 
experiment (La Flamme et al., 2006). 
 
2.3.3 GA(Copaxone®) treatment 
BALB/c mice were treated with GA (Teva Pharmaceutical Industries Ltd. Petach Tikva, 
Israel) by adding 500 µg GA per mouse to the emulsion mixture.  The emulsion was 
administered as described above (2.3.1.1).  Thus, mice were treated with GA once, on the day 
of immunisation (Toker, Slaney, Bäckström, & Harper, 2011). 
 
2.3.4 Taking tail bleeds for phenotyping 
Mice were briefly placed under a heat lamp to encourage vasodilatation and then placed in a 
restraint.  The tip of the mouse’s tail was nicked with sharp scissors and blood drops were 
collected into a sterile microcentrifuge tube that contained 500 µl 1xPBS.  The blood was 
processed as described below (2.4.2.6) for phenotyping mice. 
 
2.3.5 Creation of bone marrow chimeric mice 
6-8 week old C57BL/6 mice were given antibiotic treated water for 2 weeks (neomycin 
trisulfate 2 mg/ml, Sigma, USA).  Mice were irradiated with 900 cGy following overnight 
fasting.  Bone marrow was harvested from B6.SJL-ptprca and C57BL/6 mice by flushing the 
tibias and femurs with 1xdPBS (Invitrogen, USA) containing 1% PenStrep (Invitrogen, 
Carlsbad, CA, USA) with a 23 gauge needle (BD Biosciences, Franklin Lakes, NJ, USA).  
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The cell solution was homogenised by rapid pipetting with a 10 ml pipette and transferred to a 
clean tube.  Cells were centrifuged at 760xg for 5 minutes, the supernatant was discarded, and 
cells were resuspended in 1xPBS and counted using a trypan blue exclusion assay (see 2.4.3).  
The cells were centrifuged at 760xg and resuspended in 1xPBS at 5x107 cells/ml.  Irradiated 
mice were injected intravenously with 200 µl of B6.SJL-ptprca or C57BL/6 bone marrow cells 
(1x107 cells/mouse).  Mice were maintained on antibiotic treated water for 2 weeks to reduce 
the risk of infection as mice are immunodeficient following irradiation.  Mice were left to 
recover for 6-10 weeks and to allow full reconstitution of the bone marrow.  After 6 weeks, 
blood samples were taken via tail bleed (see 2.3.4) to assess the expression of CD45.1 and 
CD45.2 on the peripheral leukocytes, and to assess the extent of reconstitution of the bone 
marrow.  Mice were used for EAE experiments 6-10 weeks following irradiation. 
 
2.4 Ex vivo techniques 
 
2.4.1 Dissection and organ removal 
Mice were sacrificed by CO2 asphyxiation or by a lethal overdose of sodium pentobarbital 
(6 mg/mouse).  To remove the spleen, the peritoneal cavity was opened and the spleen 
removed using scissors and forceps sterilised with ethanol.  Bone marrow was harvested by 
carefully removing the skeletal tissue from the hind limbs with sterile scissors and forceps, 
and disjointing the hip.  The tibias and femurs were severed at both ends and flushed with 
1x dPBS (Invitrogen, USA) containing 1% PenStrep (Invitrogen, USA) via a 23 gauge needle 
(BD Biosciences, USA).  For the removal of brains and spinal cords, the mice were first 
perfused to remove contaminating blood cells.  To perfuse, the portal vein was severed and a 
23 gauge needle inserted into the left ventricle of the heart to slowly perfuse the mouse with 
10-20 ml 1x PBS.  Following perfusion, the skin covering the upper back and head was 
removed, the skull cap carefully cut off, and the brain removed using sterile forceps.  To 
isolate the spinal cord, the spinal column was severed at the lower back and just above the 
shoulders.  A 19 gauge needle (BD Biosciences, USA) was inserted into the lumbar end of the 
severed spinal column and 1x PBS was used to push the spinal cord out of the cervical end of 
the spinal column. 
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2.4.2 Preparation of single cell suspensions 
 
2.4.2.1 Spleens 
Following isolation, spleens were placed in wash buffer (see appendix A) or dynabead 
isolation buffer (see appendix A) for use in splenocyte restimulation assays (see 2.5.8) or 
T cell isolation (see 2.5.5), respectively.  Spleens were dissociated by passing them through a 
70 µM cell strainer (BD Biosciences, USA) into a 50 ml conical tube with wash buffer or 
Dynabead isolation buffer (see appendix A).  Cells were centrifuged at 760xg for 5 minutes.  
To remove red blood cells (RBC), splenocytes were resuspended in 2 ml RBC lysis buffer 
(Sigma, USA) for 2 minutes at room temperature.  The splenocytes were washed with 8 ml of 
wash or dynabead isolation buffer and centrifuged at 760xg for 5 minutes.  Cells were 
resuspended in fresh wash or dynabead isolation buffer as appropriate, and counted using a 
trypan blue exclusion assay (see 2.4.3). 
 
2.4.2.2 Isolation of CNS cells by Percoll 
Following isolation, brains and spinal cords were placed in 1xPBS.  Brains and spinal cords 
were dissociated by passing them through a 70 µm cell strainer (BD Biosciences, USA) into a 
50 ml conical tube with 1x PBS.  Cells were centrifuged at 760xg for 5 minutes.  For isolation 
for culture or for fluorescent activated cell sorting (FACS), cells were resuspended in 10 ml of 
70% Percoll (Sigma, USA; see appendix A) and gently overlaid with 37% and 30% Percoll 
(see appendix A).  The discontinuous Percoll gradient was centrifuged at 760xg for 
30 minutes with slow acceleration and no brake.  Mononuclear cells were removed from the 
70:37% interface, then washed by diluting the solution at least 3 fold with 1xPBS and 
centrifuging at 760xg for 5 minutes.  Cells were resuspended in MG media or FACS buffer 
(see appendix A), as appropriate, and counted using a trypan blue exclusion assay, prior to 
centrifugation at 760xg for 5 minutes and resuspention at the desired concentration in MG 
media or FACS buffer.  For flow cytometric analysis of brains alone, dissociated brains were 
resuspended in 10 ml of 37% Percoll and centrifuged at 760xg for 30 minutes with slow 
acceleration and no brake.  Myelin was removed from the surface of the Percoll and the 
excess Percoll was decanted.  Cells were then resuspended in 1x PBS, washed by 
centrifugation at 760xg for 5 minutes and resuspended in FACS buffer. 
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2.4.2.3 Microglia isolation by adhesion 
Isolation of MG by adhesion was adapted from a protocol by Yip, Kaan, Fenesan, & 
Malcangio (2009).  Spinal cords were removed as described above (2.4.1) and placed in 
Hibernate media supplemented with 1xB27 supplement and 0.5mM L-glutamine (all from 
Invitrogen, USA).  Spinal cords were minced with a blade and placed in Hibernate media 
containing 2 mg/ml papain (Sigma, USA) and incubated at 37ºC for 30 minutes.  The tissue 
was left to settle and supernatant was discarded.  2 ml of supplemented Hibernate media was 
added, the tissue broken up by repeated pipetting, the tissue was left to settle, and then the 
supernatant was collected.  This step was repeated twice more.  The cell solution was 
centrifuged at 400xg for 5 minutes and the supernatant was discarded.  Cells were 
resuspended in DFP media (see appendix A) and filtered through a 70 µm cell strainer (BD 
Biosciences, USA).  10 µl of cells were mixed with 10 µl of 20 µg/ml DAPI (Sigma, USA) 
and 10 µl was loaded onto an improved Neubauer haemocytometer (Hawksley, UK). The 
number of live cells was counted using an Olympus IX51 inverted microscope (Olympus, 
USA) using UV light generated by a mercury burner (Olumpus, USA).  Cells were plated at 
10,000, 20,000, or 40,000, cells/well in 96 or 24 well plates, or cells from a whole spinal cord 
were plated onto a non-tissue culture treated petri dish and incubated at 37ºC/5% CO2 for 2 
hours.  The media was changed, and cells were removed from the plates at 2 or 24 hours after 
plating to be used for flow cytometry, as described (see 2.9). 
 
2.4.2.4 MG isolation with CD11b beads 
Two different bead kits were use to isolate MG.  For isolation using the CELLection biotin 
binder kit (Invitrogen, USA), single cell solutions of spinal cords were obtained as described 
in 2.4.2.3, and resuspended at 1x107 cells/ml in buffer (1xdPBS with 1% bovine serum 
albumin (BSA) and 2mM Ethylenediaminetetraacetic acid (EDTA)).  Isolation was performed 
as described by the manufacturer.  Briefly, 25 µl of beads were washed by adding buffer and 
placing on a magnet and removing the supernatant.  Beads were resuspended and mixed with 
2 µg biotinylated anti-CD11b+ antibody.  This solution was incubated for 30 minutes at room 
temperature.  The mixture was washed three times by placing the solution on a magnet and 
removing the supernatant, and fresh buffer was added once the solution had been removed 
from the magnet.  The beads were mixed with cells and incubated at 4ºC for 20 minutes.  
Unbound cells were removed by washing the solution on the magnet 3 times, as previously 
described.  Cells were released from the beads by incubation with 260 units (U) of DNase I 
(Invitrogen, USA) in releasing buffer (RPMI 1640 with 1% FCS, 1 mM CaCl2 and 5 mM 
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MgCl2) for 15 minutes at room temperature, followed by vigorous pipetting.  Cells were 
removed by placing the tube on the magnet and colleting the supernatant.  The cells were then 
processed for flow cytometry as described (see 2.9). 
 
For isolation with (microglia) Microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) 
single cell suspensions of brain and spinal cord were generated by passing through a 70 µM 
cell strainer (BD Biosciences, USA).  Myelin was either not separated, or else removed by 
resuspending cells in 37% Percoll followed by centrifugation at 760xg for 30 minutes, and 
collecting the myelin from the surface.  Cells were then washed with 1xPBS.  The (microglia) 
Microbeads kit (Miltenyi Biotec, Germany) was used according to manufacturer’s 
instructions.  Briefly, cells were resuspended in 90 µl dynabead isolation buffer (see appendix 
A), 10 µl of beads were added, and the solution was incubated for 15 minutes at 4ºC.  The 
dynabead buffer was added and the solution centrifuged at 300xg for 10 minutes. The 
supernatant was then discarded and the cell-bead mix was resupended in 500 µl dynabead 
isolation buffer.  An LS column (Miltenyi Biotec, Germany) was placed in a MidiMACs 
magnet (Miltenyi Biotec, Germany) and rinsed with 3 ml of dynabead isolation buffer.  The 
cell-bead mix was added to the column and allowed to flow through before the column was 
washed 3 times with 3 ml of dynabead isolation buffer.  The column was removed from the 
magnet and 5 ml of dynabead isolation buffer added to the top of the column. Cells were 
isolated by depressing the plunger of the column down.  Cells were processed for flow 
cytometry as described (see 2.9). 
 
2.4.2.5 Isolation of microglia from chimeric mice by fluorescent activated cell sorting 
(FACS) 
Chimeric mice were generated as described in 2.3.5.  Immunised mice (and non-immunised 
controls, see 2.3.1.2) were sacrificed and central nervous tissue was removed as described 
(2.4.1).  Tissue from both brains and spinal cord were dissociated and mononuclear cells were 
isolated on a discontinuous Percoll gradient (see 2.4.2.2).  Isolated cells were stained for 
FACS as described (see 2.9) using CD45.2, CD11b and 4',6-diamidino-2-phenylindole 
(DAPI) to isolate live MG cells.  Cells were isolated using a FACS Vantage DiVa cell sorter 
at MIMR (Wellington, New Zealand).  RNA was isolated as described below (see 2.10). 
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2.4.2.6 Blood 
Blood was isolated by tail bleeds (see 2.3.4 and 2.4.1).  For phenotyping, blood (2-3 drops) 
was transferred to 15 ml conical tubes and centrifuged at 400xg for 5 minutes.  The 
supernatant was removed and the cells were resuspended in 3 ml RBC lysis buffer (Sigma, 
USA) and incubated for 20 minutes at 37ºC.  1x PBS was added and the cells were 
centrifuged at 400xg for 5 minutes.  The lysis step was repeated if required.  Cells were 
resuspended in FACS buffer (see appendix A) and processed for flow cytometry as described 
in 2.9. 
 
2.4.3 Trypan blue exclusion assay 
Cells were mixed with 0.4% Trypan blue dye (Sigma, USA) at a desired dilution (generally 
either 1:2 or 1:10).  10 µl of the cell/trypan solution was loaded into an improved Neubauer 
haemocytometer (Hawksley, Lancing, UK).  The number of live cells was counted using a 
compound microscope (CX41: Olympus, PA, USA). 
 
2.4.4 Fixation and sectioning of tissues 
Perfused brains and spinal cords were incubated in 4% paraformaldehyde (PFA, see 
appendix A) at room temperature for 48 hours.  Tissues were transferred to 30% sucrose 
solution (with 1 mM sodium azide, see appendix A) and incubated at room temperature for 
24 hours.  The tissues were transferred to fresh 30% sucrose solution and stored at 4ºC.  To 
section, fixed tissues were frozen, mounted with Jung tissue freezing medium (Leica 
Biosystems, Nussloch, Germany) and 30 µM sections were cut using a cryostat (Leica 
CM3050 S, Leica Biosystems, Germany) and transferred to a 24 well plate (approximately 
6-10 section/well) containing 1x PBS with 1mM sodium azide.  Tissue sections were stored at 
4ºC. 
2.4.5 Immunohistochemistry (IHC). 
Sections were transferred to a clean 24 well plate containing 1xPBS (3 sections per well).  
1x PBS was removed and sections were incubated with 500 µl/well peroxidise quenching 
solution for 20 minutes.  Peroxidase quenching solution was removed and sections were 
washed 3 times for 5 minutes each with TPBS (see appendix A).  After the 3rd wash, sections 
were incubated in IHC block (see appendix A) for 20 minutes.  IHC block was removed from 
the wells, and 200 µl of primary antibody (1:300; ionised calcium binding adaptor molecule 1 
(Iba1) Abcam, Cambridge, England) diluted in IHC block was added, and the sections were 
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incubated overnight at 4ºC.  The primary antibody solution was removed and sections were 
washed 3 times for 5 minutes each with TPBS.  After the 3rd wash, sections were incubated in 
200 µl of secondary antibody (1:300, biotinylated donkey-anti-goat; Jackson Laboratories, 
Bar Harbor, Maine, United States) diluted in IHC block, and incubated at room temperature 
for 2 hours.  The secondary antibody solution was removed and sections were washed 3 times 
for 5 minutes each with TPBS.  After the 3rd wash sections were incubated in 200 µl/well of 
avidin-biotin ABC kit (Vector Labs, Burlingame, California, USA) for 1 hour at room 
temperature.  The avidin-biotin ABC solution was removed, and sections were washed 3 
times for 5 minutes each with TPBS.  After the 3rd wash sections were developed using 200 
µl/well of VIP vector substrate (Vector Labs, USA).  When the colour had adequately 
developed the solution was removed, and sections were washed 3 times for 5 minutes each 
with TPBS and then mounted onto poly-L-lysine coated slides.  After 48 hours, the slides 
were counterstained with haematoxylin (see 2.4.6).   
 
2.4.6 Counterstaining with haematoxylin 
Slides were rinsed with water and the sections were covered with haematoxylin solution 
(Sigma, USA) for 20 seconds, then rinsed and placed in water.  Slides were placed in acid 
alcohol (see appendix A) for 1 minute, then transferred back to water briefly before being 
placed in 0.01% lithium carbonate (see appendix A) for 30 seconds.  Finally, the slides were 
transferred back into water.  Sections were dehydrated by successive 5 minute incubations in 
70%, 95% and 100% ethanol, before being place in xylene (Sigma, USA) for at least 5 
minutes.  Coverslips were then placed on the slides using Depex (BDH laboratory Supplies, 
Poole, England).  Sections were analysed on an Olympus IX51 inverted microscope 
(Olympus, USA), and photos were taken using CellA software (Olympus, USA). 
 
2.4.7 Scoring of Iba1 stained sections 
The intensity of the Iba1 stained sections was assessed visually.  Four brain regions, the 
cerebellum, hippocampus, olfactory bulb and brain stem, were assessed.  The sections were 
blinded for treatment group and mouse number at the time of analysis, and then un-blinded 
once the data entry had been completed.  Brain regions were given a score between 0 and 3 
based on the intensity of Iba1 staining (by comparison to pre-prepared example photos).  As 
this procedure is subjective, sections were scored individually by three separate people. 
 
Chapter 2- General methods   43 
 
2.5 In vitro techniques 
 
2.5.1 Generation of IC 
ICs were prepared by opsonising sheep red blood cells (SRBC, isolated from a healthy sheep, 
Taylor Prestons Ltd. Wellington, New Zealand) with rabbit anti-SRBC IgG polyclonal 
antibody (Sigma, USA).  To opsonise the SRBC, 1x108 SRBC/ml in 1xPBS were incubated 
with the highest non-agglutinating concentration of anti-SRBC IgG (Sigma, USA) as 
determined by an agglutination assay (see 2.5.9) for 30 minutes at room temperature on a 
rotator.  The IC solution was centrifuged at 300xg for 5 minutes to remove non-bound 
antibody and resuspended in either 1xdPBS or complete T cell media (CTCM) for in vivo or 
in vitro use, respectively. 
 
2.5.2 Bone Marrow Macrophage (BMMΦ) Culture 
Bone marrow was harvested from the femurs and tibias of 8-16 week old mice (see 2.4.1).  
Bone marrow was homogenised by repeat pipetting with a 10 ml serological pipette.  RBCs 
were lysed by incubation with 2 ml RBC lysis buffer for 2 minutes at room temperature.  
Cells were then washed in wash buffer, and resuspended at 1x106 cells/ml in CTCM.  Cells 
were cultured overnight in T75 mm2 tissue culture flasks (BD Biosciences, USA), before 
non-adherent cells were transferred to 90 mm petri dishes (Techno Plas, St Marys, Australia) 
and cultured in the presence of GM-CSF and IL-3 (both at 5 ng/ml, Peprotech, New Jersey, 
USA).  Fresh media containing GM-CSF and IL-3 (final concentration of both 2.5 ng/ml) was 
added on the 5th day in culture.  After 9 days in culture, media was removed and BMMΦ were 
isolated by blasting (using ice cold 1xdPBS (Invitrogen, USA) and rapid pipetting to detach 
the MΦ from the petri dish).  BMMΦ were replated in CTCM at 1x105 cells/well in a 96 well 
plate (BD Biosciences, USA), and cultured overnight in the presence of IFN-γ (20 U/ml).  
Following IFN-γ stimulation, BMMΦ were incubated alone or with LPS (200 ng/ml, Sigma, 
USA), in the presence or absence of IC (10 IC per MΦ, 1x106/well) for 24 hours.  For 
experiments investigating the pathways in MΦ responses and interaction with T cells, 
neutralising antibodies and recombinant cytokines were added at the time of MΦ stimulation 
or 4 hours post stimulation (for a list of antibodies and cytokines see appendix B). 
 
 
 
 
Chapter 2- General methods   44 
 
2.5.3 RAW-264.7 Cell Culture 
The established macrophage-like cell line, RAW-264.7, was a generous gift from the MIMR 
(Wellington, NZ).  The cell cultures were maintained every 72 hours by seeding a T75 mm2 
cell culture flask (BD Biosciences, USA) at 1x106 cells per 15 ml of CTCM and were then 
incubated for 72 hours at 37oC, 5% CO2.  When at 80% confluency, the monolayers were 
rinsed once in 1x dPBS (Invitrogen, USA) and then mechanically disrupted.  Cell suspensions 
were transferred to a sterile 15 ml conical tube, centrifuged at 300x g for 5 min, and assessed 
for cell viability using the Trypan blue exclusion assay (section 2.4.3).  RAW-264.7 cells 
were stimulated as described in 2.10.1.  
 
2.5.4 MG Culture 
Mice were euthanised, perfused and CNS tissue was removed as described (see 2.4.1).  MG 
were isolated for culture under sterile conditions from the brains and spinal cords of naïve 
mice.  For immediate culture, a single cell suspension of CNS tissue using a 70 µm cell 
strainer and MG were isolated using a 70:37:30% discontinuous Percoll gradient as described 
in 2.4.2.2.  MG purity was assessed by flow cytometry.  MG were seeded at 5x105 cells/well 
in CTCM in a 6 well plate and cultured at 37ºC/5% CO2 overnight.  Cells were isolated from 
6 well plates using ice cold 1x dPBS and cell viability was assessed using a trypan blue 
exclusion assay (see 2.4.3).  Alternatively, MG were seeded at 1x105 cells/well in a flat 
bottomed 96 well plate (BD Biosciences, USA) and stimulated with 20 U/ml IFN-γ overnight, 
before culture in the presence or absence of LPS (200 ng/ml, Sigma, USA) and IC 
(1x106/well).   
 
For growth in GM-CSF, brain and spinal cord was digested with papain (as described in 
2.4.3.2) and MG were isolated on a discontinuous Percoll gradient as described (2.4.2.2).  MG 
purity was assessed by flow cytometry.  All MG isolated from one mouse were seeded in 
CTCM in a T75 mm2 flask (BD Biosciences, USA) and cultured for 4-8 weeks in the presence 
of 5 ng/ml GM-CSF.  Media was changed every 3-4 days (Moussaud & Draheim, 2010).   
 
For growth in M-CSF a single cell suspension of CNS tissue using a 70 µm cell strainer and 
MG were isolated using a 70:37:30% discontinuous Percoll gradient as described in 2.4.2.2.  
MG purity was assessed by flow cytometry.  MG were resuspended in MG media 
supplemented with 10 ng/ml M-CSF and seeded at 5x105 cells/well in a 24 well plate or at 
5x104 cells/well in a flat bottomed 96 well plate, and cultured for 4 weeks, with media 
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(supplemented with 10 ng/ml M-CSF) changed every 3-4 days (Ponomarev, Novikova, 
Maresz, Shriver, & Dittel, 2005).  MG cultured in a 24 well plate were isolated using ice cold 
1x dPBS and cell viability was assessed using a trypan blue exclusion assay (see 2.4.3).  
Following 4 weeks of culture, MG cultured in 96 well plates were stimulated with IFN-γ 
overnight, before culture in the presence or absence of LPS (200 ng/ml, Sigma, USA) and IC 
(1x106/well).  In some cases, M-CSF was removed from the media 3 days prior to IFN-γ 
stimulation. 
 
2.5.5 CD4+T cell isolation 
Single cell solutions were generated from 2D2 mice (see 2.4.2.1) and 10x107 splenocytes 
were resuspended in 10 ml Dynabead isolation buffer in a 15 ml conical tube.  25 µl of 
washed mouse CD4 (L3T4) beads (placed on a magnet for 2 minutes in 1 ml dynabead 
isolation buffer, and resuspended in Dynabead isolation buffer at the original volume; 
Invitrogen, USA) were added per 1x107 splenocytes.  The splenocytes/bead solution was 
incubated for 20 minutes at 4ºC on a rotator.  The solution was place on a DynaMag magnet 
(Invitrogen, USA) and the non-bead bound cells were discarded.  The CD4 T cells/beads were 
washed 3 times by placing tube on the magnet and discarding the supernatant, and then the 
CD4 T cells/beads were resuspended at 10x107 cells/ml in CTCM.  To separate the bead 
bound cells from the beads, 10 µl of mouse CD4 DETACHaBEAD (Invitrogen, USA) per 
1x107 cells was added, and the solution was incubated on a rotator for 45 minutes at room 
temperature.  The tube was placed on a magnet and the supernatant containing CD4+ T cells 
was transferred to a fresh tube.  The beads were washed 4 more times by placing the tube on 
the magnet and harvesting the supernatant to ensure a maximal yield of cells, and counted 
using a trypan blue exclusion assay (see 2.4.3).  CD4+ T cells were washed once and used for 
MΦ or MG:T cell co-culture. 
 
2.5.6 T cell co-culture with MΦ or MG 
MΦ and MG were stimulated as described above (see 2.5.2 and 2.5.4-grown in M-CSF), with 
the exception that the IFN-γ was washed out of the cultures with warm media following 
overnight stimulation, before the next stimuli were added.  4 hours post stimulation, 2.5x105 
CD4+ T cells/well and MOG (25 µg/ml unless otherwise specified) or OVA (1 µM) was 
added to the cultures and incubated for 72 hours, at which time the supernatant was harvested 
and the cells were processed for flow cytometry.  For experiments investigating the pathways 
involved in MΦ/MG T cell interactions, neutralising/inhibitory antibodies, recombinant 
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cytokines, and chimeric proteins were added at the time of MΦ stimulation or 4 hours post 
stimulation (for a list of antibodies, cytokines and proteins see appendix B). 
 
2.5.7 CFSE cell proliferation assay 
CD4+T cells were isolated as in 2.5.5 and resuspended at 2x107 cells/ml in 1xdPBS 
(Invitrogen, USA).  625 nM carboxyfluorescein succinimidyl ester (CFSE; Sigma, USA) was 
added and incubated at room temperature for 8 minutes in the dark.  The reaction was 
quenched by adding an equal volume of 100% foetal calf serum (FCS).  Cells were washed 
once with dPBS (Invitrogen, USA) and twice with CTCM.  Cells were used in T cell co-
cultures in the presence or absence or 1 mM aminoguanidine hemisulfate (AG, Sigma, USA). 
 
2.5.8 Splenocyte restimulation assay 
Splenocytes were isolated as described above and plated in CTCM at 1x106 cells/well in a 
U-bottomed 96 well plate (BD Biosciences, USA).  Splenocytes were cultured alone, or in the 
presence of 3 µg/ml ConA for 48 hours, or 27 µg/ml MOG for 72 hours. 
 
2.5.9 Agglutination assay 
An agglutination assay was performed on every fresh batch of sheep blood to determine the 
optimum concentration of anti-SRBC IgG to use.  Serial two-fold dilutions of anti-SRBC IgG 
(Sigma, USA) in dPBS (starting at 1:50) were plated at 50 µl/well in a U bottomed 96 well 
plate in duplicate.  SRBC were added to the wells at a final concentration of 1x108 cells/well 
and incubated at room temperature for 2 hours.  The highest non-agglutinating concentration 
of anti-SRBC IgG was determined by visualisation.   
 
2.6 Cytometric bead array (CBA) 
Mouse Th1/Th2/Th17 cytokine and mouse inflammation CBA kits (BD Biosciences, USA) 
were used to assess cytokine production by cultured cells.  Briefly, 25 µl of culture 
supernatant or standards (in a serial dilution to form the standard curve) were mixed with 
25 µl mixed capture beads and 25 µl of phycoerythrin (PE) detection reagent in a V-bottomed 
plate (BD Biosciences, USA) and incubated, protected from light, at room temperature for 
2 hours.  The samples were washed twice by the addition of wash buffer and centrifugation at 
400xg for 5 minutes, then discarding the supernatant.  The samples were resuspended and 
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collected using a FACs Canto II flow cytometer (BD Biosciences, USA) and analysed using 
BD FACSDiva and FCAP Array software (BD Biosciences, USA).  The theoretical limit for 
detection ranged from 0.03-16.8 pg/ml for the mouse Th1/Th2/Th17 kit, and 2.5-52.7 pg/ml 
for the mouse inflammation kit, as described in the manufacturer’s instruction booklets.   
 
2.7 Enzyme linked immunosorbent assay (ELISA) 
Purified “capture” antibodies were diluted in either ELISA capture buffer (see appendix A) or 
1x PBS (depending on the cytokine in question), coated onto the bottom of 96 well ELISA 
plates (BD Biosciences, USA or Thermo Fisher, Massachusetts, USA) and incubated 
overnight at 4ºC.  The capture solution was removed and blocking solution (5 or 10% FCS in 
1x PBS) was used to block plates for 2 hours at room temperature.  The plates were washed 
4 times in ELISA wash buffer (0.05% Tween 20 (Sigma, USA) in PBS), 50 µl of standards 
and samples were added (standards and, if necessary, samples were diluted in block) and the 
plates were incubated overnight at 4ºC.  The standards and samples were removed and the 
plates were washed 4 times.  50 µl of biotinylated “secondary” antibody, diluted in block, was 
added.  After 1 hour incubation at room temperature the secondary antibody was removed and 
the plates were washed 6 times.  50 µl of Streptavidin conjugated horseradish peroxidase (BD 
Biosciences, USA) was added to the plates.  After 1 hour incubation at room temperature the 
solution was removed and the plates were washed 8 times.  100 µl/well of Tetramethyl 
benzidine (TMB) solution (equal parts OptEIA™ TMB A and TMB B solutions, BD 
Biosciences, USA) was used to develop the wells.  After sufficient colour had developed, the 
reaction was terminated by adding 100 µl/well stop solution (see appendix A).  Absorbance 
was measured at 450 nm on an EnSpire 2300 multilabel plate reader (PerkinElmer, 
Massachusetts, USA) and a standard curve was generated to obtain concentration values for 
the samples using the EnSpire software (PerkinElmer, USA).  For complete list of antibody 
combinations for ELISA see appendix B. 
 
2.8 Griess reaction 
Since NO is rapidly degraded into nitrite and nitrate, the Griess reaction measures nitrite as a 
indicator of NO production (Sun, Zhang, Broderick, & Fein, 2003).  Nitrate standards were 
serially diluted in CTCM.  Griess reagents A and B (see appendix A) were combined in equal 
volumes and 50 µl was added to 50 µl of the standards (NaNO2, serially diluted) and samples 
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(culture supernatant) in a flat bottomed 96 well plate.  Absorbance was measured at 570 nm 
on an EnSpire 2300 multilabel plate reader (PerkinElmer, USA) and a standard curve was 
generated to obtain concentration values of samples using the EnSpire software (PerkinElmer, 
USA).   
 
2.9 Flow cytometry 
All antibodies used in flow cytometry had been optimised to ensure both maximal signal and 
minimal background staining.  Samples were washed in FACS buffer and incubated in 50 µl 
of a mixture containing both primary antibody and 2.4G2 blocking antibody (BD Biosciences, 
USA).  Cells were stained for 20 minutes at 4ºC, then excess FACS buffer was added and the 
cells were centrifuged at 400xg for 5 minutes.  If a biotinylated antibody was used, cells were 
incubated with 50 µl of streptavidin conjugated to an appropriate fluorophore, then excess 
FACS buffer was added and the cells were centrifuged and resuspended in FACS buffer.  
Cells were analysed on a Canto II flow cytometer or a FACS Vantage DiVa cell sorter (BD 
Biosciences, USA) and data was analysed using FLOWJO 7.6.1 software (Tree Star, Ashland, 
OR, USA).  See appendix B for list of antibodies and secondary conjugates used. 
 
2.10 Isolation of mRNA from MG isolated by FACS 
Complete mRNA was isolated from sorted MG (stimulated as described for BMMΦ, see 
2.5.2) using a Dynabeads mRNA DIRECT Micro kit (Invitrogen, USA) according to 
manufacturer’s instructions.  Briefly, cells were washed in 1xPBS and resupended in 100 µl 
lysis/binding buffer.  Repeat pipetting was performed to ensure complete lysis of cells, and 
the lysates were stored at -80ºC for processing at a later date.  20 µl/sample Dynabeads 
Oligo (dT)25 were washed with 1 ml lysis/binding buffer by placing the bead/buffer solution 
on a DynaMag™-Spin magnet (Invitrogen, USA) for 1 minute. The beads were removed from 
the magnet and resuspended in their original volume with lysis/binding buffer.  20 µl of 
washed beads per sample was mixed with the lysed cell solutions and incubated for 5 minutes 
at room temperature with rotation.  The samples were washed by placing the sample on the 
magnet for 1 minute and discarding supernatant, then the tube was removed from the magnet 
and 100 µl of wash buffer A was added.  The sample was washed once more with wash buffer 
A, and resuspended in wash buffer B, then transferred to a new tube and washed once with 
wash buffer B.  After the final wash, the bead-mRNA solution was resuspended in 20 µl of ice 
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cold 10 mM Tris-HCL.  mRNA was eluted by heating the solution to70ºC for 2 minutes and 
then immediately placing the tube on the magnet and collecting the mRNA containing 
supernatant.  mRNA was used immediately for cDNA generation or stored at -80ºC until 
required.  
 
2.10.1 Isolation of mRNA from RAW-264.7 Cell Lines for PCR Optimisation 
RAW-264.7 cells were seeded at 5.25x105 cells per 4 mL of CTCM supplemented with 
20 U/ml of IFN-γ in a 60 mm diameter petri dish and incubated at 37 oC, 5% CO2 for 18 
hours.  Cells were then cultured with or without 200 ng/ml LPS stimulation for a further 24 
hours.  The confluent monolayer of approximately 5x106 cells was rinsed once in 1x dPBS 
(Invitrogen, USA) before applying 1 ml of Trizol® (Invitrogen). The Trizol®-treated sample 
was transferred to a 1.5 ml microfuge tube and shaken with 0.2 mL of chloroform, incubated 
at room temperature for 3 minutes, and centrifuged at 4000x g for 15 minutes.  The aqueous 
layer was collected to a new RNase-free tube and 2 volumes of room temperature absolute 
ethanol was added.  The ethanol mixture was then applied to a High Pure RNA Isolation Kit 
spin column (Roche; Basel, Switzerland) by centrifugation at 8,000xg in a 2 ml collection 
tube. Samples were then prepared according the manufacturer’s instructions. mRNA was used 
immediately for cDNA generation or stored at -80ºC until required. 
 
2.11 Generation of cDNA 
cDNA was generated by a reverse transcription (RT) reaction using a SuperScript III 
First-Strand Synthesis SuperMix kit (Invitrogen, USA) according to manufacturer’s 
instructions.  Briefly, 2 µl of RT master mix 1 (Table 2.1) was added to 6 µl of RNA.  The 
solution was incubated at 65ºC for 5 minutes and then immediately placed on ice for at least 
1 minute.  12 µl of master mix 2 (Table 2.1) was added to the solution.  The solution was 
incubated at 50ºC for 50 minutes followed by 85ºC for 5 minutes to terminate the reaction.  
cDNA was used immediately or stored at -80ºC until required.  
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Table 2.1 RT master mixes 
 Reagent 
Volume per 
reaction (20 µl 
final) 
Volume 
added per 
reaction 
RT master 
mix 1 
Oligo (dT)20 1 µl 2 µl  
Annealing buffer 1 µl 
RT master 
mix 2 
2x First-Strand Reaction mix 10 µl 
12 µl  
SuperScript III/RNaseOUT Enzyme mix 2 µl 
2.12 Quantitative Polymerase Chain Reaction (qPCR) 
 
2.12.1 Primers 
Primers used in this study (Table 2.2) were synthesised by Invitrogen (USA).  Lyophilised 
primers were reconstituted at 250 µM with DEPC treated H2O and stored at -80ºC.  10 µM 
working stocks were generated by dilution of primers in DEPC treated water.   
 
Table 2.2 Gene specific primers 
Gene Protein Product length  Primer sequence (3'5') 
Il12b IL-12p40 255 base pairs 
Forward ATGGCCATGTGGGAGCTGGAGAAAG 
Reverse GTGGAGCAGCAGATGTGAGTGGCT 
Ppia Cyclophillian A 
98 base 
pairs 
Forward GTCTCCTTCGAGCTGTTTGC 
Reverse GAGGAACCCTTATAGCCAAATCC 
 
2.12.2 qPCR reaction 
qPCR was performed using a Platinum SYBR Green qPCR SuperMIX-UDG kit (Invitrogen, 
USA).  4.5 µl of cDNA template was added to duplicate wells of a 96 well PCR plate 
(Thermofisher, USA) for each gene.  20.5 µl of qPCR master mix containing the appropriate 
gene specific primers were added to the appropriate wells.  The PCR plate was briefly mixed 
and centrifuged at 400xg for 2 minutes.  qPCR was performed on a CFX Connect™ 
Real-Time PCR Detection System, using the PCR program described in Table 2.4.  Following 
amplification, a melt curve was performed between 65ºC and 95ºC at 0.5ºC increments. 
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Table 2.3 qPCR master mix 
 Reagent 
Volume per 
reaction (25 µl 
final) 
qPCR master 
mix 
Platinum SYBR Green qPCR SuperMIX-UDG 12.5 µl 
Forward primer (10 µM) 0.5 µl 
Reverse primer (10 µM) 0.5 µl 
DEPC treated H2O 7.0 µl  
 
Table 2.4 PCR cycling conditions 
Temperature 
(ºC) Time Process Cycles 
50 2 minutes  1 
95 2 minutes  1 
5 15 seconds  
40 55 10 seconds  
72 30 seconds Plate read 
95 10 seconds  1 
65 95  Melt curve  
 
2.12.3 Gel electrophoresis 
The size of the PCR products was assessed by gel electrophoresis using a 2% agarose gel 
(Bioline, London, UK) v/w in 1x TAE buffer (see appendix A) with 1 µg/ml ethidium 
bromide.  Gels were run at 100V for 45-100 minutes.  To determine product size, a 1 Kb plus 
ladder (Invitrogen, USA) was utilised.  The gel was visualised under UV light. 
2.13 Graphs and statistics 
All graphs and statistical analyses were generated using GraphPad Prism 6 (GraphPad 
Software Inc., La Jolla, CA, USA). To to find and remove outliers present in sample data, the 
ROUT test in Graphpad Prism was applied, when the ROUT test was applied, the most stringent 
test paramaters available in Graphpad Prism (Q=0.1%) were used to ensure only the most 
definitive outliers were removed.  Comparisons between two groups were performed using an 
unpaired Student’s t test, and for non-parametric comparison of two groups a Mann Whitney test 
was applied.  For comparison of more than two treatment groups, a one way ANOVA with a 
Tukey’s multiple comparison post test was performed.  To compare groups based on two 
variables (e.g. multiple groups of immunised mice over disease course), statistics were 
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calculated using a two way ANOVA with a Sidak’s multiple comparisons post test.  p values 
below 0.05 were considered significant. 
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3.3 Results 
 
3.3.1 Type II activation of MΦ with IC 
Exposure of IFN-γ-primed MΦ to LPS causes classical activation and leads to a significant 
upregulation of IL-12 compared to unstimulated MΦ (i.e. medium alone; Figure 3.1b).  
Consistent with previous studies (Anderson & Mosser, 2002; Tierney et al., 2009), this 
production of IL-12 was significantly attenuated in IFN-γ-primed MΦ that were cultured with 
LPS in the presence of IC (LPS+IC) compared to LPS alone, although levels were still 
significantly increased compared to medium alone (Figure 3.1b).  In addition, MΦ incubated 
with LPS+IC had significantly increased levels of IL-10 compared to all other culture 
conditions (Figure 3.1a).  In contrast to MΦ cultured with LPS+IC, MΦ that were cultured 
with IC in the absence of LPS produced only low levels of IL-12 or IL-10 and were similar to 
MΦ cultured with medium alone (Figure 3.1a and b).   
 
As expected, classically activated MΦ upregulated the expression of PD-L1 and CD40 
compared to unstimulated MΦ.  In comparison, MΦ cultured with LPS+IC significantly down 
regulated their expression of PD-L1 and showed a trend towards decreased levels of CD40 
(Figure 3.1c and d) as reported previously (Tierney et al., 2009).  Although the decrease in 
CD40 did not reach statistical significance in this study, previous work has demonstrated that 
this decrease is both significant and consistent (Tierney et al., 2009).  As with cytokine 
production, MΦ cultured with IC in the absence of LPS had a similar expression of PD-L1 
and CD40 as unstimulated MΦ (Figure 3.1c and d).  Taken together, the reduced expression 
of IL-12, CD40, and PD-L1 along with the increased IL-10 found when IFN-γ-primed MΦ 
were cultured with LPS+IC compared to LPS alone are indicative of type II MΦ activation 
(Figure 3.1). 
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Figure 3.1.  Type II activated MΦ (LPS+IC) express less IL-12, CD40, and PD-L1 and 
more IL-10 than classically activated MΦ (LPS).  BMMΦ from C57BL/6 mice were plated 
at 1x105 and primed with 20 U/ml IFN-γ overnight before stimulation with 200 ng/ml LPS, 
LPS+IC (10 IC per MΦ) or IC alone for 24 hours.  IL-10 (a) and IL-12p40 (b) levels were 
measured by ELISA.  Expression of PD-L1 (c) and CD40 (d) was assessed by flow 
cytometry.  Shown are the means and SEM of triplicate wells from 13 experiments (a and b) 
or of flow cytometry data from 2 combined experiments (c and d).  *p<0.05, **p<0.01, 
****p<0.0001 by a one-way ANOVA with Tukey’s multiple comparison post test. 
a. b. 
c. d. 
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3.3.2 Optimisation of co-culture conditions 
2D2 transgenic mice express T cell receptors that are specific for the myelin protein MOG35-55 
(Vβ11 and Vα3.2; Bettelli et al., 2003).  This strain spontaneously develops optic neuritis in 
approximately 30% of animals and EAE in around 4% due to impaired tolerance (Bettelli et 
al., 2003).  To ensure that each 2D2 mouse expresses the MOG-specific TCR, T cells were 
routinely isolated via tail bleeds and confirmed to be positive for both Vα3.2 (Figure 3.2a) and 
Vβ11 (Figure 3.2b).  CD4+ T cells isolated from the spleens of 2D2 mice were also 
consistently found to be suitably pure (94.8±0.67; mean ± SEM from 11 experiments).  
Consistent with previous reports 2D2 CD4+ T cells produced IL-2 in response to MOG35-55, 
but not OVA peptide and did not produce IL-2 in the absence of peptide (Figure 3.2c; (Bettelli 
et al., 2003). 
 
In order to optimise the culture system for presentation of antigen by MΦ, the response of 
T cells to MOG35-55 presented by classically activated MΦ was evaluated using IL-2 as a read 
out of T cell activity.  As shown in Figure 3.3, 2D2 CD4+ T cells responded to MOG35-55 in a 
concentration dependent fashion.  Because previous studies have used 25 µg/ml MOG35-55 and 
this peptide concentration led to high level IL-2 production in our T cell culture system, this 
peptide concentration was used for all subsequent experiments (Li et al., 2009).   
 
Previous work has shown that type II activated MΦ produce decreased levels of IL-12 and 
increased levels of IL-10 compared to classically activated MΦ when cultured alone (Figure 
3.1a and b; Anderson & Mosser, 2002).  Interestingly, this altered cytokine profile is 
maintained when MΦ are cultured with T cells (Figure 3.4a and b).  This finding shows that 
the presence of naïve T cells does not cause the MΦ to alter their phenotype and suggests that 
this phenotype is maintained over the culture time.  While it is possible that some of the IL-10 
is being produced by T cells that have been activated to a Treg or Th2 phenotype, it is likely 
that most of the IL-10 is being produced by MΦ, which are known to produce high levels of 
IL-10 upon type II activation. 
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Figure 3.2.  CD4+ cells isolated from 2D2 mice express Vα3.2 and Vβ11 and are specific 
for MOG.  (a and b) Blood was obtained by tail bleed and the expression of Vα3.2 (a) and 
Vβ11 (b) were assessed by flow cytometry. R1 (a) contains CD4+Vα3.2+ cells and R2 (b) 
contains CD4+Vβ11+ cells.  Shown are representative plots from 1 mouse.  (c) BMMΦ were 
stimulated with 20 U/ml IFN-γ overnight and then cultured with or without LPS (200 ng/ml).  
Four hours post-stimulation, purified CD4+2D2 T cells were added and cultured in the 
presence or absence of MOG35-55 (25 µg/ml) or OVA peptide (1 µM).  After 72 hours, IL-2 
was measured using a CBA.  Shown are the means and SEM of triplicate wells from one 
experiment. ***p<0.001 and ****p<0.0001 by one-way ANOVA with Tukey’s multiple 
comparison post test.   
 
a. b. 
c. 
CD
4 
Vα3.2 Vβ11 
R1 
R2 
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Figure 3.3.  CD4+ T cells respond to MOG in a concentration-dependent fashion.  
BMMΦ were stimulated with 20 U/ml IFN-γ overnight and then cultured with or without LPS 
(200 ng/ml).  After four hours, purified CD4+2D2 T cells were added to the MΦ cultures in 
the presence or absence of MOG35-55.  After 72 hours, IL-2 was measured in the culture 
supernatants by ELISA.  Shown are the means and SEM of triplicate wells from one 
experiment. ****p<0.0001 by two-way ANOVA with Sidak’s multiple comparison post test. 
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Figure 3.4.  Type II activated MΦ retain their cytokine profile in MΦ:T cell co-cultures.  
BMMΦ were stimulated with 20 U/ml IFN-γ overnight and then cultured alone or with LPS 
(200 ng/ml) with or without IC (10 per MΦ).  After four hours, purified CD4+2D2 T cells and 
MOG35-55(25 µg/ml) were added to the MΦ cultures for 72 hours.  IL-10 (a) was measured in 
the culture supernatant by ELISA and CBA, and IL-12p40 (b) was measured by ELISA.  
Shown are the means and SEM of values combined from 16 (IL-10) or 17 (IL-12) 
independent experiments. ****p<0.0001 by one-way ANOVA with Tukey’s multiple 
comparison post test.   
 
a. b. 
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3.3.3 Classically activated MΦ bias the T cell response to Th1 
Upon activation, T cells alter the expression of several cell surface markers.  These changes 
include upregulation of CD44 and down regulation of CD62L; thus, activated T cells are 
considered to be CD44hiCD62Llo.  In MΦ:T cell co-cultures, T cells cultured with classically 
activated MΦ in the presence of MOG35-55 express lower levels of CD62L (Figure 3.5a) and 
higher levels of CD44 (Figure 3.5b) compared to T cells cultured with unstimulated MΦ or in 
the absence of MOG35-55.  In addition, T cells cultured with classically activated MΦ also 
express higher levels of CD25 (Figure 3.5c), which is known to be upregulated on activated 
T cells.  The level of IL-2 produced by T cells cultured with classically activated MΦ is 
greater than that produced by T cells cultured with unstimulated MΦ demonstrating that 
classically activated MΦ are more efficient at activating T cells in an antigen-specific manner 
(Figure 3.5d).  Similarly, the expression of CD25 on T cells cultured with classically activated 
MΦ is also enhanced compared to co-cultures with unstimulated MΦ (Figure 3.5c).  Overall, 
the alteration in the levels of CD62L, CD44, CD25 and IL-2 demonstrate that T cells cultured 
with classically activated MΦ achieve a more activated state than those cultured with 
unstimulated MΦ.   
 
To determine how antigen presentation by classically activated MΦ affected T cell biasing, 
the production of IFN-γ (prototypical Th1 cytokine), IL-17A (Th17 cytokine), and the 
expression of CD124 (IL-4Rα; upregulated on Th2 cells) was determined. T cells cultured 
with classically activated MΦ produced higher levels of IFN-γ compared to T cells cultured 
with unstimulated MΦ (Figure 3.6a).  Moreover, the decreased expression of CD124 on 
T cells cultured with classically activated MΦ suggests the T cells are becoming less 
responsive to IL-4 and thus are deviating away from a Th2 type response (Figure 3.6d).  
Given that classically activated MΦ have been shown to drive Th1 responses (Anderson and 
Mosser, 2002) it is likely that this decrease in CD124 is due to the T cells differentiating into 
Th1 cells.  Interestingly, IL-6 was significantly increased in cultures containing classically 
activated MΦ (Figure 3.6c) and while this cytokine along with TGF-β drives Th17 
development, no difference in IL-17A was detected (Figure 3.6b). Overall the decreased 
expression of CD124 and increased production IFN-γ supports the conclusion that classically 
activated MΦ bias the T cell response towards a Th1 phenotype. 
 
Because proliferation is the hallmark of an antigen-specific T cell response, MOG-specific 
T cell proliferation was assessed in the co-cultured using the CFSE dye dilution assay.  This 
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method demonstrated that despite significant cytokine production by the T cells, CD4+ T cells 
cultured with classically activated MΦ did not proliferate at all while those cultured with 
unstimulated MΦ did (Figure 3.7a, c, and e).  Since the proliferation of T cells can be 
inhibited by NO, which inhibits proliferation, reportedly without affecting the cytokine profile 
(van der Veen, Dietlin, Dixon Gray, & Gilmore, 2000), the presence of NO was measured by 
Griess reaction.  In contrast to co-cultures of T cells and unstimulated MΦ, which produced 
only very low levels of NO, high levels of NO were detected in co-cultures containing 
classically activated MΦ (Figure 3.7e).  In order to verify that this high level of NO can 
inhibit the proliferation of the CD4+ T cells in this co-culture system, 1 mM AG was added to 
the cultures to specifically inhibit iNOS and thus prevent NO production (Figure 3.7e).  The 
addition of AG had no effect on the proliferation of T cells cultured with unstimulated MΦ, 
which was expected as there was very little NO in the absence of AG (Figure 3.7c-f).  
However, when AG was added to cultures with classically activated MΦ, there was an 
increase in the proliferation of T cells indicating that the high NO levels prevented T cell 
proliferation (Figure 3.7a, d, e, and f).   
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Figure 3.5.  Classically activated MΦ activate T cells more efficiently than un-stimulated 
MΦ.  BMMΦ were stimulated with 20 U/ml IFN-γ overnight and then cultured alone or with 
200 ng/ml LPS.  After four hours, purified CD4+2D2 T cells were added to the cultures with 
25 µg/ml MOG.  Cells were cultured for 72 hours and the expression of CD62L (a), CD44 
(b), and CD25 (c) was assessed by flow cytometry and IL-2 levels in the culture supernatants 
by ELISA (d).  Data was subjected to the ROUT test which removed 1 outlier from CD25 
(un-stimulated), before statistics were calculated.  Shown are the means and SEM of triplicate 
wells from 19 (CD62L, CD44 and CD25) or 15 (IL-2) independent experiments.  *p<0.05, 
****p<0.0001 by unpaired Student’s t test.   
 
a. b. 
c. d. 
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Figure 3.6.  Classically activated MΦ induce Th1 T cell biasing.  BMMΦ were stimulated 
with 20 U/ml IFN-γ overnight and then cultured alone or with LPS (200 ng/ml).  After four 
hours, purified CD4+2D2 T cells were added to the cultures with 25 µg/ml MOG.  Cells were 
cultured for 72 hours and IFN-γ (a) and IL-17A (b) levels were measured by ELISA.  IL-6 (c) 
was measured by CBA and CD124 (d) by flow cytometry.  Data was subjected to the ROUT 
test which removed 1 outlier from IFN-γ (unstimulated) and 1 from CD124 (unstimulated), 
before statistics were calculated.  Shown are the means and SEM of triplicate wells from 15 
(IFN-γ), 12 (IL-17A), 3 (IL-6) or 19 (CD124) independent experiments. ****p<0.0001 by 
unpaired Student’s t test.   
a. b. 
c. d. 
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Figure 3.7.  Classically activated MΦ produce high levels of NO which inhibits the 
proliferation of T cells.  BMMΦ were stimulated with 20 U/ml IFN-γ overnight and then 
cultured with or without LPS (200 ng/ml) in the presence or absence of 1 mM AG.  After four 
hours, purified CFSE-labelled CD4+2D2 T cells and MOG (25 µg/ml) were added to the 
cultures.  Cells were cultured for 72 hours.  Cells were analysed by flow cytometry to assess 
proliferation without (a, c) or with (b, d) 1 mM AG, proliferation is expressed as percentage 
per generation (e).  Nitrite levels in the culture supernatants were measured by Griess reaction 
(f).  Shown are representative plots and data from one of two representative experiment.  
****p<0.0001 by one-way ANOVA with Tukey’s multiple comparison post test. 
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3.3.4 Type II activated MΦ induce biasing of the T cell response 
Both type II and classically activated MΦ produced similarly high levels of NO, which can be 
inhibited by the addition of 1 mM AG to the cultures (Figure 3.8a).  In the absence of AG, no 
antigen-specific proliferation was measured in co-cultures with either type II or classically 
activated MΦ.  The addition of 1 mM AG to the cultures to inhibit NO production allowed 
MOG-driven T cell proliferation to be evaluated (Figure 3.8b).  In the presence of AG, type II 
activated MΦ induced slightly greater T cell proliferation than classically activated MΦ, 
however, this did not reach statistical significance (Figure 3.8b). 
 
To assess how type II activated MΦ altered the activation state of T cells in addition to 
slightly enhancing proliferation, the expression of markers associated with activation were 
assessed including CD62L, CD44, and CD25.  T cells cultured with type II activated MΦ 
expressed higher levels of CD62L, which is down-regulated upon activation, and lower levels 
of CD44, which is upregulated on activated T cells, compared to T cells cultured with 
classically activated MΦ (Figure 3.9a and b).  In comparison, CD25, which is expressed on 
activated lymphocytes, and is also strongly associated with the Treg and Th2 lineages, was 
not significantly altered on T cells cultured with type II compared to classically activated MΦ 
(Figure 3.9c).  Additionally, despite the slight increase in T cell proliferation induced by type 
II activated MΦ, there was no difference in the amount of IL-2 produced by T cells cultured 
with type II and classically activated MΦ (Figure 3.9 d).  Overall, these changes in cell 
surface marker expression suggests that the T cells exposed to type II MΦ are not as activated 
as those exposed to classically activated MΦ, despite having equal or higher proliferative 
potential (Figure 3.8).   
 
As reported previously, IFN-γ production by T cells cultured with type II activated MΦ was 
decreased compared to those co-cultured with classically activated MΦ (Figure 3.10a, 
Anderson & Mosser, 2002), and this decrease in IFN-γ is suggestive of a phenotypic switch 
away from the Th1 lineage.  However, the production of IL-17A, the prototypical Th17 
cytokine, was increased by T cells cultured with type II activated MΦ compared to classically 
activated MΦ (Figure 3.10b).  IL-6 is one of the essential cytokines involved in Th17 
differentiation (Bettelli et al., 2006), yet surprisingly, IL-6 levels were modestly but 
significantly lower in cultures containing type II MΦ compared to cultures containing 
classically activated MΦ (Figure 3.10c) suggesting that it is not an increase in IL-6 that is 
driving the IL-17A production.  Additionally, T cells cultured with type II MΦ expressed 
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higher levels of CD124 compared to T cells cultured with classically activated MΦ (Figure 
3.10d).  Because CD124 is upregulated on Th2 cells in order to increase their responsiveness 
to IL-4, this receptor can be used as a surrogate for IL-4 production, as IL-4 is rapidly taken 
up in an autocrine loop making detection in culture supernatants difficult.  IL-4 levels were 
measured by CBA or ELISA in several independent experiments; however, the levels of IL-4 
were below detection (data not shown).  Together these results indicate that T cells are being 
biased away from a Th1 phenotype and toward a mixed Th17/Th2 type response. 
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Figure 3.8.  Type II activated MΦ slightly enhanced proliferation of T cells in the 
absence of NO.  BMMΦ were stimulated with 20 U/ml IFN-γ overnight and then cultured 
with LPS (200 ng/ml) alone or with IC (10 per MΦ) in the presence or absence of 1 mM AG.  
After four hours, purified CFSE-labelled CD4+2D2 T cells and MOG (25 µg/ml) were added 
to the cultures and cultured for 72 hours.  Nitrite levels in the culture supernatants were 
measured using a Griess reaction (a), and proliferation was analysed by flow cytometry (b).  
Shown are the means and SEM combined from 2 independent experiments.  ****p<0.0001 by 
one-way ANOVA with Tukey’s multiple comparison post test (a). 
 
a. b. 
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Figure 3.9.  Type II activated MΦ differentially activated T cells.  BMMΦ were 
stimulated with 20 U/ml IFN-γ overnight and then cultured with LPS (200 ng/ml) alone or 
with IC (10 per MΦ).  After four hours, purified CD4+2D2 T cells and MOG (25 µg/ml) were 
added to the cultures and cultured for 72 hours.  CD62L (a), CD44 (b), and CD25 expression 
(c) were analysed by flow cytometry, and IL-2 levels by ELISA (d). Shown are the means and 
SEM of triplicate wells combined from 19 (CD62L, CD44 and CD25) or 15 (IL-2) 
independent experiments, and the results are expressed as percentage of LPS stimulated. 
**p<0.01 and ****p<0.0001 by unpaired Student’s t test. 
 
a. b. 
c. d. 
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Figure 3.10.  In MΦ:T cell co-culture conditions, type II activated MΦ induce biasing of 
the T cell response away from Th1 phenotype.  BMMΦ were stimulated with 20 U/ml 
IFN-γ overnight and then cultured with LPS (200 ng/ml) alone or with IC (10 per MΦ).  After 
four hours, purified CD4+2D2 T cells and MOG (25 µg/ml) were added to the cultures and 
cultured for 72 hours.  IFN-γ (a), IL-17A (b) levels were measured by ELISA, IL-6 (c) levels 
were measured by CBA and CD124 (d) expression was assessed by flow cytometry.  Data 
was subjected to the ROUT test which removed 4 outliers from IFN-γ (type II MΦ), before 
statistics were calculated.  Shown are the means and SEM of triplicate wells combined from 
15 (IFN-γ), 12 (IL-17A), 3 (IL-6) or 19 (CD124) independent experiments, and the results are 
expressed as percentage of LPS stimulated. **p<0.01, ***p<0.001, and ****p<0.0001 by 
unpaired Student’s t test. 
 
a. b. 
c. d. 
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3.4 Discussion 
The studies in this chapter aimed to evaluate and compare the ability of type II and classically 
activated MΦ to induce biasing of the T cell response.  Consistent with previous reports 
(Anderson & Mosser, 2002) classically activated MΦ were able to induce a Th1 response 
from naïve T cells characterised by the production of high levels of IFN-γ.  In contrast, T cells 
activated by type II activated MΦ produced lower levels of IFN-γ, consistent with the T cell 
response being directed away from a Th1 type response.  Although no IL-4 was detected in 
these cultures, this does not mean that IL-4 was not produced as it can be taken up quickly in 
an autocrine manner.  Indeed, the increased level of CD124 (the α chain of the IL-4 receptor) 
on T cells cultured with type II MΦ suggests an increased ability to respond to IL-4, which 
could contribute to low or undetectable levels of IL-4 in the culture supernatant.  In addition, 
increases in CD124 levels suggest that type II MΦ are biasing the T cells towards a Th2 
phenotype.  However, a surprising finding of this study is that type II activated MΦ also 
induce a robust and consistent increase in IL-17A; a finding that has not been reported 
elsewhere to date.   
 
The novel finding that type II activated MΦ induced IL-17A production from T cells is 
surprising given that IL-10, which is produced in high levels by type II MΦ, suppresses IL-
17A production (Gu et al., 2008).  Induction of IL-17A by regulatory/suppressive cells of the 
myeloid lineage has been seen previously (Chatterjee et al., 2013).  Myeloid derived 
suppressor cells have been shown to be capable of inducing IL-17A production from naïve 
T cells and was associated with increased IL-6 and TGF-β production (Chatterjee et al., 
2013).  Thus, there could be a number of potential explanations for the increase in IL-17A in 
this study.  The most obvious is that type II activated MΦ are inducing a shift towards Th17 
responses; however, several other findings make this possibility unlikely.  Firstly, CD124 is 
up regulated in type II MΦ:T cell cultures and to date it has not been documented that Th17 
cells up regulate CD124; and furthermore given that IL-4 is counter regulatory for Th17 cells 
(Harrington et al., 2005), an up regulation of CD124 on Th17 cells would be unlikely.  
Secondly, while IL-6 is present in both classical and type II MΦ:T cell cultures, it is slightly 
but significantly decreased in cultures with type II MΦ demonstrating that it is not an increase 
in IL-6 that is driving IL-17A production and thus Th17 biasing.  However, GA activates 
MΦ/monocytes to an activation state that strongly resembles type II activation and have been 
shown increase production of TGF-β (Weber et al., 2007).  TGF-β is often considered 
immunoregulatory and is involved in the formation of Tregs.  However, in the presence of 
IL-6, TGF-β induced Th17 development (Bettelli et al., 2006).  Although it is decreased, IL-6 
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is still present in the co-cultures containing type II MΦ and this level may be high enough to 
drive Th17 production in the presence of TGF-β.  To our knowledge it has not been 
documented that MΦ stimulated with LPS+IC up-regulate TGF-β.  However, the similarity 
between GA and LPS+IC stimulated MΦ suggests that increased TGF-β production by type II 
MΦ is a possibility.  An increase in TGF-β production provides a potential pathway for 
increased IL-17A levels in this system.  It has also been demonstrated that under some 
conditions Th17 cells can also produce IL-10, and that these cells have regulatory properties 
and are protective in EAE (McGeachy et al., 2007).  Therefore it is possible that type II MΦ 
are inducing a regulatory Th17 subset as opposed to an inflammatory Th17 subset. 
 
Another possible explanation for the increased IL-17A production by T cells activated by type 
II MΦ is that the increase is a reaction to the reduced level of IL-12 and IFN-γ in cultures 
containing type II MΦ.  As both IL-12 and IFN-γ inhibit IL-17A production (Harrington et 
al., 2005; Komiyama et al., 2006) it is possible that the decreases in IL-12 and IFN-γ have 
allowed for an increase in IL-17A.  Additionally, there is evidence for the transient nature of 
Th17 cells (Kurschus et al., 2010; Lee et al., 2009) and it is therefore possible that the IL-17A 
producing cells in these cultures may not represent a fully differentiated subset but may 
instead be a transient population that has arisen due to the lack of inhibitory cytokines.  To 
determine if the population is in fact a distinct subset, the T cells could be restimulated after 
7 days to see if the expression of IL-17A is maintained over time.  In addition, determining if 
the T cells cultured with type II MΦ expressed RORγt, the master regulator of the Th17 cell 
lineage (Ivanov et al., 2006), and were exclusive producers of IL-17A, as IL-17A has been 
seen to be co-expressed with other cytokines such as IFN-γ (Kurschus et al., 2010; Lee et al., 
2009) would also confirm if these T cells were biased to become Th17 cells.  
 
While the decrease in IFN-γ and the increase in CD124 certainly demonstrate that biasing of 
the T cell response by type II is occurring and that the T cell response is likely being biased 
towards a Th2 response, the biasing is not as marked as that which has been observed in 
previous studies (Anderson & Mosser, 2002; Edwards et al., 2006).  While significant the 
decrease in IFN-γ is slight and may not on its own be biologically relevant, however, this 
change in combination with other effects of type II MΦ on T cells may have an effect over all.  
There are several factors which could explain this difference including mouse strain and T 
cell clone.  One important factor to consider is the strain of mice used for the experiments.  In 
previous work MΦ were derived from BALB/c mice (Anderson & Mosser, 2002; Edwards et 
al., 2006), whereas in the current study the MΦ were derived from C57BL/6 mice as the 2D2 
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mouse strain is on a C57BL/6 background (Bettelli et al., 2003).  The strain of mouse is 
relevant here as C57BL/6 mice preferentially produce a Th1 type immune response, whereas 
BALB/c mice preferentially produce a Th2 type response (Mills, Kincaid, Alt, Heilman, & 
Hill, 2000).  It therefore may be that the T cells from mice with a BALB/c background, as 
used in previous studies, were more susceptible to Th2 biasing conditions than the T cells 
from a C57BL/6 background used in this study.   
 
In addition to the mouse background, the T cell clone and TCR may also be involved in 
biasing though altered signalling pathways post TCR activation.  Weak signalling through the 
TCR, such as with antigen that the TCR has a weak affinity for or low level of antigen which 
the TCR has a high affinity for, biases the T cell response towards a Th2 response, whereas 
high affinity antigen at a sufficient concentration will drive the T cell response to a Th1 
response (Tao, Constant, Jorritsma, & Bottomly, 1997; Yamane & Paul, 2013).  It is likely 
that the OVA specific T cell clone used previously (Anderson & Mosser, 2002) and the MOG 
specific T cell clone used in the current study have different affinities for their respective 
ligands, which could affect the biasing of the T cell response in co-culture with classical or 
type II activated MΦ. 
 
In addition, it is possible that the time point of 72 hours used to assess T cell phenotype was 
too early to be able to accurately assess IL-4 production.  It generally takes longer for IL-4 to 
be upregulated compared to IFN-γ (Bird et al., 1998); therefore, this early time point may not 
truly demonstrate the level of IL-4 production and T cell biasing that is occurring.  
Restimulation of the T cells at 7 days would possibly give a better idea of the level of IL-4 
production as Anderson et al. (2002) and Edwards et al. (2006) found in their studies 
(Anderson & Mosser, 2002; Edwards et al., 2006).  Finally, because IL-4 is rapidly taken up 
by CD124-expressing cells, assessing intracellular IL-4 by flow cytometry may yield a more 
accurate picture of T cell biasing in this study. 
 
The MΦ used in this study were type II activated in response to LPS+IC and produced more 
IL-10 and less IL-12 compared to classically activated MΦ when cultured alone and with 
T cells.  However, the level of IL-12 produced was comparatively high compared to previous 
studies (Anderson & Mosser, 2002; Edwards et al., 2006).  Therefore, it is possible that this 
elevated level of IL-12 may also be contributing to the less pronounced biasing of T cells in 
this study given the importance of IL-12 in Th1 biasing, (Kaplan et al., 1996) and its ability to 
negatively regulate Th2 biasing by inhibiting GATA3 (Ouyang et al., 1998).  This difference 
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in IL-12 production may be due to the higher concentration of LPS used in this study 
(200 ng/ml) compared to previous work (10 ng/ml) (Anderson & Mosser, 2002; Edwards et 
al., 2006).   
 
In this study, T cells cultured with type II activated MΦ had a less activated phenotype, 
characterised by lower expression of CD44 and higher expression of CD62L, compared to 
T cell cultured with classically activated MΦ.  This finding is in contrast to previous work in 
which T cells cultured with type II activated MΦ had the more activated profile (Edwards et 
al., 2006).  The difference here may again come down to mouse strain and the T cell clone.  
Edwards et al., (2006) used an OVA specific T cell clone from a BALB/c background.  It 
would not be unexpected for T cells from a BALB/c background to be more easily activated 
towards the Th2 phenotype and display markers of activation more strongly.  Whereas in the 
current study, 2D2 T cells from a C57BL/6 background may be more easily activated under 
Th1 inducing conditions.  Therefore, it is possible that the degree of activation of T cells by 
classical or type II MΦ is strain and TCR dependent.  While the degree of T cell activation is 
significantly different between cultures containing classical and type II activation, this 
difference is less marked when compared to the levels seen on T cells cultured with 
unstimulated MΦ.  However, the exact role the change in activation has in driving the T cell 
response and T cell biasing is not known. 
 
PD-L1 is expressed on macrophages along with many other cells and binds to PD-1 on T cells 
to negatively regulate T cell proliferation (Carter et al., 2002; Konkel et al., 2010).  Type II 
activated MΦ were found to express lower levels of PD-L1 compared to classically activated 
MΦ, and it is possible that this decrease in PD-L1 is partially responsible for the increased 
activation state of T cells cultured with type II activated MΦ.  Due to the decrease in PD-L1, 
it was hypothesised that T cells cultured with type II activated MΦ would have a higher rate 
of proliferation compared to those cultured with classically activated MΦ.  However, because 
the overall increase represented only a modest increase in proliferation rate which did not 
reach significance, the functional consequences of the decreased level of PD-L1 on T cell 
responses remains unclear. 
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3.5 Summary 
In summary, classically activated MΦ biased T cells toward a Th1 phenotype, while type II 
activated MΦ biased T cells away from a Th1 and towards a Th2-like phenotype.  However, 
in a novel finding, type II activated MΦ also promoted the production of IL-17A from T cells 
by a mechanism that has not yet been established.  Furthermore, T cells activated by type II 
activated MΦ had a less activated phenotype but had a higher proliferative capacity compared 
to classically activated MΦ.   
 
 
 
  
 
 
 
 
Chapter 4:  
Elucidating the mechanisms involved 
in T cell biasing by Type II MΦ 
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4.1 Introduction 
It has been proposed by Anderson & Mosser, (2002) that the biasing of T cell responses by 
classical and type II activated MΦ is caused solely by the differential production of IL-12 and 
IL-10.  In the Anderson and Mosser study, IL-12-/- and IL-10-/- MΦ were classically or type II 
activated and it was found that they were unable to induce Th1 or Th2 biasing, respectively 
(Anderson & Mosser, 2002).  Additionally, while the deletion of either IL-10 or IL-12 
maintained the cytokine profile of classically and type II activated MΦ, the absolute values 
appeared to be altered compared to wild type MΦ with IL-10-deficient MΦ producing more 
IL-12 and IL-12-deficient mice producing less IL-10, suggesting a possible effect of gene 
deletion on the MΦ beyond the deleted gene (Anderson & Mosser, 2002).  While this study 
certainly supports the role for IL-10 and IL-12 in T cell biasing, it does not allow for 
developmental effects of gene deletion or the temporal effects of altering IL-10 and IL-12 
over the course of a MΦ:T cell co-culture which could account for some of the changes seen 
in this study.   
 
Genetic deletion has been shown to alter the development of bone marrow derived MΦ.  For 
example, a recent study has shown that MΦ isolated from the bone marrow of IL-4Rα 
(CD124) deficient mice produce higher levels of both IL-12 and IL-10 compared to wild type 
controls and this difference was due to a different environment in vivo and not to in vitro 
culture conditions (La Flamme et al., 2012).  Overall this finding indicates that exposure to 
cytokines during development in the bone marrow may affect the final phenotype of the MΦ.  
Therefore, it is possible that deletion of IL-10 or IL-12 will alter the cytokine environment 
during MΦ development and cause developmental differences in the MΦ.  Due the possible 
effects of gene deletion, the current study aimed to investigate the role of IL-10 and IL-12 in 
T cell biasing using blocking antibodies and recombinant proteins.  As the IL-10 and IL-12 
will only be blocked upon activation it can be assumed that these MΦ were functionally 
normal upon stimulation, and that any effect seen is a direct result of blocking or enhancing 
IL-10 and IL-12 and not a functional change that is an artefact of gene deletion.  The 
cytokines can also be blocked or added either at the time of MΦ stimulation or at the time 
T cells are added to the culture, to help elucidate any temporal effects that IL-12 or IL-10 may 
have on the MΦ themselves versus the T cells.  In addition, this method has the potential to 
assess the effect of different levels of cytokine by titrating the neutralising antibodies and the 
recombinant cytokines. 
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In addition to IL-12 and IL-10 levels, there are other molecules that are differentially 
expressed on type II MΦ compared to classically activated MΦ.  These include CD40 and 
PD-L1, which are both significantly down-regulated after type II activation (Tierney et al., 
2009).  CD40 and PD-L1 are members of the co-stimulatory or co-inhibitory family of 
receptors involved in T cell:APC interactions and due to their differential expression on type 
II activated MΦ, were investigated for their involvement in T cell biasing by classically and 
type II activated MΦ.  It has previously been demonstrated that different levels of CD40 
signalling to the APC results in differential activation, with lower levels of CD40 stimulation 
resulting in increased IL-10 and higher levels of stimulation increasing IL-12 production 
(Mathur et al., 2004; Murugaiyan et al., 2006).  Furthermore, CD40+/+ DC drive Th1 
responses while CD40+/- have been shown to activate T cells to a phenotype that resembles 
Tregs (S. Martin et al., 2010).  As CD40 has been consistently found to be decreased on type 
II MΦ (Tierney et al., 2009), the possible role of CD40 levels in T cell biasing by classically 
and type II MΦ was investigated.   
 
A study by Loke and Allison (2003) found that PD-L1 and PD-L2 are differentially regulated 
by T cell cytokines, with PD-L1 being up regulated on MΦ by Th1 cytokines and PD-L2 by 
Th2 cytokines (Loke & Allison, 2003).  This finding suggests PD-L1 and PD-L2 may have 
roles in inhibiting different subsets of T cells.  This idea is further supported by data from 
PD-L1 deficient mice with EAE and L. mexicana infection.  In EAE, where Th1 responses are 
detrimental, PD-L1 deficiency results in increased disease severity, whereas in L. mexicana 
infection where Th1 responses are protective PD-L1 deficiency is not detrimental (Carter et 
al., 2007; Liang et al., 2006).  Together these studies suggest that without PD-L1, Th1 
responses may be enhanced due to a lack of the inhibitory effect that PD-L1 provides; 
therefore PD-L1 may have a role in regulating Th1 responses over Th2.  The decrease in 
PD-L1 on type II MΦ does not have a large effect on the proliferation of T cells in vitro as 
seen in chapter 3, however, it is possible that the decrease in PD-L1 may be involved in T cell 
biasing.  Although the association of PD-L1 with T cell responses is to inhibit Th1 responses, 
there is some evidence that it is also capable of promoting T cell responses (Wang et al., 
2003).  Therefore, it is possible that the level of signalling through PD-1 by PD-L1, or the 
environment in which the T cell is stimulated may be relevant.  To this end, the potential of 
PD-L1 to influence T cell biasing was investigated. 
 
Finally, previous results from this thesis have shown that in addition to affecting the Th1/Th2 
dichotomy, type II activated MΦ also induce an increase in IL-17A production.  As the 
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IL-17A producing Th17 subsets had not been identified at the time of the initial study into T 
cell biasing by type II MΦ (Anderson & Mosser, 2002), IL-17A production was not 
investigated in this study.  Therefore, the pathways involved in IL-17A production by T cells 
cultured with type II MΦ and the factors involved in the modulation of the level of IL-17A 
have not previously been investigated. 
 
4.2 Aims 
The aim of this study was to investigate potential pathways involved in T cell biasing by type 
II MΦ compared to classically activated MΦ.  These pathways include both soluble factors 
and cell surface markers that are differentially expressed on type II activated MΦ (i.e. IL-12, 
IL-10, CD40, and PD-L1). 
 
4.2.1 Specific aims 
1. To investigate the effect of blocking or enhancing IL-10 and IL-12 on MΦ alone. 
2. To investigate the effect of blocking or enhancing IL-10 and IL-12 on T cell biasing 
by classically compared to type II activated MΦ. 
3. To investigate the effect of inhibiting the CD40/CD40L pathway on T cell biasing by 
classically compared to type II activated MΦ. 
4. To investigate the effect of enhancing or inhibiting the PD-1/PD-L1 pathway on T cell 
biasing by classically compared to type II activated MΦ. 
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4.3 Results 
In order to investigate possible pathways involved in T cell biasing, recombinant cytokines 
were employed and in addition, cytokine blocking antibodies were used to neutralise IL-10 
and IL-12 or inhibit CD40:CD40L (MΦ:T cell) or PD-L1:PD-1 (MΦ:T cell) interactions.  
Because MΦ express FcR, which bind the constant region of antibodies, it is possible that 
non-specific ligation by antibodies could alter the function or phenotype of the MΦ and this 
possibility must be addressed first.  Indeed, the IC used in this study works by interacting with 
FcγR (Sutterwala et al., 1998), and the high density of antibodies on the IC crosslinks the 
FcγR which along with TLR-4 ligation, results in type II activation (Gallo, Gonçalves, & 
Mosser, 2010).  As IC are washed before use to remove any unbound antibody, it is unlikely 
that there are free antibodies present in cultures containing IC.  While individual antibodies 
(i.e. not IC) are unlikely to cross link the receptors as strongly, they may have a weaker effect 
on MΦ.  Therefore, isotype control antibodies were employed to assess the non-specific effect 
of antibodies on MΦ:T cell interactions.  Different isotype control antibodies were employed 
based on the isotype of the blocking antibody in question. 
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4.3.1 Effect of blocking or enhancing IL-10 and IL-12 on MΦ activation states 
In order to assess how IL-10 and IL-12 are involved in T cell biasing by type II and 
classically activated MΦ, the direct effect of these cytokines on MΦ activation was assessed 
using blocking antibodies for IL-10 and IL-12, or recombinant cytokines.  Additionally, the 
temporal involvement of these cytokines was investigated by comparing the effects of altering 
the cytokine balance at the time of stimulation or 4 hours post stimulation (i.e. when the 
T cells will be added in co-culture experiments).  Because the comparative phenotype of 
classically activated and type II activated MΦ, and their effects on T cells, was specifically 
evaluated in Chapter 3, for the following experiments, which investigate the effect of 
inhibiting or activating specific pathways of classical or type II activated MΦ and their 
interactions with T cells, these groups will be analysed independently.  This approach was 
selected because it is likely that these treatments will have different effects on these two 
distinct MΦ populations (i.e. there will be an interaction between the type of MΦ and the 
treatments). 
 
The addition of recombinant IL-10 (rIL-10) to MΦ cultures decreased the production of IL-12 
when added at the time of MΦ stimulation but had no effect if added 4 hours post stimulation 
(Figure 4.1b).  The almost complete inhibition of IL-12 production by the addition of rIL-10 
was observed in both type II and classically activated cultures.  As expected, IL-10 was 
readily detected in cultures containing rIL-10 (Figure 4.1a).  These results confirm that the 
presence of high levels of IL-10 at the time of MΦ stimulation can abolish IL-12 production 
in both classically and type II activated MΦ and suggests that an early production of IL-10 by 
type II MΦ may be involved in the decreased level of IL-12 produced by type II MΦ.  While 
the addition of excess IL-10 at the time of stimulation abolished IL-12 production, the effect 
of IL-10 induced by type II activation on IL-12 needed to be assessed.  In cultures containing 
a blocking antibody against IL-10 (αIL-10), no IL-10 was detected in the culture supernatants 
(Figure 4.1a).  As the blocking antibody and the antibody used for detection of IL-10 by 
ELISA are the same, it is likely that there is still IL-10 in present in the supernatant; however, 
this is unlikely to be biologically active as it is antibody bound.  The addition of αIL-10 did 
not alter the production of IL-12 by either classically activated or type II MΦ (Figure 4.1b).  
This is consistent with previous work in our laboratory that demonstrated that blocking IL-10 
at the time of stimulation does not alter the production of IL-12 by classically or type II 
activated MΦ (Kharkrang, 2010).   
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In contrast to the decreased IL-12 production by the addition of rIL-10, supplementing the 
cultures with recombinant IL-12 protein (rIL-12p70) did not have a significant effect on IL-10 
production when added with the stimuli or 4 hours post stimulation (Figure 4.2a).  By 
24 hours post-stimulation, the level of IL-12 in LPS-stimulated cultures with and without the 
additional rIL-12 were similar (Figure 4.2a).  The addition of a blocking antibody against IL-
12 (αIL-12) significantly reduced the amount of IL-12 detectable in the culture supernatant of 
both classically and type II activated MΦ (Figure 4.2b).  However, the addition of the isotype 
control antibody did cause a slight but significant decrease in IL-12 in cultures containing 
type II MΦ, demonstrating a non-specific effect may account for a small amount of the 
change, this effect was small compared to the effect of αIL-12 (Figure 4.2b).  Furthermore, 
there was no significant change in the level of IL-10 in the presence of the αIL-12 (Figure 
4.2a).  As with αIL-10, the antibody used for blocking and detection of IL-12 by ELISA are 
the same, thus, while it is likely that IL-12 is still present in the culture supernatant it will be 
antibody bound and will therefore likely be inactive.  Together these results suggest that the 
reduced IL-12 produced by type II activated MΦ is not responsible for the enhanced IL-10 
production.  Together these results suggest that any effect of blocking IL-12 in MΦ:T cell 
co-cultures would be due to the absence of IL-12 alone and not due to a downstream 
enhancement in IL-10 by the MΦ.   
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Figure 4.1.  Increasing the level of IL-10 in BMMΦ cultures at the time of stimulation 
decreased IL-12 production, however addition of a blocking antibody for IL-10 did not 
affect the levels of IL-12 in culture supernatants.  BMMΦ from C57BL/6 mice were plated 
at 1x105 and primed with 20 U/ml IFN-γ overnight before stimulation with LPS (200 ng/ml) 
alone or with IC (10 IC per MΦ) for 24 hours.  rIL-10 (5 ng/ml), αIL-10 (JES5-2A5, 2 µg/ml) 
or rat isotype (IgG1, 2 µg/ml) was added to cultures either with the stimuli (0 hour) or 4 hours 
post stimulation.  IL-10 (a) and IL-12p40 (b) levels were measured by ELISA.  Shown are the 
means and SEM of triplicate wells from one (rIL-10) or two (aIL-10) experiment.  *p<0.05, 
****p<0.0001 by a one-way ANOVA with Tukey’s multiple comparison post test, stars 
indicate comparison to no Ab/protein. 
 
a. 
b. 
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Figure 4.2.  Altering the level of IL-12 in BMMΦ cultures did not have a significant 
effect on IL-10 levels in culture supernatants.  BMMΦ from C57BL/6 mice were plated at 
1x105 and primed with 20 U/ml IFN-γ overnight before stimulation with LPS (200 ng/ml) 
alone or with IC (10 IC per MΦ) for 24 hours.  rIL-12p70 (5 ng/ml), αIL-12 (C15.6, 2 µg/ml) 
or rat isotype (IgG1, 2 µg/ml) was added to cultures either with the stimuli (0 hour) or 4 hours 
post stimulation.  IL-10 (a) and IL-12p40 (b) levels were measured by ELISA.  Shown are the 
means and SEM of triplicate wells from two or more experiments.  ****p<0.0001 by a one-
way ANOVA with Tukey’s multiple comparison post test, stars indicate comparison to IgG1. 
 
a. 
b. 
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4.3.2 Effect of blocking or enhancing IL-10 and IL-12 on the ability of classically and 
type II MΦ to bias the T cell response 
 
4.3.2.1 Altering IL-10 levels in MΦ:T cell co-cultures 
Similar to the neutralisation of IL-10 in MΦ only cultures (Figure 4.1 and Kharkrang, 2010), 
the addition of αIL-10 to MΦ:T cell co-cultures significantly decreased the level of detectable, 
and likely bioactive, IL-10 (Figure 4.3a).  The addition of αIL-10 did not have a significant 
effect on the production of IL-12 (Figure 4.3b).  This result demonstrates that the effect of the 
blocking antibody was similar in MΦ:T cell co-cultures compared to cultures with MΦ alone.  
The levels of IL-10 in culture supernatant where higher when rIL-10 was added with the 
T cells compared to addition with the MΦ stimuli (Figure 4.3a) possibly due to higher uptake 
when rIL-10 was added with the MΦ.   
 
Consistent with the results seen in Figure 4.1, the addition of rIL-10 decreased the production 
of IL-12 by both classical and type II activated MΦ when added at the time of MΦ 
stimulation (Figure 4.3b).  This result indicates that the MΦ phenotype is maintained during 
the MΦ:T cell co-culture.  The addition of αIL-10 or rIL-10 did not change the expression of 
the activation markers CD44 and CD62L significantly nor did the addition of αIL-10 or rIL-
10 significantly alter the levels of CD25 and IL-2 (see appendix C).   
 
Although no difference was detected in T cell activation parameters, the addition of αIL-10 
resulted in increased IFN-γ levels produced by T cells cultured with type II and classically 
activated MΦ, this increase was significant compared to the isotype control (Figure 4.4a).  
This elevation suggests that an increased production of IL-10 by type II MΦ may be at least 
partly responsible for the decreased production of IFN-γ by T cells when cultured with type II 
MΦ.  In the same manner that the neutralisation of IL-10 led to increased IFN-γ production, 
the addition of rIL-10 to MΦ:T cell co-cultures resulted in decreased the production of IFN-γ 
from T cells stimulated by both classically and type II activated MΦ (Figure 4.4a).  However, 
this decrease only occurred when rIL-10 was added to the co-cultures at the time of MΦ 
stimulation and not when the rIL-10 was added at the same time as the T cells (Figure 4.4a).  
This early effect suggests that the IL-10 may be acting primarily on the MΦ, as opposed to on 
the T cells directly, and that the effect of the IL-10 occurs in the first 4 hours of stimulation.   
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Additionally, despite the changes in IFN-γ production, αIL-10 did not have a significant effect 
on the level of IL-17A in supernatants from T cells cultured with either classical and type II 
activated MΦ, although a non-significant trend toward increased levels exists in the presence 
of αIL-10, suggesting that the increased production of IL-17A by T cells cultured with type II 
MΦ is not a result of increased IL-10 in these cultures (Figure 4.4b).  Furthermore, the 
addition of rIL-10 at the time of MΦ stimulation reduced the level of IL-17A production in 
cultures containing classically activated MΦ but had no significant effect in cultures 
containing type II MΦ (Figure 4.4b).  This suggests that the increased IL-10 production by 
type II MΦ was not likely to be responsible for the increase IL-17A in these cultures.  Finally, 
the level of CD124 was not altered by the addition of αIL-10 or rIL-10 (Figure 4.4c), 
suggesting that if IL-10 contributes to Th2 biasing by type II MΦ, it is not by increasing the 
sensitivity of T cells to IL-4. 
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Figure 4.3.  The effect of αIL-10 and rIL-10 on IL-10 and IL-12 production by MΦ was 
maintained in MΦ:T cell co-culture.  BMMΦ were stimulated with IFN-γ (20 U/ml) 
overnight and then cultured with LPS (200 ng/ml) with or without IC (10 per MΦ).  After four 
hours, purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were added to the MΦ cultures for 
72 hours.  rIL-10 (5 ng/ml), αIL-10 (JES5-2A5, 2 µg/ml) or rat isotype (IgG1, 2 µg/ml) was 
added to cultures either with the stimuli (0 hour) or with the T cells (4 hour).  IL-10 (a) and 
IL-12 (b) were measured by ELISA.  Shown are the means and SEM of triplicate wells from 
three or more experiments, IL-12 data is presented as a percentage of LPS with no 
antibody/protein.  *p<0.05, and ****p<0.0001 by one-way ANOVA with Tukey’s multiple 
comparison post test, stars indicate comparison to no Ab/protein for recombinant proteins and 
to IgG1 for blocking antibodies.   
a. 
b. 
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Figure 4.4.  Altering IL-10 levels in BMMΦ:T cell co-cultures affected IFN-γ levels but 
not IL-17A levels or CD124 expression on T cells.  BMMΦ were stimulated with IFN-γ (20 
U/ml) overnight and then cultured with LPS (200 ng/ml) with or without IC (10 per MΦ).  
After four hours, purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were added to the MΦ 
cultures for 72 hours.  rIL-10 (5 ng/ml), αIL-10 (JES5-2A5, 2 µg/ml) or rat isotype (IgG1, 
2 µg/ml) was added to cultures either with the stimuli (0 hour) or with the T cells (4 hour).  
IFN-γ (a) and IL-17A (c) were measured in the culture supernatant by ELISA, and CD124 (b) 
expression was measured by flow cytometry.  Shown are the means and SEM of triplicate 
wells from three or more experiments, IL-17A data is presented as a percentage of LPS with 
no antibody/protein.  *p<0.05, ****p<0.0001 by one-way ANOVA with Tukey’s multiple 
comparison post test, stars indicate comparison to no Ab/protein for recombinant proteins and 
to IgG1 for blocking antibodies. 
a. 
b. 
c. 
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4.3.2.2 Altering IL-12 levels in MΦ:T cell co-cultures 
To further investigate the role of MΦ cytokines in T cell biasing, the IL-12 pathway was 
assessed.  The addition of αIL-12 to MΦ:T cell cultures resulted in a significant decrease in 
the detectable levels of IL-12 in cultures containing classical or type II activated MΦ when 
added both with the MΦ stimuli and with the T cells (Figure 4.5b).  This change was 
consistent with adding αIL-12 to MΦ alone (Figure 4.2b), although the level of IL-12 
remaining in MΦ:T cell cultures containing αIL-12 suggests that the cytokine was not 
completely neutralised (Figure 4.5b).  Although the IL-12 was not completed blocked, the 
levels in the MΦ:T cell co-cultures were significantly decreased and resulted in altered 
responses such as the decrease in IFN-γ described bellow (Figure 4.6a).  Neutralisation of IL-
12 in MΦ:T cell cultures did not significantly alter the production of IL-10.  There was a 
non-significant trend towards reduced levels of IL-10 when added at the time of MΦ 
stimulation, however, there was also a change seen with the isotype control antibody in 
cultures containing classically activated MΦ, suggesting the possibility of some non-specific 
effects with the IL-10 level (Figure 4.5a).  To further study the IL-12 pathway, rIL-12 was 
used.  The addition of rIL-12 to MΦ:T cell co-cultures did not alter the levels of IL-10 
produced (Figure 4.5a).  There was a trend towards increased levels of IL-12 which was 
significant in cultures containing classically activated MΦ, when rIL-12 was added with the T 
cells (Figure 4.5b).  This relatively small change in IL-12 levels may have been be due to the 
high levels of IL-12 present in these cultures even in the absence of rIL-12, and this small 
increase could easily have been absorbed by the level of IL-12 produced after 72 hours in 
culture.   
 
While the addition of αIL-12 or rIL-12 in MΦ:T cell co-cultures did not affect the activation 
state of the T cells cultured with either classically or type II activated MΦ as evidenced by 
similar expression of CD44, CD62L, CD25, and IL-2 (See appendix C), T cell biasing was 
altered.  In particular, IFN-γ production was significantly decreased in co-cultures containing 
either classically and type II activated MΦ.  This decrease was evident when αIL-12 was 
added with the MΦ stimuli or the T cells (Figure 4.6a).  Moreover, this change in IFN-γ 
production correlated with the decreased levels of IL-12 seen with the addition of αIL-12 
(Figure 4.5b).  The addition of rIL-12 caused a significant increase in the level of IFN-γ 
produced by T cells cultured with type II activated MΦ. This increase was not observed in co-
cultures with classically activated MΦ and was evident when the rIL-12 was added either at 
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the time of MΦ stimulation or at the time of T cell addition (Figure 4.6a).  Furthermore, the 
increase in IFN-γ production only in type II MΦ co-cultures after rIL-12 addition suggests 
that the decreased level of IL-12 may be at least partly responsible for the decreased level of 
IFN-γ produced by T cells cultured with type II MΦ.   
 
IL-17A levels were not altered by the addition of rIL-12, nor were they altered by the addition 
of αIL-12 (Figure 4.6b).  IL-17A is increased in MΦ:T cell co-cultures containing type II MΦ 
compared to classically activated MΦ and these type II MΦ:T cell co-cultures also have 
decreased levels of IL-12.  These data suggest that the decreased level of IL-12 produced by 
type II MΦ is not responsible for the increased IL-17A.  Additionally, neither adding αIL-12 
or rIL-12 reduced the level of CD124 on T cells (Figure 4.6c), suggesting the increased 
sensitivity of T cell cultured with type II MΦ is not due to the decreased IL-12 found in these 
cultures. 
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Figure 4.5.  The effect of αIL-12 and rIL-12 on IL-10 and IL-12 production by MΦ was 
maintained in MΦ:T cell co-culture.  BMMΦ were stimulated with IFN-γ (20 U/ml) 
overnight and then cultured with LPS (200 ng/ml) with or without IC (10 per MΦ).  After four 
hours, purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were added to the MΦ cultures for 
72 hours.  rIL-12p70 (5 ng/ml), αIL-12 (C15.6, 2 µg/ml) or rat isotype (IgG1, 2 µg/ml) was 
added to cultures either with the stimuli (0 hour) or with the T cells (4 hour).  IL-10 (a) and 
IL-12 (b) was measured by ELISA.  Shown are the means and SEM of triplicate wells from 
two or more experiments, IL-12 data is presented as a percentage of LPS with no 
antibody/protein.  *p<0.05, **p<0.01 and ****p<0.0001 by one-way ANOVA with Tukey’s 
multiple comparison post test, stars indicate comparison to no Ab/protein for recombinant 
proteins and to IgG1 for blocking antibodies.   
 
 
a. 
b. 
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Figure 4.6.  Altering IL-12 levels in BMMΦ:T cell co-cultures affected IFN-γ levels but 
not IL-17A levels or CD124 expression on T cells.  BMMΦ were stimulated with IFN-γ (20 
U/ml) overnight and then cultured with LPS (200 ng/ml) with or without IC (10 per MΦ).  
After four hours, purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were added to the MΦ 
cultures for 72 hours.  rIL-12p70 (5 ng/ml), αIL-12 (C15.6, 2 µg/ml) or rat isotype (IgG1, 2 
µg/ml) was added to cultures either with the stimuli (0 hour) or with the T cells (4 hour).  
IFN-γ (a) and IL-17A (c) were measured in the culture supernatant by ELISA, and CD124 (b) 
expression was measured by flow cytometry.  Shown are the means and SEM of triplicate 
wells from three or more experiments, IL-17A data is presented as a percentage of LPS with 
no antibody/protein.  *p<0.05 and ****p<0.0001 by one-way ANOVA with Tukey’s multiple 
comparison post test, stars indicate comparison to no Ab/protein for recombinant proteins and 
to IgG1 for blocking antibodies. 
a. 
b. 
c. 
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4.3.3 Effects of alterations to the PD-1/PD-L1 pathway on the ability of classically and 
type II MΦ to bias the T cell response 
 
Because the changes in IL-10 and IL-12 production by type II and classically activated MΦ 
could account primarily for changes in IFN-γ production and not other markers of Th biasing 
such as CD124 and IL-17A, other pathways known to be altered in type II activation were 
investigated.  Specifically, previous work has shown that the expression of both CD40 and 
PD-L1 is significantly reduced on type II activated MΦ compared to classically activated MΦ 
(Tierney et al., 2009) and these molecules play key roles in MΦ:T cell interactions.  To study 
the PD-1/PD-L1 pathway, a blocking antibody for PD-1 (αPD-1) and a PD-L1 chimeric 
protein (PD-L1ch) were used.  The αPD-1 antibody binds to the PD-1 receptor on the T cells 
and prevents interaction with molecules on the MΦ.  As αPD-1 targets the PD-1 receptor on 
the T cells, it will inhibit interaction with both PD-L1 and PD-L2.  However, type II and 
classically activated MΦ express only very low levels of PD-L2 (Tierney et al., 2009), and so 
it is likely that any effects of blocking PD-1 will be due to changes in interaction with PD-L1.  
The PD-L1ch protein is a chimera of murine PD-L1 and Fc fragment of human IgG1 
connected via a peptide linker (IEGRMD).  The PD-L1ch binds to and stimulates PD-1, 
mimicking the effect of PD-L1 on the MΦ cell surface.   
 
To find the optimum concentration of αPD-1 a titration of the antibody was performed.  The 
addition of the αPD-1 antibody did not appear to have a large effect on IFN-γ, IL-17A or IL-2 
production or CD124 expression (see appendix C), however, the greatest change appeared to 
occur at 2 µg/ml, therefore this concentration was chosen for further study.  To help determine 
that the effects observed were due to the blocking of the PD-1/PD-L1 pathway, and not a 
result of the antibodies binding to the FcγR on the MΦ, an isotype control was also used.  
Similar to αPD-1, the effect of the PD-L1ch was titrated in MΦ:T cell co-culture conditions 
and was compared to the control protein.  Addition of the PD-L1ch appeared to have little 
effect on IFN-γ, IL-17A and CD124, while IL-2 showed a trend towards decreased production 
at higher concentrations (see appendix C).  Due to this decrease in IL-2 production, 8 µg/ml 
was selected for the subsequent experiments.   
 
 
As expected, addition of αPD-1 to block PD-1 signalling on T cells did not affect the 
production of IL-10 and IL-12 by MΦ in the co-cultures (Figure 4.7).  There was also no 
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significant difference in the expression of CD44, CD62L and CD25 following the addition of 
αPD-1 or the PD-L1ch (see appendix C).  Addition of the αPD-1 antibody significantly 
reduced the production of IL-2, and there was a trend towards decreased levels of IL-2 in the 
presents of the PD-L1ch (Figure 4.8c).  However, these changes were also seen with the 
isotypes, suggesting this is a non-specific effect.  Despite the decrease in IL-2 production, the 
αPD-1 and PD-L1ch did not appear to alter the production of other cytokines or markers 
associated with Th biasing significantly.  IFN-γ, CD124 and IL-17A were all unaltered by the 
presence of αPD-1, and additionally, IL-17 was not affected by the PD-L1ch (Figure 4.8a, b 
and d).  Both IFN-γ and CD124 decreased in the presence of the PD-L1ch, however, this 
change was not significant, and changes in the control protein make these results difficult to 
interpret.  Additionally, as there is no change in the parameters measured, a second possibility 
is that the αPD-1 and the PD-L1ch are not active in this system.  Overall, these data suggest 
that altering the PD-1/PD-L1 pathway with the addition of αPD-1 does not have a strong 
affect on the activation state of T cells nor their biasing in this MΦ:T cell co-culture system, 
this result should be confirmed using another method, such as RNAi and positive controls.   
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Figure 4.7.  Blocking or stimulating the PD-1/PD-L1 pathway in MΦ:T cell co-culture 
did not affect IL-10 or IL-12 production by MΦ.  BMMΦ were stimulated with IFN-γ (20 
U/ml) overnight and then cultured with LPS (200 ng/ml) with or without IC (10 per MΦ).  
After four hours, purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were added to the MΦ 
cultures for 72 hours.  αPD-1 (2 µg/ml, RMP1-14), rat isotype (2 µg/ml, IgG2a), PD-L1ch (8 
µg/ml) or control protein (8 µg/ml) was added.  IL-10 (a) and IL-12 (b) were measured by 
ELISA.  Shown are the means and SEM of triplicate wells from one-four (IL-10) or three-six 
(IL-12) combined experiments.   
 
 
a. 
b. 
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Figure 4.8.  Blocking or stimulating the PD-1/PD-L1 pathway did not affect T cell 
biasing in MΦ T cell co-culture.  BMMΦ were stimulated with IFN-γ (20 U/ml) overnight 
and then cultured with LPS (200 ng/ml) with or without IC (10 per MΦ).  After four hours, 
purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were added to the MΦ cultures for 72 
hours.  αPD-1 (2 µg/ml, RMP1-14), rat isotype (2 µg/ml, IgG2a), PD-L1ch (8 µg/ml) or 
control protein (8 µg/ml) was added.  IFN-γ (a), IL-17A (b) and IL-2 (c) were measured in the 
culture supernatant by ELISA, and CD124 (d) expression was measured by flow cytometry.  
Shown are the means and SEM of triplicate wells from two-six (IFN-γ), two-five (IL-17A) or 
one-five (CD124 and IL-2) combined experiments.  *p<0.05, **p<0.01 by one-way ANOVA 
with Tukey’s multiple comparison post test. stars indicate comparison to no Ab/protein, 
unless otherwise shown.   
 
 
a. b. 
c. d. 
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4.3.5 Blocking the CD40/CD40L pathway in MΦ:T cell co-cultures 
Due to the decreased expression of CD40 seen on type II MΦ (Tierney et al., 2009), as well as 
the proposed link between the strength of the CD40 signal and T cell biasing, the role of 
CD40 in T cell biasing by type II MΦ was investigated.  To explore the role of CD40, an 
antibody specific for the CD40L (αCD40L) was added to the cultures, this antibody binds to 
CD40L and prevents interaction with CD40, effectively inhibiting signalling through the 
CD40 pathway.  To find the optimum antibody concentration to inhibit CD40/CD40L 
interaction the effect of the antibody was titrated from 0.5-8 µg/ml.  Titration of the αCD40L 
demonstrated that production of several cytokines (IFN-γ, IL-17A and IL-2) as well as the 
expression of CD124 was maintained across all doses of αCD40L (see appendix C).  In 
contrast, the isotype control hamster, which controls for non-specific antibody effects, 
demonstrated decreased levels of all of these markers (see appendix C).  A concentration of 
4 µg/ml of αCD40L was chosen for further investigation because this concentration 
demonstrated a large difference between the αCD40L antibody and the isotype control, 
without the complete abrogation in IL-2 production seen when using 8 µg/ml isotype control 
(see appendix C).   
 
The addition of αCD40L to MΦ T cell co-cultures did not alter the levels of IL-12 produced, 
and there was a significant increase in IL-10 production in cultures containing classically 
activated MΦ.  However, there was considerable variability in the data, with some changes 
also evident in the isotype control (Figure 4.9).  The presence of αCD40L did not induce a 
change in the expression of CD44, CD62L and CD25 (see appendix C).  Since these markers 
are all associated with T cell activation, this finding suggests that decreasing CD40 signalling 
does not affect the activation state of the T cells.  While there was a trend towards lower 
production of IL-2 in the presence of αCD40L, a similar decrease was seen with the isotype 
control, suggesting that this change was a non-specific effect caused by the presence of 
antibody (Figure 4.10c).   
 
Reduced levels of CD40 signalling have been associated with Th2 responses and in addition 
the absence of CD40 signalling has been shown to abolish Th2 responses.  Due to the 
decreased expression of CD40 on type II MΦ, this signalling pathway is likely to be reduced 
compared to signalling on classically activated MΦ.  It was therefore hypothesised that the 
greatest effect of blocking CD40 signalling in this system would be on Th biasing and 
specifically Th2 responses.  In contrast to expectations, while IL-17A and CD124 expression 
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were unaltered by the addition of αCD40L (Figure 4.10b and c), IFN-γ production was 
altered.  MΦ:T cell co-cultures with αCD40L showed a trend towards increased IFN-γ and 
this increase was observed in co-cultures with either classically and type II activated MΦ 
(Figure 4.10a).  In the experiment shown, there was a significant effect of using the isotype 
control antibody, which reduced IFN-γ production.  Because this effect was opposite to that of 
adding αCD40L, this effect is likely to be specific to αCD40L and not due to the presence of 
antibody in general.  However, this result needs to be cautiously interpreted (Figure 4.10a).  
These experiments suggest that inhibiting CD40 signalling may enhance IFN-γ but has little 
effect on IL-17A or CD124.  However, the possibility that the antibody is not active should be 
taken into account when assessing this data.  Taken together, these findings suggest that the 
decrease of CD40 on type II MΦ is not involved in the increase in IL-17A production or the 
increased sensitivity of these cells to IL-4 nor can it explain the reduced IFN-γ produced by T 
cells stimulated by type II activated macrophages. 
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Figure 4.9.  Blocking the CD40/CD40L pathway did not significantly affect the 
production of IL-10 and Il-12 by MΦ in MΦ:T cell co-cultures.  BMMΦ were stimulated 
with IFN-γ (20 U/ml) overnight and then cultured with LPS (200 ng/ml) with or without IC 
(10 per MΦ).  After four hours, purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were 
added to the MΦ cultures for 72 hours.  4 µg/ml of αCD40L (MR1) or hamster isotype control 
antibody (IgG1) was added.  IL-10 (a) and IL-12 (b) was measured by CBA and ELISA.  
Shown are the means and SEM of triplicate wells from one of two experiments (IL-12) or 2 
combined IL-10. *p<0.05 by one-way ANOVA with Tukey’s multiple comparison post test.   
a. b. 
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Figure 4.10.  Blocking the CD40/CD40L pathway induced a non-significant increase in 
IFN-γ production by T cells cultured with classically and type II activated MΦ but did 
not alter IL-17A production or CD124 expression.  BMMΦ were stimulated with IFN-γ 
(20 U/ml) overnight and then cultured alone or with LPS (200 ng/ml) with or without IC 
(10 per MΦ).  After four hours, purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were 
added to the MΦ cultures for 72 hours.  4 µg/ml of αCD40L or hamster isotype control 
antibody (IgG1) was added.  IFN-γ (a), IL-17A (b) and IL-2 (c) were measured in the culture 
supernatant by CBA and ELISA, and CD124 (d) expression was measured by flow cytometry.  
Shown are the means and SEM of triplicate wells from one of two (IFN-γ, IL-17A and IL-2) 
or data from one of two (CD124) experiments.  *p<0.05 and **p<0.01 by one-way ANOVA 
with Tukey’s multiple comparison post test.   
 
a. b. 
d. 
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4.4 Discussion 
This chapter focused on elucidating the pathways involved in the biasing of T cells by type II 
and classically activated MΦ.  Anderson and Mosser (2002) initially attributed the T cell 
biasing by type II MΦ to their altered level of IL-10 and IL-12 production.  This conclusion 
was based on experiments using IL-12 and IL-10 deficient MΦ, however, the phenotype of 
these MΦ was altered by the deletion of these genes, which complicates the results and makes 
their interpretation challenging (Anderson & Mosser, 2002).  In the current study, blocking 
antibodies and recombinant proteins were used to assess the effect of IL-10 and IL-12 on 
T cell biasing by classically and type II activated MΦ.  As stated in the results section, the 
blocking antibodies for IL-10 and IL-12 are also used in detection, thus it is likely that IL-10 
and IL-12 still exist in the cultures but are antibody bound, this could be confirmed using an 
antibody that binds a different epitope of the cytokines 
 
IL-10 is well known to have inhibitory effects on MΦ, and has been shown to reduce the 
production of several proinflammatory cytokines produced by MΦ including IL-12 
(Kobayashi et al., 2012; Moore, de Waal Malefyt, Coffman, & O’Garra, 2001).  IL-10 
produced by MΦ can act in an autocrine manner to reduce IL-12 production (Sica et al., 
2000).  Consistent with previous results from our laboratory, blocking IL-10 did not alter the 
level of IL-12 production by MΦ alone in this system (Kharkrang, 2010).  These results 
suggest that IL-10 production by type II MΦ is not responsible for the down regulation of 
IL-12 seen in this activation state.  However further increase in IL-10 levels by the addition of 
rIL-10 decreased the production of IL-12 when added at the time of MΦ stimulation, but not 
when added 4 hours post stimulation.  The absence of a change in IL-12 when the rIL-10 was 
added at 4 hours could be due to the IL-10 being ineffective or not at a high enough 
concentration to alter an already established response, alternatively this may potentially be 
due to the IL-12 not being taken up by the MΦ.  Therefore, the addition of rIL-10 may have 
effectively stopped further IL-12 production by the MΦ, but the IL-12 produced by MΦ in the 
4 hours before rIL-10 addition may still be present in the supernatant.  However, previous 
work in our laboratory has demonstrated that IL-12 production by classically and type II 
activated MΦ is very low up to 4 hours post stimulation (Kharkrang, 2010).  This suggests the 
IL-12 present when rIL-10 is added to cultures at 4 hours is a result of the rIL-10 being 
ineffective at this time point and not IL-12 left over from early production.   
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It has previously been shown that MΦ can become less responsive to IL-10 following LPS 
stimulation.  Alveolar MΦ stimulated with LPS exhibit decreased responsiveness to IL-10 due 
to inhibited signalling through the IL-10 receptor.  Also, pre-treating peritoneal MΦ with LPS 
decreased the ability of IL-10 to inhibit ceramide-induced TNF-α production (Fernandez, 
Jose, Avdiushko, Kaplan, & Cohen, 2004).  Therefore it is likely that the MΦ in the current 
study had reduced responsiveness to IL-10 after 4 hours in culture, and therefore, addition of 
rIL-10 after 4 hours in culture did not induce down regulation of IL-12.   
 
Addition of αIL-12 to MΦ cultures successfully reduced detectable IL-12 levels without 
having a significant effect on IL-10 production, although there was a non-significant trend 
towards decreased levels of IL-10.  rIL-12 did not induce a significant change in either IL-10 
or IL-12.  While MΦ express the receptor for IL-12 (Grohmann et al., 2001; Kataoka, 
Komazawa, Oboki, Morii, & Nakano, 2004) and signalling through the IL-12 receptor can 
further enhance IL-12 production (Grohmann et al., 2001), the amount of rIL-12 (5 ng/ml) 
may not have been enough to alter the levels of IL-10 and IL-12 in this culture, given the high 
level of IL-12 produced by the MΦ themselves.   
 
In MΦ:T cell co-culture conditions, altering the levels of IL-10 and IL-12 through blocking 
antibodies and recombinant cytokines had little effect on the activation state of the T cells.  
Earlier studies in this thesis (Chapter 3) identified 3 molecules that were differentially 
expressed on T cells cultured with classically or type II MΦ; these were IFN-γ, IL-17A and 
CD124.  IFN-γ levels were significantly affected by increasing or decreasing the amount of 
IL-10 or IL-12 in culture, however, IL-17A and CD124 were not significantly affected in 
most cases (Table 4.1).  The PD-1/PD-L1 and CD40/CD40L pathways did not have strong 
effects on the biasing of T cell responses by type II and classically activated MΦ (Table 4.1).  
The effects seen with αIL-10 and αIL-12 were in line with the current literature  For example, 
αIL-12 neutralised IL-12 efficiently and inhibited IFN-γ production.  Since as IL-12 is known 
to be essential for Th1 development, this result is in line with previous reports (Kaplan et al., 
1996; Zhu et al., 2010).  This data supports the set up of the current assay and suggests it is 
working as expected. 
 
IL-10 is an anti-inflammatory cytokine known to reduce the production of IFN-γ by T cells 
and has been implicated in T cell biasing by type II activated MΦ (Anderson & Mosser, 
2002).  IL-10 mediates the majority of its effects by inducing down regulation of 
inflammatory cytokines and co-stimulatory molecules on APC (Ding, Linsley, Huang, 
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Germain, & Shevach, 1993; Fiorentino, Zlotnik, Mosmann, Howard, & O’Garra, 1991; 
Fiorentino, Zlotnik, Vieira, et al., 1991).  This includes inhibiting production of IL-12 by APC 
(Kobayashi et al., 2012).  As IL-12 is important in Th1 development, this decrease in IL-12 
inhibits Th1 biasing and thus IFN-γ by T cells (Kaplan et al., 1996; Moore et al., 2001).  
However, T cells do express receptors for IL-10, and IL-10 is capable directly acting on 
T cells to inhibit the production of cytokines (Couper, Blount, & Riley, 2008; Naundorf et al., 
2009).   
 
When αIL-10 was added to MΦ:T cell co-cultures at the time of MΦ stimulation, T cells 
cultured with type II and classically activated MΦ significantly increased production of IFN-
γ.  Despite a similar decrease in IL-10 levels when the αIL-10 was added with the T cells, 
there was no increase in IFN-γ in these cultures.  This suggests that in the 4 hours between the 
stimulation of the MΦ and the addition of T cells, the IL-10 present in the cultures may have 
acted on the MΦ in an autocrine manner to induce a change in phenotype, and that the effect 
of the decrease in the IL-10 is due to direct effects on the MΦ and not on the T cells.  IL-12 is 
not altered when IL-10 is blocked however, IL-10 affects other molecules produced by MΦ 
including IL-1, TNF and CD80/CD86 (Ding et al., 1993; Moore et al., 2001).  It is possible 
that autocrine signalling of IL-10 is affecting a pathway other than IL-10 such as 
co-stimulation which have not been measured in the current study.   
 
Increasing the level of IL-10 in MΦ:T cell co-culture supports the role of IL-10 in T cell 
biasing by type II MΦ.  The addition of rIL-10 to cultures resulted in a significant decrease in 
IFN-γ production, which correlated with decreased production of IL-12.  Similar to the results 
seen in MΦ cultured alone, and in MΦ:T cell cultures with the addition of αIL-10, this change 
was only observed when the rIL-10 was added at the time of MΦ stimulation and not when it 
was added with the T cells.  IL-10 is known to inhibit IL-12 production (Kobayashi et al., 
2012; Moore et al., 2001), and as IL-12 is a key cytokine in the induction of Th1 cells, the 
reduction of IFN-γ is to be expected.  These results suggest that the IL-10 may be involved in 
the regulation of IFN-γ by type II MΦ.  The amount of rIL-10 added to the cultures was 
5 ng/ml.  This amount of IL-10 is higher by approximately 2-3 fold than that which is 
detected in the supernatant of cultures containing type II MΦ, which may explain why the 
rIL-10 has a much more dramatic effect than IL-10 produced endogenously by the MΦ in 
culture.  In addition, adding the rIL-10 provides an instant high level of IL-10 that does not 
require production by MΦ, as the rIL-10 can act earlier it may be contributing to the increased 
effectiveness of the exogenous IL-10, compared to that which is produced by MΦ.  The 
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decrease in IFN-γ occurred when the rIL-10 was added when the MΦ were stimulated but not 
when it was added with the T cells, despite the levels of IL-10 being higher when rIL-10 is 
added with the T cells.  This supports the major effect of the IL-10 being on the MΦ, not on 
the T cells directly and that the IL-10 acts on the MΦ soon after stimulation.   
 
Another key cytokine implicated in biasing of T cell responses by classical or type II MΦ is 
IL-12 (Anderson & Mosser, 2002).  When αIL-12 was added at the time of MΦ stimulation a 
trend towards decreased the production of IL-10 was observed, this trend was not seen at 4 
hours, however, the isotype control antibody had some effect in these experiments and thus it 
is possible that this change was non-specific.  However, MΦ have receptors for IL-12 
(Grohmann et al., 2001) and it is possible that a certain level of feedback though these 
receptors is necessary to stimulate IL-10 production, which also may explain this downward 
trend.  IL-12 is a key cytokine in the development of Th1 cells and IFN-γ production (Kaplan 
et al., 1996).  Therefore, it is possible that the decreased IL-12 production by type II MΦ may 
be involved in T cell biasing by reducing signalling through the IL-12 receptor and STAT-4 
activation.  Detectable IL-12 levels were similarly reduced by αIL-12 in conditions containing 
both classical and type II MΦ.  Consistent with the role of IL-12 in Th1 development and 
IFN-γ production; in the current study, blocking IL-12 significantly inhibited the production 
of IFN-γ by T cells cultured with both classically and type II activated MΦ.  This 
demonstrates that in the absence of IL-12 signalling, MΦ were unable to drive Th1 responses 
and is consistent with previous reports (Anderson & Mosser, 2002).  The effects of αIL-12 
were evident when added with the MΦ stimuli and with the T cells, this suggests that the IL-
12 could potentially be acting on the T cells as opposed to directly on the MΦ.  Due to the 
well known effect of IL-12 on T cells to induce Th1 responses, it is likely that this effect is 
due to a reduction in the signalling to T cells and not to an indirect effect on MΦ. 
 
In the current study, addition of rIL-12 did not cause an increase in the levels of IL-12 
detected in the culture supernatants.  However, this does not mean that the rIL-12 is not being 
added at a sufficient level to be having an effect.  Previous work in our laboratory has 
demonstrated that IL-12 production by classical or type II activated MΦ is comparably low at 
2-4 hours of culture (Kharkrang, 2010), this early period of culture corresponds closely to the 
time points rIL-12 is added in the current study.  Therefore, while the level of rIL-12 added to 
cultures is moderate over the entire course of the culture, it is likely that it is causing a 
significant increase in the early time points of the culture.  The rIL-12 could therefore be 
looked upon as an increase in early IL-12.  Given the role of IL-12 in Th1 development an 
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increase in IL-12 may be thought to cause an increase in IFN-γ production.  In the current 
study, addition of rIL-12 did not cause an increase in IFN-γ production in cultures containing 
classically activated MΦ, however, the levels of IFN-γ were significantly increased in type II 
MΦ containing cultures.  This increase in IFN-γ was not only significantly increased 
compared that produced by T cells cultured with type II MΦ in the absence of rIL-12, but also 
increased above the levels produced by cultures containing classically activated MΦ and 
rIL-12.  This suggests that in the presence of exogenous IL-12, type II MΦ may be more 
effective at biasing T cells towards a Th1 response than classically activated MΦ.   
 
The large increase in IFN-γ production occurs only in T cells cultured with type II activated 
MΦ suggesting that there is an intrinsic difference between classically and type II activated 
MΦ in presenting to T cells that extends beyond the IL-12/IL-10 dichotomy.  There are 
several possibilities as to what this difference could be.  Type II activated MΦ are known to 
express lower levels of PD-L1 compared to classically activated MΦ (Tierney et al., 2009).  
PD-L1 is known to have an inhibitory effect on the production of IFN-γ (Schreiner et al., 
2004; Schreiner, Bailey, Shin, Chen, & Miller, 2008; Yamazaki et al., 2005), and there is 
evidence that PD-L1 is particularly important in the regulation of Th1 cells.  The reduction in 
PD-L1 on type II MΦ may result in less of an inhibitory signal to the T cells, and 
consequently a higher production of IFN-γ.  It has also been reported that type II activated 
MΦ increase expression of both MHC class II and CD86 (Edwards et al., 2006), thus it is 
possible that these T cells are receiving an increased stimulatory signal which is leading to 
increased levels of IFN-γ production.   
 
IL-12 has a strong role in inducing T cell biasing, and the results of this study suggest that the 
decreased level of IL-12 produced by type II activated MΦ may play a role in the biasing of 
T cell responses.  In addition to IL-12, it has been proposed that IL-10 may play a role in 
T cell biasing.  IL-10 inhibits IL-12 production by MΦ (Kobayashi et al., 2012); however, in 
this study, blocking IL-10 production did not affect the level of IL-12 produced by MΦ 
cultured alone, suggesting that although IL-10 can act in an autocrine manner (Sica et al., 
2000), increased IL-10 production by type II MΦ is not responsible for the decreased IL-12.  
In MΦ:T cell co-cultures there is no significant change in IL-10 production after IL-12 
blocking.  This result suggests that the effects that blocking IL-10 have on MΦ T cell co-
cultures are independent of changes in IL-12 production.   
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Given the inhibitory role IL-12 and IFN-γ have on IL-17 production (Harrington et al., 2005; 
Komiyama et al., 2006), it was postulated that the decrease in these cytokines in cultures 
containing type II MΦ may be responsible for the increased levels of IL-17A in the same 
cultures.  However, reduction in IL-12 levels using αIL-12, caused a decrease in IFN-γ 
without affecting IL-17A production.  IL-17A production was also not altered by increased 
level of IFN-γ in this system.  This finding suggests that the decreased levels of IL-12 and 
IFN-γ in cultures containing type II activated MΦ are not responsible for the increased levels 
of IL-17A.  There was a significant reduction of IL-17A following the addition of rIL-10 to 
cultures containing classically activated MΦ at the time of MΦ stimulation; this same 
alteration was not seen in cultures containing type II activated MΦ.  This suggest the 
increased IL-10 produced by type II MΦ is not responsible for the increased IL-17A and 
suggests the pathways controlling IL-17A production may be different when T cell are 
stimulated with classical or type II MΦ.  Furthermore, the absence of a change in CD124 
expression demonstrate that the change in IL-10 and IL-12 expression by type II MΦ is not 
responsible for the increased responsiveness of T cells cultured with type II activated MΦ to 
IL-4.  Over all this data shows that the increases in IL-17A and CD124 by T cells cultured 
with type II MΦ occurs independently of the changes in IL-10 and IL-12, suggesting that 
another, as yet unidentified pathway, contributes to the biasing of T cells by type II MΦ.   
 
Together these data suggest that the major role of IL-10 and IL-12 in regulating the T cell 
response is in controlling IFN-γ production.  The data supports the hypothesis that the 
decreased level of IL-12 produced by type II activated MΦ is involved in T cell biasing, at 
least as far as IFN-γ production.  In addition, IL-10 and IL-12 levels appear to be only 
involved in the regulation of IFN-γ production and not of other markers of T cell biasing such 
as IL-17A and CD124.   
 
IL-4 production was not assessed in this model due to the difficulty in detecting it in culture 
supernatants.  Assessment of IL-4 production, for example by flow cytometry, will be 
important in confirming the roles of these cytokines in T cell biasing.  The major role of the 
IL-12 appears to be on the T cells themselves as altering the IL-12 level does not alter MΦ 
cytokines that were measured, but alters the T cells when IL-12 levels are altered at 0 or 4 
hours, however it is possible the effect is at least partly on the MΦ.  Alternatively, the major 
role of the IL-10 appears to be on the MΦ as altering IL-10 affects the MΦ cytokines 
themselves, T cells are also affected but both MΦ and T cells are only affected when the IL-
10 level is altered at stimulation.  If the major effect of IL-10 was on T cell a similar effect 
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would be expected when IL-10 levels are altered at stimulation and the time the T cells were 
added, however, the IL-10 may be in part acting on T cells directly.  It is possible that there is 
another aspect of the MΦ which drives the Th1 response that is altered on type II MΦ 
compared to classically activated MΦ.  This factor may be a cytokine or a cell surface 
molecule.  For example, type II activated MΦ have recently been shown to produce IL-4 (La 
Flamme et al., 2012), which may have a role in altering T cell responses.  Two potential 
molecules that are altered on type II MΦ compared to classically activated MΦ are CD40 and 
PD-L1. 
 
As the changes in IL-12 and IL-10 production by type II MΦ appeared to only be involved in 
the level of IFN-γ production by T cells, other pathways were investigated.  PD-L1 is 
significantly decreased on type II activated MΦ compared to classically activated MΦ 
(Tierney et al., 2009).  PD-L1 is generally considered to provide inhibitory signals to T cells 
(Carter et al., 2002; Konkel et al., 2010; Tsushima et al., 2007), although stimulatory roles for 
PD-L1 have been reported (Wang et al., 2003).  The reports of PD-L1 having both stimulatory 
and inhibitory effects on T cells suggest that the action of PD-L1 may be conditional.  It is 
possible that the strength of the PD-L1 signal may be involved in biasing T cell responses.  
Due to the decreased expression of PD-L1 on type II MΦ, the PD-1/PD-L1 pathway was 
investigated for a possible role in T cell biasing.  In this study, the interaction between PD-1 
and PD-L1 were interrupted using a blocking antibody that binds PD-1.  As neither classically 
or type II activated MΦ express high levels of PD-L2 (Tierney et al., 2009), the effect of the 
αPD-1 antibody can be considered to be a result of disrupted PD-1/PD-L1 interactions and not 
PD-1/PD-L2 interactions.  In addition, a PD-L1 chimeric protein was used to mimic 
stimulation of the PD-1 receptor to investigate the effects of increased expression of PD-L1 
on MΦ, such as on classical activated MΦ.   
 
The effect of the PD-1/PD-L1 signalling pathway is thought to be mainly on the T cell.  
However, there is some evidence that ligation of PD-L1 and PD-L2 on DC can lead to 
phenotypic changes in a process known as “reverse signalling” (Kuipers et al., 2006).  It is 
therefore possible that changing the level of PD-1/PD-L1 interaction may have an effect on 
the MΦ.  However, the production of IL-10 and IL-12 were not disrupted by the presence of 
αPD-1 in culture, suggesting that reverse signalling does not have a role in MΦ function 
under the current conditions.  In addition the level of IL-12 and IL-10 production by classical 
and type II activated MΦ was not altered by the addition of the PD-L1ch.   
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As PD-1 pathways are inhibitory to T cells, decreasing the interaction between PD-1 and 
PD-L1 would likely increase the activation state of T cells.  Therefore, the activation state of 
T cells in the presence of αPD-1 was assessed, however, blocking the PD-1/PD-L1 pathway 
did not affect the activation state on MΦ.  This result may suggest that in these cultures PD-
L1 is not providing an inhibitory signal to T cells.  The MΦ in this study are highly activated 
and effective APC which drive T cell activation efficiently.  Therefore, inhibition of the PD-
L1 pathway may not further increase the ability of MΦ to induce activation of T cells.  The 
αPD-1 was used at 2 µg/ml in this study, however, αPD-1 has been used previously in 
proliferation assays at 5 µg/ml and been shown to support proliferation (Yamazaki et al., 
2005).  It is therefore possible that the antibody was not used at a high enough concentration.  
2 µg/ml was chosen as it appeared to have the greatest effect in titrations.  In addition, the 
decrease in PD-L1 on type II activated MΦ did not significantly alter T cell proliferation 
(Chapter 3).  Therefore, a slightly lower concentration of αPD-1 than one which alters 
proliferation may potentially be more accurate at mimicking the change in PD-L1 expression 
on type II activated MΦ, in other conditions.  However, given the absence of an effect of the 
αPD-1, it is also possible that the αPD-1 was not active in this assay, thus further experiments 
are required to confirm these data. 
 
The activation state of T cells was also assessed in the presence of PD-L1ch, to increase the 
signalling through the PD-1 receptor on T cells.  Inclusion of the PD-L1ch in MΦ:T cell 
co-cultures did not significantly alter the activation state of the T cells.  However, as blocking 
this pathway does not have an effect on T cell activation it is unlikely that the altered PD-L1 
expression on type II MΦ is involved in altered levels of T cell activation by type II MΦ.  In 
this study the PD-L1ch was used at 8 µg/ml.  This protein has been used previously to inhibit 
the proliferation of T cells at 5 µg/ml (Vogt et al., 2006), therefore, it is likely that 8 µg/ml is a 
sufficient concentration to be effective in these culture conditions, however, the it is also 
possible that the PD-L1ch was not active in the current study, thus these results should be 
confirmed through further experimentation.  
 
In addition to the effects on T cell activation, the effect of the PD-L1 pathway on biasing was 
also assessed.  Neither adding αPD-1 or PD-L1ch affected the production of IL-17A.  This 
suggests that the decreased expression of PD-L1 on type II MΦ is not responsible for the 
increase in IL-17A production by T cells cultured with type II MΦ.  Furthermore, blocking 
the PD-1/PD-L1 pathway did not affect CD124 production.  There was a trend towards lower 
expression of CD124 on T cells cultured in the presence of the PD-L1ch; however, as this 
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decrease was also seen in on T cells cultured with the control protein, it is most likely non-
specific.  The production of IFN-γ was not significantly affected by the addition of αPD-1.  
The addition of PD-L1ch resulted in a decrease in IFN-γ in cultures containing type II MΦ, 
however; there were also changes seen with the control protein which makes interpretation of 
these results difficult.  Overall these results suggest that the decreased expression of PD-L1 by 
type II activated MΦ does not alter T cell biasing.    
 
In addition to PD-L1, type II MΦ also express lower levels of CD40 (Tierney et al., 2009).  
CD40 signalling is important in activation of MΦ and has a dual role in the production of 
cytokines such as IL-10 and IL-12 in MΦ and DC (Mathur et al., 2004; Murugaiyan et al., 
2006).  In addition, different levels of CD40 expression or stimulation have been associated 
with biasing of T cell responses by DC (S. Martin et al., 2010; Murugaiyan et al., 2006).  
Furthermore, previous studies have shown that CD40 is essential for both Th1 and Th2 type 
responses (K. A. Campbell et al., 1996; MacDonald et al., 2002; Poudrier et al., 1998).  Due 
to the dichotomous role of CD40, this study aimed to investigate the role of the CD40/CD40L 
pathway in T cell biasing in type II MΦ.  Low level stimulation of CD40 leads to increased 
production of IL-10, whereas high level stimulation leads to increased IL-12 (Mathur et al., 
2004).  It is therefore possible that in interacting with T cells, type II activated MΦ, with their 
lower expression of CD40, would be stimulated to produce more IL-10, which could promote 
inhibition of IL-12 production by MΦ, and thus less IFN-γ production by T cells.  Conversely, 
classically activated MΦ which have a much higher expression of CD40 will receive higher 
stimulation when cultured with T cells which may induce them to up regulate IL-12, 
potentially driving Th1 responses. 
 
The role of CD40 in T cell biasing by type II activated MΦ was investigated using an 
antibody against CD40L.  This antibody binds to CD40L and inhibits interactions with CD40, 
reducing the signalling to CD40 on the T cell.  Previous studies suggest that this reduction in 
CD40 signalling should result in decreased IL-12 production (Mathur et al., 2004).  However, 
addition of αCD40L to cultures did not affect the production of IL-12 by either classically or 
type II activated MΦ.  Furthermore, there was no significant change in the levels of CD124 
expressed or the production of IL-17A or IFN-γ, although there was a non-significant trend 
towards an increase in IFN-γ production.  Previous studies have used higher concentrations of 
αCD40L antibodies (e.g. 10 µg/ml, DeKruyff, Gieni, & Umetsu, 1997) compared to the 
4 µg/ml used in the current study.  The concentration used in here was chosen as the strong 
effect of the isotype control antibody at higher concentration would make distinguishing 
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specific effects difficult.  It is therefore possible that this antibody in this study was not used 
at a high enough concentration; however, there are alternative possibilities.  For example, 
CD40 interactions have previously been shown to be essential to the induction of Th1 
responses under certain conditions; however, this is associated with deficiency in IL-12 
production in the absence of CD40 stimulation (K. A. Campbell et al., 1996).  However, in 
the current study MΦ were already expressing high levels of IL-12 in response to LPS, a 
process which does not require CD40 ligation (DeKruyff et al., 1997).  Therefore, further 
stimulation of the MΦ via CD40 may be unable to induce higher levels of IL-12 production.  
Indeed, human monocytes treated with LPS show decreased responsiveness to CD40 
stimulation (Sinistro et al., 2007).  Therefore interaction with CD40 on T cells may not further 
stimulate IL-12 production, thus removal of this signal does not result in a change in IL-12 
production. 
 
While CD40 may not stimulate classically activated MΦ to produce IL-12 under the current 
conditions, it is still possible that the reduced CD40 interactions between T cells and type II 
activated MΦ may be involved in T cell biasing by type II MΦ.  IFN-γ did show a slight 
increase in IFN-γ production in the presence of αCD40L.  It is possible that low 
CD40/CD40L interactions between type II MΦ and T cells induce an inhibitory response (that 
is inhibitory to IFN-γ production by the T cells) and that further lowering CD40 stimulation 
prevents CD40/CD40L interactions completely, resulting in the removal of this inhibitory 
signal.  The result of low level CD40 stimulation may be a change in IL-10 production as 
IL-10 is associated with low level CD40 stimulation (Mathur et al., 2004).  It is also possible 
that this low level of CD40 stimulation alters another pathway in type II MΦ.  However, these 
results are preliminary, and while interesting, merit further investigation.  Altering the level of 
CD40 signalling suggests that this pathway does not alter IL-17A production nor does it affect 
IL-4 responsiveness (as measured by CD124 expression), implying another pathway is 
involved in these changes.   
 
Alteration in the level of CD40 signalling also did not alter the activation state of T cells in 
culture with either classically or type II activated MΦ.  IL-2 did show a non-specific decrease 
in production in the presence of αCD40L, however, as this was also seen in the isotype 
control, it may not be a real change due to lower CD40 signally, instead being simply a result 
of antibody in the culture.  Isotype control antibodies account for the effects caused by 
antibodies binding non-specifically to the FcR on cells.  However, it should also be 
considered that the effect of antibodies binding to FcR may be exaggerated when using 
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isotype controls.  It is possible that, as these antibodies do not bind to anything they are more 
likely to end up attached to an FcR than a specific antibody which will bind to its target.  
Therefore, care must be taken from both sides when interpreting data using specific antibodies 
and non-specific controls.  Due to that absence of any significant affect on T cell biasing by 
MΦ in the presence of aCD40L, this suggests that the decreased expression of CD40 on type 
II MΦ is not a key factor involved in T cell biasing by type II MΦ, however, it is possible that 
the αCD154 antibody was not active in the current culture as there was not much change in 
the markers measure, thus this data should be confirmed through further experimentation.   
 
4.5 Summary 
The results of the current study demonstrate that the level of IL-12 production by MΦ has a 
strong role in T cells biasing by classically and type II activated MΦ, as seen in its role in 
IFN-γ production, by directing acting on the T cell themselves.  Furthermore the level of 
IL-10 production by MΦ also has an effect of IFN-γ production by T cells.  Unlike IL-12, the 
IL-10 appeared to exert its effects by acting on the MΦ, not on the T cell directly.  This study 
also suggested that the reduction of CD40 and PD-L1 on type II MΦ do not have a strong role 
in biasing the T cell response.  None of the pathways investigated in this study had a 
significant effect on the level of IL-17A production or CD124 expression by T cells, which 
are expressed more highly on T cells cultured with type II MΦ compared to those cultured 
with classically activated MΦ.  This data contradicts the report by Anderson & Mosser 
(2002), which suggested that the IL-10/IL-12 dichotomy was the only important factor 
involved in differential T cell biasing by classically and type II activated MΦ.  Instead, while 
IL-10 and IL-12 are involved in the regulation of IFN-γ, this study suggests that there will be 
other pathways affecting the ability of type II and classically activated MΦ to bias the T cell 
response.  In order to further investigate the pathway of T cell biasing, other markers of T cell 
responses, such as IL-4, should be assessed.  IL-4 is difficult to detect in culture, partly due to 
its rapid reuptake by T cells.  Therefore, further studies should include assessment of IL-4 by 
flow cytometry.  It is highly likely that many pathways are involved in the biasing of T cell 
responses by type II MΦ, and while the alterations in individual pathways do not have an 
effect, there may be a cumulative effect by altering multiple pathways at once.  The necessity 
of using control proteins can make experimentation of the results quite difficult and in 
addition, some of the pathways, particularly the CD40/CD154 and PD-1/PD-L1 did not show 
any change in the markers measured, and thus need to be treated with caution.  Further 
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investigation of the current pathways, for example using genetically deficient mice or RNAi, 
would provide further information on any roles these pathways might play in T cell biasing. 
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5.1 Introduction 
In the past, much of the research conducted in the study of MG in vitro has employed cultures 
derived from neonatal or embryonic animals (Gingras, Gagnon, Minotti, Durham, & Berthod, 
2007; Giulian & Baker, 1986).  These cultures are often grown as mixed glial cultures with 
astrocytes present, and sometimes growth factors such as GM-CSF are added (Gingras et al., 
2007; Giulian & Baker, 1986).  Under these conditions neonatal/embryonic microglia survive 
and proliferate (Schell et al., 2007).  This method has been used for many years and is 
considered a valid way of looking at MG in vitro (Giulian & Baker, 1986; Schell et al., 2007). 
However, it does have certain drawbacks, namely that neonatal MG are functionally different 
to adult MG due to the environment in which they are found, and the different roles the MG 
play at different stages of development (Moussaud & Draheim, 2010; Schell et al., 2007). 
 
There are also several MG cell lines developed from neonatal brains available (Schell et al., 
2007).  These cell lines include Ra-2, 6-3, N9, N13 and BV-2 (Henn et al., 2009; Righi et al., 
1989; Sonobe et al., 2005).  There are limitations with the use of cell lines for the study of 
MG in vitro, as they have been shown to be functionally different to primary microglia under 
several conditions and are therefore unlikely to accurately model adult MG in vivo (Henn et 
al., 2009; Sonobe et al., 2005).  Although, they are useful for performing large scale 
experiments where the number of cells required would be prohibitive if using primary MG.  
Cell lines are a valid model, but as with the neonatal MG, the differences they have from adult 
MG need to be taken into account.  Due to these differences a protocol for the isolation and 
culture of adult murine MG was optimised in this chapter. 
 
Several methods for the isolation of MG from adult animals have been described in the 
literature.  Adult MG were first isolated from the brains of naïve rats by Sedgwick et al. in 
1991 (Sedgwick et al., 1991).  This method employed the use of a Percoll gradient to isolate 
the cells on the basis of specific gravity and is a commonly used method for the isolation of 
microglia.  Percoll is a semi aqueous solution composed of polyvinyl-pyrrolidone-coated 
colloidal silica-gel particles (Wakefield, Gale, Berridge, Jordan, & Ford, 1982).  In some 
studies, MG have been isolated using Percoll and expanded in culture with the use of growth 
factors such as M-CSF and GM-CSF (Moussaud & Draheim, 2010; Ponomarev et al., 2005).  
Cell sorting techniques (both magnetic beads and FACS) are also a common method for MG 
isolation and are often used in combination with Percoll.  Another method for the isolation of 
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adult MG makes use of the adherent properties of MG to isolate them from other cell types in 
the CNS (Yip et al., 2009).   
 
5.2 Aims 
The aim of this chapter was to compare several of these methods in order to develop a 
protocol for the isolation and culture of adult murine microglia in our laboratory for their in 
vitro analysis.   
 
5.2.1 Specific aims 
1. To assess adherence, Percoll gradients and magnetic bead sorting as possible methods 
for the isolation of adult murine MG. 
2. To assess the survivability and in vitro responsiveness of MG that had been isolated 
with optimised techniques. 
3. To assess the effect that expansion with M-CSF or GM-CSF has on the survivability 
and responsiveness of MG in vitro. 
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5.3 Results 
5.3.1 Isolation of MG from adult mice 
In order to evaluate ex vivo responses of MG from adult mice, several methods of isolation 
were compared and optimised. 
 
5.3.1.1 Adhesion 
The first method of isolation of MG from the spinal cord used a protocol described by Yip et 
al., (2009) which relied on adhesion.  This method involved mincing the spinal cord and 
enzymatically digesting it using papain.  In Yip et al. MG were plated onto glass cover slips 
for immunocytochemical analysis; however, because for these studies the MG needed to be 
isolated for FACs analysis, the MG were instead plated in a variety of plastic tissue culture 
equipment.  The cells were plated at 10,000, 20,000, or 40,000, cells/well in 96 or 24 well 
plates, or cells from a whole spinal cord were plated onto a non-tissue culture treated petri 
dish.  The medium was replaced after 2 hours, during which time the MG should have 
adhered to the plastic surface.  MG were removed from the plates at 2 or 24 hours after 
plating and assessed by flow cytometry for purity (Figure 5.1).  This protocol resulted in 
extremely low yields with insufficient purity and was therefore abandoned (Figure 5.1).   
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Figure 5.1.  Isolation of MG by adhesion results in insufficient yield and purity for in 
vitro culture conditions.  A spinal cord a from BALB/c mouse (n=1) was digested with 
papain before being washed and plated in a flat bottomed 96 well plate at 40,000 cells/well.  
Cells were incubated at 37ºC/5% CO2 for 2 hours at which time the medium was changed.  
Cells were isolated from culture using ice cold PBS at this time (a) and at 24 hours (a) after 
culture and assessed by flow cytometry.  Shown are plots from one experiment. 
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a. b. 
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5.3.1.2 Beads 
A second technique used magnetic bead kits to isolate MG from adult mice.  Two different 
magnetic bead setups were used, the CELLection™ Biotin Binder Kit (Invitrogen, USA) and 
CD11b (microglia) Microbeads (Miltenyi biotec, Germany).  The CELLectionTM Biotin 
Binder Kit employs magnetic beads which are attached to streptavidin via a DNA linker.  
Thus, any biotinylated antibody will bind to these beads and be used to isolate the target cells.  
As MG are the only cells in a normal CNS to express CD11b, this marker was chosen for MG 
isolation.  Once the MG are bound to the beads, the CD11b negative cells can be removed by 
placing the tube on a magnet and removing the supernatant, thus removing anything not 
bound to the magnetic beads.  Bead-bound CD11b positive cells can then be released using 
DNase I which severs the link between the bead and the streptavidin.  After incubation with 
DNase I, the solution is placed back on the magnet and the supernatant containing released 
MG cells can be isolated.   
 
Spinal cords were used to test the isolation of MG using this kit; however, few cells were 
obtained with this method.  It appears that the reason for the low yield of cells is that the MG 
did not detach from the beads as anticipated (Figure 5.2).  Very few CD45+ cells were seen in 
the supernatant that was isolated following DNase I treatment, which theoretically should 
have contained the MG, based on the principles of the isolation (Figure 5.2b).  However, a 
large number of CD45+ events was found in the “bead-bound” fraction following DNase I 
treatment (Figure 5.2a).  R1 may represent bead-bound cells and R2 beads that are not bound 
to cells (as the beads may have different auto fluorescence when bound to cells). Conversely, 
the cells may have detached during the process of staining for flow cytometry, thus R1 would 
represent MG and R2 beads (Figure 5.2a).  These data suggest that MG do not efficiently 
detach from beads, making this an undesirable method for the isolation of adult MG. 
 
The second bead method, CD11b Microbeads, was tested on both brains and spinal cords.  
Unlike the first bead method, this procedure was successful at isolating MG; however, the 
yield was still low.  In addition, there appeared to be large amounts of debris in the “purified” 
cells.  Figure 5.3 (a and d) shows that while CD45+ cells were isolated, only a very small 
percentage of the total events were CD45+ suggesting that the sample was impure, containing 
a large amount of debris.  Removing the myelin from the CNS preparation using 37% Percoll 
before using the beads did not produce a significant reduction in the amount of debris seen by 
flow cytometry (Figure 5.3b and e).   
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Figure 5.2.  Microglia attach to beads labelled with CD11b but do not detach.  Spinal 
cords from BALB/c mice were digested with papain to create a single cell suspension before 
incubation with magnetic beads labelled with CD11b for 20 minutes at 4ºC.  Beads were 
washed to remove negative cells and then incubated with 250 U of DNase for 15 minutes at 
room temperature.  Cells that were released from beads were collected by placing the solution 
on a magnet and removing the supernatant. Both bead bound (a) and released cells (b) were 
analysed by flow cytometry.  Shown are plots from one experiment. 
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5.3.1.3 Percoll 
The most successful technique for the isolation of adult MG was to use a Percoll gradient 
composed of 3 layers of Percoll in decreasing concentrations (70%, 37% and 30%).  This 
technique was compared to the isolation of MG using the CD11b Microbeads method and was 
found to produce a higher yield of cells with less debris (Figure 5.3c and f).  To help ensure 
the highest possible yield, both the brains and the spinal cords were used to isolate MG.  The 
cells isolated from the CNS using Percoll were analysed by flow cytometry to verify the 
identity and purity, and MG were routinely found to be a distinct population CD45loCD11b+ 
(Figure 5.4).  MG cells isolated using a Percoll gradient were routinely found to be suitably 
pure (83.16±1.585 %; mean±SEM from 26 experiments). 
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Figure 5.3. Percoll results in a cleaner population with more cells than magnetic beads. 
The brains and spinal cords of BALB/c mice were digested with accutase and MG were 
isolated with either CD11b Microbeads directly (a, d; n=1 mouse) or following the removal of 
myelin with 37% Percoll (b, e; n=1 mouse), or by Percoll gradient (c, f; n=1 mouse).  Cells 
were stained with CD45 and analysed by flow cytometry.  Live cells were gated using the 
FSC-SSC gate shown (a, b, c), and then CD45+ cells were gated as shown (d, e, f).  The 
number of CD45 positive cells (g), and the percentage of total events that were CD45 positive 
(h) were assessed.  Data is from one experiment. 
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Figure 5.4. Cells isolated using a Percoll gradient are CD45lo CD11b+, which are 
consistent with MG, and are of a sufficient purity for culture.  The brains and spinal cords 
of BALB/c mice were digested with accutase, and MG were isolated by Percoll gradient.  
Cells were stained with CD45and CD11b (a) or corresponding isotype control antibodies (b).  
Shown are representative plots from one experiment. 
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5.3.2 Culture of MG isolated from adult mice 
To assess the in vitro responsiveness of MG freshly isolated from adult mice, MG from the 
CNS of adult BALB/c and C57BL/6 mice isolated using Percoll gradients were cultured 
overnight in the presence or absence of IFN-γ, followed by stimulation with LPS for 24 hours.  
MG were shown to produce the proinflammatory cytokine IL-12 in a concentration dependent 
fashion in response to LPS challenge (Figure 5.5).  MG from C57BL/6 mice produced higher 
levels of IL-12 compared to those from BALB/c, and IFN-γ increased the level of IL-12 
produced by MG in response to LPS (Figure 5.5).  As C57BL/6 mice had a stronger response, 
this strain was chosen for all experiments after optimisation was complete. 
 
The low level of cytokines produced by the MG suggests that MG produce very low levels of 
cytokines; however, an alternative explanation is that there are too few cells to produce a high 
concentration of cytokines.  It is well known that extensive cell death often occurs in the early 
stages of adult MG culture (Aloisi, Simone, Columba-Cabezas, Penna, & Adorini, 2000; 
Brannan & Roberts, 2004); therefore, cell death resulting in low cell numbers in the cultures 
may be responsible for the low levels of cytokines detected.  To assess this possibility, 
24 hours after plating cells for culture (without any stimulation) MG were removed from 
culture plates by blasting with ice cold PBS.  After blasting, cells isolated from the culture 
plate were counted using a trypan blue exclusion assay.  However, in all experiments in which 
cells were plated at 1x105 cells/well in a 96 well plate, no live cells were observed.  This 
finding was confirmed using flow cytometry, where no CD45 or CD11b positive events were 
detected. 
 
Other authors have reported between 42-80% viability after 24 hours in culture (Aloisi et al., 
2000; Brannan & Roberts, 2004).  To test the number of cells surviving after 24 hours in 
culture, cells were plated at 5x105 in a 6 well plate.  Cells harvested from plates after 24 hours 
in culture were assessed by flow cytometry, using CD45 and CD11b to identify the MG.  
After 24 hours in culture, cells remained CD45+ CD11b+ (Figure 5.6).  Cells taken from plates 
after 24 hours in culture were re-plated at 1x105 cells/well in a 96 well plate.  These cells were 
stimulated with 200 ng/ml of LPS after overnight stimulation with IFN-γ; however no 
detectable levels of IL-12 were produced, indicating either that further cell death had occurred 
or that the remaining cells were not competent IL-12 producing cells.  
 
The average yield of live microglia from 6 well plates was 31.1% (Table 5.1).  To attempt to 
increase the yield of MG after immediate isolation and culture the protocol was altered.  
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These adjustments included different types of Percoll gradients, which have been reported to 
isolate larger numbers of MG (De Haas, Boddeke, Brouwer, & Biber, 2007), and other 
methods for dissociation of the tissue which may be gentler than the mechanical dissociation 
using a 70 µm nylon mesh cell strainer used previously in this study, and included glass 
homogenisers, wire mesh and enzymes.  However, none of these methods increased the yield 
or survival of the MG.  Due to the low number of cells that can be isolated from mice and the 
low number of MG that survive in culture, very large numbers of mice would be needed for 
each experiment.  Because of these large numbers, other methods for MG culture were 
pursued.  
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Figure 5.5.  MG isolated from the CNS of adult mice produce IL-12 in response to LPS 
in a concentration dependent fashion.  MG isolated from 19 week old BALB/c (n=3, a) and 
18 week old C57BL/6 (n=4, b) mice were plated at a density of 1x105 cells/well in a flat 
bottom 96 well plate and cultured overnight in the presence or absence of IFN-γ.  MG from 
BALB/c mice (a) or C57BL/6 mice (b) were stimulated with 50ng/ml or 250ng/ml LPS for 24 
hours.  IL-12p40 production was measured by ELISA.  Shown are the means and SEM from 
duplicate wells, or single wells where no error bar is present, from one experiment. 
 
 
a. b. 
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Figure 5.6.  MG retain their expression of CD45 and CD11b following 24 hours in 
culture.  MG isolated from the CNS of IL-4Rα-/- mice (n=4) using a Percoll gradient were 
plated at 5x105 cells per well in CTCM.  After 24 hours in culture, media was removed and 
MG were removed from the wells with ice cold PBS.  Cells were stained with CD45 and 
CD11b (freshly isolated, a; 24 hours, b). Plots are from one experiment. 
 
 
 
 
 
Table 5.1. MG have low survival following 24 hours in culture.  MG isolated from the 
CNS of IL-4Rα-/- (n=4 mice in experiment 1; and n=4 mice in experiment 3) or BALB/c (n=4 
mice in experiment 2) using a Percoll gradient were plated at 5x105 cells per well in CTCM in 
a 6 well plate.  After 24 hours in culture, media was removed and MG were removed from the 
wells with ice cold PBS and counted using a trypan blue exclusion assay. 
Mouse strain Experiment Number of cells recovered (24 hours) Percentage viable 
IL-4Rα-/- 1 175,555  35.1 
BALB/c 2 184,000  36.8 2 140,000  28.0 
IL-4Rα-/- 3 133,333  26.7 3 144,444 28.9 
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5.3.3 Expansion of MG in vitro 
MG are capable of self renewal and can expand when given growth factors such as M-CSF or 
GM-CSF.  Moussaud & Draheim (2010) described a protocol for the isolation and culture of 
MG from adult mice using GM-CSF.  This protocol grows MG from mixed glial cells, 
isolated from adult mice, using GM-CSF until the MG reach confluence and detach from the 
surface of the culture flask.  This protocol was attempted twice; neither time did the MG reach 
confluence, even after twice the length of time in culture as described previously (Moussaud 
& Draheim, 2010).  In addition, when MG were harvested from these flasks with ice cold PBS 
(as they did not detach) and the suspension was counted with trypan blue, only a very small 
number of live cells could be isolated. 
 
Ponomarev et al. (2005) described a similar protocol to the one described by Moussaud & 
Draheim (2010), but isolated MG using a 70:40% Percoll gradient and grew MG for 4 weeks 
in the presence of M-CSF, as opposed to GM-CSF.  In this study MG were isolated using a 
70:37:30% Percoll gradient and plated at 449,334 and 384,000/cells a well (in 2 separate 
experiments, n=5 and 4 mice respectively) in a 12 well plate in the presence of 10 ng/ml 
M-CSF.  The media was changed every 3-4 days for 4 weeks.  MG showed focal areas of 
proliferation in culture as early as 11 days and maintained a ramified morphology after 4 
weeks in culture (Figure 5.7).  After 4 weeks in culture MG were harvested by blasting wells 
with ice cold PBS with the intent to reseed the cells for stimulation.  However in both 
experiments only 18,000 cells were recovered from each well (as determined by a trypan blue 
exclusion assay) following blasting.   
 
Because it is likely that the MG did not survive the harvesting procedure, MG were plated in a 
96 well, flat bottomed, tissue culture plate at 50,000 cells/well and grown in the presence of 
M-CSF for 4 weeks. The MG were then cultured for 3 days without M-CSF, before overnight 
incubation with or without IFN-γ and stimulation with LPS.  IL-12 cytokine production was 
then assessed in supernatants after 24 hours of stimulation, IL-12 demonstrated the MG are 
capable of responding to LPS with the production of a proinflammatory cytokine (Figure 8a).  
However, as the cells became less healthy following culture without M-CSF for 3 days, the 
protocol was altered and the M-CSF was removed at the time of IFN-γ stimulation, so it was 
not present during stimulation (Figure 8b).  MG which had the M-CSF removed 3 days before 
IFN-γ stimulation produced lower levels of IL-12 than those which were left with M-CSF 
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until the day of stimulation (Figure 8).  These results suggest the MG do not survive well 
without the M-CSF. 
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Figure 5.7.  MG proliferate in culture containing M-CSF.  MG were isolated from the 
CNS of C57BL/6 mice (n=5) using a Percoll gradient and grown in the presence of 10 ng/ml 
M-CSF for 4 weeks.  After 11 days in culture, clusters of proliferation were clearly visible (a), 
and surive at least 4 weeks in in vitro culture (b).  Pictures are from one representative 
experiment. 
 
a. 
b. 
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Figure 5.8. MG produce higher levels of IL-12 when M-CSF is retained in culture until 
the day of stimulation.  MG isolated from adult C57BL/6 mice (n=5) were plated at a 
density of 5x104 cells/well in a flat bottom 96 well plate and cultured for 4 weeks in media 
containing 10 ng/ml M-CSF.  M-CSF was removed either 3 days (a) or immediately prior to 
overnight stimulation with IFN-γ.  Cells were stimulated with 200 ng/ml LPS for 24 hours.  
IL-12 production was measured by ELISA.  Shown are means and SEM of triplicate wells 
from three combined experiments (a) or one representative experiment (b).  **p<0.01, 
***p<0.001 by unpaired Student’s t test. 
a. b. 
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5.4 Discussion 
In this chapter a protocol for isolating and culturing adult MG was optimised.  Several 
different protocols were attempted for the isolation of adult MG based on reports in the 
literature, including isolation on the basis of adhesive properties, CD11b expression using 
magnetic beads, and isolation based on their specific gravity using a Percoll gradient (Aloisi 
et al., 2000; Sedgwick, Schwender, Gregersen, Dörries, & Meulen, 1993; Yip et al., 2009).  It 
was determined that only Percoll gradients gave both sufficient yield and purity for in vitro 
culture systems.  Furthermore, it was shown that MG experience a high rate of cell death in 
the first 24 hours of culture, making direct culture of these cells impossible without using 
prohibitively large numbers of mice.   
 
Several papers have used freshly isolated MG without culturing the cells long term with 
growth factors (Aloisi et al., 2000; Brannan & Roberts, 2004; Schell et al., 2007).  These 
papers report between 42-80% survival of MG after 24 hours in culture and would therefore 
be likely to require large numbers of animals (Aloisi et al., 2000; Brannan & Roberts, 2004; 
Ponomarev et al., 2005).  MG are notoriously difficult to maintain in long term culture, and 
even in short term culture it can be extremely difficult to avoid widespread cell death 
(Moussaud & Draheim, 2010).  Indeed, in the current study, MG only had a viability of 
31.1±2.03% (mean±SEM) following 24 hour culture.  Due to the low numbers of cells that 
were surviving the first 24 hours in culture, a different method was employed which involved 
culturing MG in the presence of growth factors such as GM-CSF or M-CSF (Moussaud & 
Draheim, 2010; Ponomarev et al., 2005).  MG grew in both GM-CSF and M-CSF; however, 
M-CSF was used in this protocol instead of GM-CSF because M-CSF is thought to be 
ubiquitously expressed in the CNS and maintains MG in a resting/ramified phenotype, while 
GM-CSF alters MG to take on a phenotype that is more similar to DC (Ponomarev et al., 
2005). 
 
This study found that growing MG in the presence of M-CSF resulted in the MG maintaining 
the ramified morphology of resting MG and express similar surface markers to ex vivo 
isolated MG, with no expression of MHC II, CD86 or CD40, which is consistent with resting 
MG (Ponomarev et al., 2005).  Using this protocol MG were grown successfully and shown to 
produce IL-12 after LPS stimulation.  Initially, M-CSF was removed from the cells 3 days 
before priming with IFN-γ, as this was suggested when using GM-CSF, to prevent any effect 
that the M-CSF may have on the responses of the MG  (Moussaud & Draheim, 2010); 
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however, removing the M-CSF appeared to have a detrimental effect on MG.  As M-CSF is 
ubiquitously expressed in the CNS it may be required for their survival long term (Ponomarev 
et al., 2005), therefore, the protocol was altered so M-CSF was left in the media until IFN-γ 
priming.  This resulted in higher levels of cytokine production, likely due to healthier cells. 
 
The isolation and culture of adult MG for functional in vitro assays is desirable due to the 
documented differenced between adult MG, neonatal MG, and MG cell lines.  Neonatal MG 
are functionally different from those isolated from adult mice in a number of ways.  For 
example, the production of NO by neonatal MG cultures has been shown to be higher than 
that of ex vivo isolated adult microglia.  Also, the cytokine production by adult MG and 
neonatal MG is not identical and adult MG have also been show to be less effective at cross 
presenting antigens than neonatal MG (Beauvillain et al., 2008; Schell et al., 2007).  Due to 
these differences between adult and neonatal MG, the data obtained in these studies, while 
providing an interesting glimpse into the function of MG, must be interpreted with an 
understanding that the system may not model the CNS perfectly.  In addition, study of 
neonatal MG does not allow for the study of MG ex vivo following treatment, nor is the data 
obtained directly comparable to in vivo studies. 
 
Cell lines are also commonly used to study MG; however, there are differences between the 
cell lines and primary MG, although some of these cell lines more closely model primary MG 
than others.  For example, Ra-2 and 6-3 do not produce detectable levels of IL-12 or IL-23 
under conditions that induce the same cytokines from a neonatal MG culture (Sonobe et al., 
2005).  BV-2 is the most frequently used and most well characterised of all the MG cell lines.  
In a study comparing the LPS response of BV-2 cells to neonatal MG cultures and in vivo MG 
responses, BV-2 cells were shown to respond similarly but not identically.  The authors of this 
paper highlighted the fact that long term use of cell lines by individual laboratories can result 
in selection of the cell lines, and therefore skewed results are possible (Henn et al., 2009).  
The major advantage of these cells is that the number of cells available means that large 
experiments can be undertaken without the need to sacrifice large numbers of animals.  
Consequently, cell lines may be of particular use in early proof of concept work, or in 
situations where the number of cells required would make doing the experiment with primary 
cells difficult.  Due to the differences in both neonatal MG and cell lines compared to primary 
MG, it was considered necessary to optimise a protocol for the isolation of adult murine 
microglia. 
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5.5 Summary 
In conclusion, a wide variety of different techniques were attempted for the culture of adult 
MG.  It was found that isolation of MG using a Percoll gradient gave the purest yield with the 
highest number of cells.  MG do not survive well in vitro and it was found that culturing the 
MG with M-CSF was the most productive way of maintaining the cells in vitro and increasing 
cell survival. 
 
  
 
 
 
Chapter 6:  
Type II Activation of Adult Microglia 
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6.1 Introduction 
Type II activation of MΦ has been well described, but while several studies have suggested 
that MG are capable of type II activation (Kim et al. 2004), the phenotype of these MG has 
not been as well characterised.  Specifically, Kim et al. (2004) reported that human MG 
exposed to supernatants from T cells isolated from GA-treated patients expressed higher 
levels of IL-10 and lower levels of TNF-α and CD40 compared to MG exposed to 
supernatants of T cells isolated from untreated patients.  This finding suggests GA can 
indirectly induce a type II like phenotype in MG (Kim et al., 2004).  GA has been shown to 
increase the production of IL-10 and decrease TNF-α in cultured neonatal MG isolated from 
rats (Pul et al., 2011).  Furthermore, in a Theiler's encephalomyelitis virus model of MS, 
treatment with anandamide (an endocannabinoid) causes MG to up regulate IL-10 and down 
regulate IL-12p70 and IL-23, a phenotype which is suggestive of type II activation (Correa et 
al., 2011).  Because these studies have focused primarily on the IL-12/IL-10 balance, the 
ability of MG to express the full spectrum of type II activation, has not been determined nor 
has the ability of MG to be type II activated by IC been studied previously.   
 
The local environment of a tissue can affect the way in which the immune response develops 
in that organ.  For example, over expression of proinflammatory molecules can alter the 
clinical course of EAE.  Over expression of IL-6 specifically in the cerebellum of C57BL/6 
mice conditions the local milieu and results in a shift from a primarily spinal cord located 
disease (with the classic symptoms of ascending paralysis) to one in which lesion 
development is targeted to the cerebellum (these mice display altered disease signs such as 
ataxia) (Quintana et al., 2009). This phenotype was not the same for all inflammatory 
cytokines, as increases in IL-12 in the cerebellum did not result in atypical EAE (Quintana et 
al., 2009).  Alteration in anti-inflammatory cytokines also alters disease progression.  
Delivery of fibroblasts retrovirally transformed to express IL-10 directly into the CNS results 
in lowered severity of EAE and decreased expression of MHC II on resident MG (Croxford, 
Feldmann, Chernajovsky, & Baker, 2001).  In a similar manner MG can regulate the local 
immune environment altering neurological disease expression. 
 
MG are known to be competent APC and are considered the major APC in the CNS in both 
normal and inflammatory conditions.  Several in vitro studies have demonstrated the ability of 
MG to activate both naïve and memory T cells (Krakowski & Owens, 1997; Li, Wang, Guo, 
Bai, & Yu, 2007).  Thus one mechanism by which MG may regulate CNS immune responses 
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involves interactions with T cells.  MG are known to produce IL-12 in vivo which is drives 
Th1 type responses (Krakowski & Owens, 1997), and inhibition of MG activation in vivo 
results in reduced disease severity in EAE (Heppner et al., 2005).  Also, specific deletion of 
IL-23, which stabilises pathogenic Th17 cells, in the CNS of mice but not in the periphery, 
reduces disease severity in EAE and skews the Th response in the CNS towards a Th2 profile 
(Becher, Durell, & Noelle, 2003).  Conversely, MG have also been shown to have potential 
regulatory properties in vivo, for example the production of IL-4 by MG has been suggested 
as a regulatory mechanism in EAE (Ponomarev et al., 2007).  Additionally MG have been 
shown to express increased levels of PD-L1 at peak disease (Magnus et al., 2005)., and since 
PD-L1 provides inhibitory signals to T cells, it is likely that this increase is a regulatory 
mechanism to reduce CNS inflammation.  Therefore, the activation of MG to a more 
regulatory phenotype (i.e. type II activation) may be protective in EAE by modifying the 
T cell response phenotype in the CNS. 
6.2 Aims and objectives 
The primary aim of this chapter was to investigate the effects of prototypical classical and 
type II activating stimuli on primary adult murine MG to determine if MG could be type II 
activated like MΦ.  Activation of MG was assessed on the basis of cytokine production, as 
well as the expression of CD40 and PD-L1, which are known to be altered in type II 
activation.  Finally, given the ability of type II activated MΦ to bias Th responses, this chapter 
also aimed to establish if MG are capable of inducing T cell biasing in a similar fashion to 
type II activated MΦ. 
 
6.2.1 Specific aims: 
1. To compare cytokine production by MG stimulated under classical or type II 
activating conditions to assess the phenotypic change of the MG. 
2. To evaluate changes in expression of surface markers, such as CD40 and PD-L1 on 
MG induced by classical or type II activating conditions. 
3. To investigate the ability of classically and type II activated MG to activate T cell and 
bias the T cell response. 
4. To determine if the PD-L1 pathway is involved in biasing of the T cell response by 
classically and type II activated MG. 
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6.3 Results 
 
6.3.1Type II activation of MG with IC as demonstrated by changes in cytokine 
production 
As shown previously (Aloisi, Penna, Cerase, Menéndez Iglesias, & Adorini, 1997; Moussaud 
& Draheim, 2010), when cultured with LPS, MG significantly up regulated production of 
IL-12 compared to medium alone (Figure 6.1b).  In contrast, when MG were cultured with 
LPS in the presence of IC (i.e. type II activated), the MG produced significantly less IL-12 
compared to those cultured with LPS alone (Figure 6.1a).  MG cultured with LPS+IC also 
produced higher levels of IL-10 compared to LPS stimulated MG, however, this did not reach 
statistical significance (Figure 6.1a).  MG cultured in medium alone or IC alone produced 
only low levels of IL-12 and IL-10 (Figure 6.1a and b).  This pattern of cytokine expression in 
LPS+IC-treated MG is suggestive of type II activation and the changes are consistent with 
those seen when MΦ are type II activated. 
 
In addition to IL-10 and IL-12, the production of several other proinflammatory molecules 
was assessed (Figure 6.2).  Under type II activating conditions the level of IL-6 produced by 
MG was significantly lower compared production by LPS stimulated MG.  Despite the 
decrease in IL-6 and IL-12, Monocyte chemoattractant protein 1 (MCP-1) and TNF-α 
production was not significantly altered by type II activating compared to classical activating 
conditions (Figure 6.2).  Unstimulated MG produced very low levels of these cytokines 
(Figure 6.2).  Although MCP-1 and TNF-α production were not significantly different when 
the M-CSF was removed just prior to IFN-γ stimulation, when the M-CSF was removed from 
the cultures 3 days prior to IFN-γ stimulation, a different pattern was observed.  By removing 
M-CSF earlier, a significant down regulation of IL-6, MCP-1 and TNF-α under type II 
activating conditions was observed (see appendix C).  Under these conditions, IL-12 levels 
had the same pattern of expression as when M-CSF was maintained for longer (see appendix 
C).  Therefore the decreases in IL-12 and IL-6 under type II activating conditions were highly 
consistent and may represent phenotypical alternations in the MG while the changes to TNF-α 
and MCP-1 will require further elucidation.  Finally, this reduction in IL-6 as well as IL-12 
further supports the evidence that LPS+IC activated MG to a regulatory or type II activated 
state. 
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Figure 6.1.  MG are type II activated when cultured with LPS+IC.  MG were isolated 
from the CNS of adult mice (n=5) and plated at 5x104 cells/well in a flat bottomed 96 well 
plate in the presence of M-CSF (5 ng/ml).  After 4 weeks in culture M-CSF was removed and 
MG were primed with 20 U/ml IFN-γ overnight before stimulation with LPS (200 ng/ml) with 
or without IC (106/well) for 24 hours.  IL-10 (a) and IL-12p40 (b) levels were measured by 
ELISA.  Shown are the means and SEM from triplicate wells from two (IL-12p40, b) or three 
(IL-10, a) combined experiments.  IL-10 data was subjected to the ROUT test which removed 
outliers, before statistics were calculated.  ****p<0.0001 by one way ANOVA with a Tukey’s 
multiple comparison post test. 
 
a. b. 
Chapter 6- Type II Activation of Adult Microglia 140 
 
 
 
Figure 6.2.  MG cultured with LPS+IC produce less inflammatory cytokines and 
chemokines compared to LPS alone.  MG were isolated from the CNS of adult mice (n=5) 
and plated at 5x104 cells/well in a flat bottomed 96 well plate in the presence of M-CSF 
(5 ng/ml).  After 4 weeks in culture M-CSF was removed and MG were primed with 20 U/ml 
IFN-γ overnight followed by stimulation with LPS (200 ng/ml) with or without IC (106/well) 
for 24 hours.  IL-6 (a), MCP-1 (b) and TNF-α (c) levels were measured by CBA.  Shown are 
the means and SEM of triplicate wells from one experiment.  **p<0.01, ***p<0.001 by one 
way ANOVA with a Tukey’s multiple comparison post test. 
 
c. 
a. b. 
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6.3.2 Alterations in the expression in cell surface markers on type II activated MG 
Type II MΦ are most commonly identified on the basis of their cytokine profile; however, 
previous work indicates that the expression of several cell surface markers is also of 
importance (Tierney et al., 2009).  For example, type II MΦ are known to express lower 
levels of several co-stimulatory markers including CD40 and PD-L1 (Tierney et al., 2009).  
To assess whether type II activated MG follow this same pattern of cell surface expression, 
MG were harvested 24 hours post stimulation and analysed by flow cytometry.  When 
stimulated with LPS alone, MG expressed higher levels of both CD40 and PD-L1 compared 
to media alone (Figure 6.3a and b).  This change is consistent with classical activation of 
macrophages (Tierney et al., 2009).  When MG were cultured with LPS+IC, the levels of 
CD40 expression was not different to MG stimulated with LPS alone (Figure 6.3a).  In 
contrast, MG cultured with LPS+IC had a decreased expression of PD-L1 compared to MG 
cultured with LPS alone, which is reminiscent of type II activated MΦ (Figure 6.3b).  Due to 
the low viability of MG once they have been removed from culture, flow cytometric analysis 
of MG was only successfully performed once.  In all other experiments, not enough MG 
survived the process of preparation for flow cytometry to provide robust results. 
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Figure 6.3.  MG cultured with LPS+IC have altered expression of co-stimulatory 
markers compared to culture with LPS alone.  MG were isolated from the CNS of adult 
mice (n=5) and plated at 5x104 cells/well in a flat bottomed 96 well plate in the presence of 
M-CSF (5 ng/ml).  After 4 weeks in culture M-CSF was removed 3 days before MG were 
primed with 20 U/ml IFN-γ overnight followed by stimulation with LPS (200 ng/ml) with or 
without IC (106/well) for 24 hours.  MG were removed from culture plates by blasting with 
ice cold PBS after 24 hours in culture.  CD40 (a) and PD-L1 (b) levels were assessed by flow 
cytometry.  Data is from one experiment, each data point represents 3 combined wells. 
a. b. 
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6.3.3 T cell biasing by type II activated MG 
In order to evaluate the ability of MG to activate T cells, a co-culture system was developed 
based on the co-culture system used to study MΦ:T cell interactions in Chapters 3 and 4.  
Using this co-culture system, it was found that MG could drive antigen specific T cell 
responses under non-biasing conditions (i.e. unstimulated MG).  Specifically, in the presence 
of MOG, increased IFN-γ and IL-2 were detected compared to cultures in which MOG was 
absent (Figure 6.4a and b).  These results indicate that the T cell response was antigen-
specific and that this model is amenable to assessing antigen-specific MG:T cell interactions. 
 
In this culture system, classically activated MG produced higher levels of IL-12 compared to 
type II activated MG (Figure 6.5b).  In addition, co-cultures containing type II activated MG 
showed a trend towards increased production of IL-10 compared to those containing 
classically activated MG (Figure 6.5a).  These data demonstrate that the respective activation 
states of the MG are maintained in T cell co-culture conditions.   
 
In MG:T cell co-cultures, T cells cultured with unstimulated MG and T cell cultured with 
classically or type II activated MG did not have significantly different expression of the 
activation markers, CD44, CD62L and CD25.  In particular, similar expression of CD44 and 
by T cells co-cultured with unstimulated, classical or type II activated MG was observed 
(Figure 6.6a).  While CD62L and CD25 expression appeared to be higher on T cells 
co-cultured with type II activated MG, this increase did not reach significance (Figure 6.6b 
and c).  However, IL-2 production was significantly elevated in co-cultures with type II 
activated MG compared to classical activation (Figure 6.6d).  The expression of these markers 
was antigen specific as demonstrated by the low level of IL-2 production in the absence of 
MOG (Figure 6.4b); therefore, the similarity in activation marker expression on T cells from 
these MG co-cultures is not due to the absence of antigen-recognition by the T cells.  Because 
T cells cultured with unstimulated MΦ were significantly less activated compared to those 
cultured with classically activated MΦ (as seen in Chapter 3), these data suggest that these 
primary MG may have an enhanced ability to activate T cells compared to MΦ despite 
showing similar activation states. 
 
Similar to the activation markers, T cells cultured with MG produced a high level of IFN-γ 
regardless of the MG activation state (Figure 6.7a).  This finding is in stark contrast to 
MΦ:T cell co-cultures in which T cells cultured with classically activated MΦ produced 
Chapter 6- Type II Activation of Adult Microglia 144 
 
significantly higher levels of IFN-γ compared to those with unstimulated MΦ (see Chapter 3).  
T cells cultured with type II activated MG showed a trend towards an increased expression of 
CD124 suggesting that the T cells cultured with type II MG may have an increased sensitivity 
to IL-4 similar to that of T cells in unstimulated MG co-cultures (Figure 6.7c).  Finally, as 
observed with the MΦ:T cell co-cultures, T cells cultured with type II MG produced 
significantly higher levels of IL-17A compared to T cells cultured with either classical or 
unstimulated MG (Figure 6.7b).  Overall, these data suggest that type II activated MG activate 
T cells in a distinct manner to type II activated MΦ despite having similar activation profiles.   
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Figure 6.4.  Under non-biasing conditions MG can present to T cells and drive an 
antigen specific response.  MG were isolated from the CNS of adult mice (n=5) and plated at 
5x104 cells/well in a flat bottomed 96 well plate in the presence of M-CSF (5 ng/ml).  After 
4 weeks in culture M-CSF was removed and MG were primed with 20 U/ml IFN-γ overnight 
before purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were added to the MG cultures for 
72 hours.  IFN-γ (a) and IL-2 (b) levels were measured by ELISA.  Shown are the mean and 
SEM of at least duplicate wells from two combined experiments.  **p<0.01, ***p<0.001 by 
unpaired Student’s t test. 
 
 
 
a. b. 
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Figure 6.5.  MG in T cell co-culture retain their cytokine profiles.  MG were isolated from 
the CNS of adult mice (n=5) and plated at 5x104 cells/well in a flat bottomed 96 well plate in 
the presence of M-CSF (5 ng/ml).  After 4 weeks in culture M-CSF was removed and MG 
were primed with 20 U/ml IFN-γ overnight before stimulation with LPS (200 ng/ml) with or 
without IC (106/well).  After four hours, purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) 
were added to the MG cultures for 72 hours.  IL-10 (a) and IL-12 (b) levels were measured by 
ELISA.  Shown are means SEM of triplicate wells from seven combined experiments.  
****p<0.0001 by one way ANOVA with a Tukey’s multiple comparison post test. 
 
a. b. 
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Figure 6.6.  Classical or type II activation of MΦ does not significantly alter the 
activation of T cells in co-culture compared to un-stimulated MG.  MG were isolated 
from the CNS of adult mice (n=5) and plated at 5x104 cells/well in a flat bottomed 96 well 
plate in the presence of M-CSF (5 ng/ml).  After 4 weeks in culture M-CSF was removed and 
MG were primed with 20 U/ml IFN-γ overnight before stimulation with LPS (200 ng/ml) with 
or without IC (106/well).  After four hours, purified CD4+2D2 T cells and MOG35-55 
(25 µg/ml) were added to the MG cultures for 72 hours.  CD44 (a) CD62L (b) and CD25 (c) 
expression was measured by flow cytometry, and IL-2 (d) levels ELISA.  Shown are the 
means and SEM of triplicate wells from seven combined experiments.  *p<0.05 by one-way 
ANOVA with a Tukey’s multiple comparison post test. 
 
 
a. b. 
c. d. 
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Figure 6.7.  Biasing of the T cell response by MG is not identical to the biasing induced 
by MΦ.  MG were isolated from the CNS of adult mice (n=5) and plated at 5x104 cells/well 
in a flat bottomed 96 well plate in the presence of M-CSF (5 ng/ml).  After 4 weeks in culture 
M-CSF was removed and MG were primed with 20 U/ml IFN-γ overnight before stimulation 
with LPS (200 ng/ml) with or without IC (106/well).  After four hours, purified CD4+2D2 
T cells and MOG35-55 (25 µg/ml) were added to the MG cultures for 72 hours.  IFN-γ (a) and 
IL-17A (b) levels were measured by ELISA, and CD124 (c) expression was measured by flow 
cytometry.  Shown are the means and SEM of at triplicate wells from seven combined 
experiments.  ****p<0.0001 by one-way ANOVA with a Tukey’s multiple comparison post 
test. 
 
 
 
 
a. b. 
c. 
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6.3.4 The PD-1/PD-L1/2 pathway in biasing of the T cell response by adult MG 
Similarly to the investigations into the pathways involved in T cell biasing by classically 
activated and type II activated MΦ presented in chapter 4, the abitlity of classically and type 
II activated MG to bias T cell responses was specifically evaluated in above.  Therefore, for 
the following experiments, which investigate the effect of inhibiting or activating specific 
pathways in classical or type II activated MG, these groups will be analysed independently, as 
was done for the pathways investigated in Chapter 4.  This approach was selected because it is 
likely that these treatments will have different effects on these two distinct MG populations. 
 
6.3.4.1 Blocking the PD-1/PD-L1/2 pathway in MG:T cell co-cultures 
To understand if the reduced expression of PD-L1 on MG could affect T cell activation and 
biasing in MG:T cell co-cultures, the ability of PD-L1 and PD-L2 to ligate PD-1 on the T cell 
was blocked by the addition of αPD-1 antibody.  As observed with MΦ:T cell co-cultures, the 
addition of αPD-1 did not alter the cytokine profile of the MG (Figure 6.8).  MG in T cell 
co-cultures which contained αPD-1 expressed similar levels of IL-12 (Figure 6.8b) to MG 
cultured in the absence of αPD-1.  There was a trend towards decreased IL-10 with the 
addition of the αPD-1 in all culture conditions, and this reached significance in cultures 
containing classically activated MG (Figure 6.8a).  However, it should be noted that IL-10 
production was also significantly lower in all cultures in the presence of the isotype control 
making it difficult to draw any solid conclusions from these findings (Figure 6.8a). No 
difference in the expression of CD44, CD62L and CD25, or IL-2 was detected in co-cultures 
to which αPD-1 was added (Figure 6.9) which suggests that blocking the PD-1 pathway does 
not affect the activation state of T cells when antigen has been presented by classical or type 
II activated MG it this system.  Furthermore, the addition of αPD-1 did not affect the 
production of IFN-γ or IL-17A, or the level of CD124 expression on T cells in co-cultures 
containing unstimulated, classically, or type II activated MG (Figure 6.10).  These data 
suggest that in this system, blocking the PD-1/PD-L1 pathway does not alter these indicators 
of antigen-specific T cell responses and suggest that a reduced expression of PD-L1 is not 
likely to be involved in T cell biasing in this system, however, as no effect is seen it is also 
possible that the molecule is not active in this system. 
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Figure 6.8.  Blocking the PD-1/PD-L1/2 pathway did not significantly alter IL-10 or 
IL-12 production by MG.  MG were isolated from the CNS of adult mice (n=5) and plated at 
5x104 cells/well in a flat bottomed 96 well plate in the presence of M-CSF (5 ng/ml).  After 
4 weeks in culture M-CSF was removed and MG were primed with 20 U/ml IFN-γ overnight 
before stimulation with LPS (200 ng/ml) with or without IC (106/well).  After four hours, 
purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were added to the MG cultures for 
72 hours.  To block PD-1/PD-L1 interactions, 2 µg/ml of anti PD-1 (RMP1-14) or rat isotype 
was added to cultures with the stimuli.  IL-10 (a) and IL-12 (b) levels were measured by 
ELISA.  Shown are the means and SEM of triplicate wells from two combined experiments.  
*p<0.5, by one way ANOVA with a Tukey’s multiple comparison post test. 
 
 
a. b. 
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Figure 6.9.  Blocking the PD-1/PD-L1/2 pathway did not alter T cell activation by MG.  
MG were isolated from the CNS of adult mice (n=5) and plated at 5x104 cells/well in a flat 
bottomed 96 well plate in the presence of M-CSF (5 ng/ml).  After 4 weeks in culture M-CSF 
was removed and MG were primed with 20 U/ml IFN-γ overnight before stimulation with 
LPS (200 ng/ml) with or without IC (106/well).  After four hours, purified CD4+2D2 T cells 
and MOG35-55 (25 µg/ml) were added to the MG cultures for 72 hours.  To block PD-1/PD-L1 
interactions, 2 µg/ml of anti PD-1 (RMP1-14) or rat isotype was added to cultures with the 
stimuli.  CD44 (a) CD62L (b) and CD25 (c) expression was measured by flow cytometry, and 
IL-2 (d) levels were measured by ELISA.  Shown are the means and SEM of triplicate wells 
from two combined experiments.   
a. b. 
c. d. 
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Figure 6.10.  Blocking the PD-1/PD-L1/2 pathway did not significantly alter T cell 
biasing by MG.  MG were isolated from the CNS of adult mice (n=5) and plated at 
5x104 cells/well in a flat bottomed 96 well plate in the presence of M-CSF (5 ng/ml).  After 
4 weeks in culture M-CSF was removed and MG were primed with 20 U/ml IFN-γ overnight 
before stimulation with LPS (200 ng/ml) with or without IC (106/well).  After four hours, 
purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were added to the MG cultures for 
72 hours.  To block PD-1/PD-L1 interactions, 2 µg/ml of anti PD-1 (RMP1-14) or rat isotype 
was added to cultures with the stimuli.  IFN-γ (a) and IL-17A (b) levels were measured by 
ELISA, and CD124 (c) expression was measured by flow cytometry.  Shown are the means 
and SEM of triplicate wells from two combined experiments. 
 
 
a. b. 
c. 
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6.3.4.2 Stimulating the PD-1/PD-L1 pathway in MG:T cell co-cultures 
To further assess whether the decreased expression of PD-L1 on type II MG was involved in 
T cell biasing, PD-L1ch was used to stimulate the PD-1 receptor, which results in increased 
signalling through PD-1.  Similar to the addition of αPD-1 (Figure 6.8), the addition of the 
PD-L1ch did not have any effect on IL-10 or IL-12 production by MG (Figure 6.11).  
Although there did appear to be a trend towards decreased IL-10 with the addition of the 
PD-L1ch, this trend was also seen in the presence of the control protein.  In addition, the 
PD-L1ch did not alter the activation state of the T cell in the co-cultures as assessed by CD44, 
CD62L and CD25 expression (Figure 6.12a, b and c).  Furthermore, the PD-L1ch did not 
change in the level of IL-2 production under any of the MG stimulation conditions (Figure 
6.12d).  As found with the addition of αPD-1, the addition of the PD-L1 chimera to the 
co-cultures did not alter the level of IFN-γ or IL-17A (Figure 6.13a and b).  Moreover, CD124 
expression on T cells was not altered by PD-L1ch (Figure 6.13c).  Taken together, these data 
suggest that the PD-1/PD-L1 pathway is not involved in the induction of T cell biasing in this 
MG:T cell co-culture system despite the decreased expression of PD-L1 on type II activated 
MG, however, an alternate possibility is that the molecule is not active in this system, based 
on the absence of a change in any marker. 
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Figure 6.11.  Stimulating the PD-1/PD-L1 pathway did not significantly alter IL-10 or 
IL-12 production by MG.  MG were isolated from the CNS of adult mice (n=5) and plated at 
5x104 cells/well in a flat bottomed 96 well plate in the presence of M-CSF (5 ng/ml).  After 
4 weeks in culture M-CSF was removed and MG were primed with 20 U/ml IFN-γ overnight 
before stimulation with LPS (200 ng/ml) with or without IC (106/well).  After four hours, 
purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were added to the MG cultures for 
72 hours.  To stimulated PD-1, 8 µg/ml of PD-L1ch or a control IgGch was added to cultures 
with the stimuli.  IL-10 (a) and IL-12 (b) levels were measured by ELISA.  Shown are the 
means and SEM of triplicate wells from two combined experiments.   
 
a. b. 
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Figure 6.12.  Stimulating the PD-1/PD-L1 pathway did not alter T cell activation by MG.  
MG were isolated from the CNS of adult mice (n=5) and plated at 5x104 cells/well in a flat 
bottomed 96 well plate in the presence of M-CSF (5 ng/ml).  After 4 weeks in culture M-CSF 
was removed and MG were primed with 20 U/ml IFN-γ overnight before stimulation with 
LPS (200 ng/ml) with or without IC (106/well).  After four hours, purified CD4+2D2 T cells 
and MOG35-55 (25 µg/ml) were added to the MG cultures for 72 hours.  To stimulated PD-1, 
8 µg/ml of PD-L1ch or a control IgGch was added to cultures with the stimuli.  CD44 (a) 
CD62L (b) and CD25 (c) expression was measured by flow cytometry, and IL-2 (d) levels 
were measured by ELISA.  Shown are the means and SEM of triplicate wells from two 
combined experiments.   
a. b. 
c. d. 
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Figure 6.13.  Blocking the PD-1/PD-L1 pathway does not significantly alter T cell 
biasing by MG.  MG were isolated from the CNS of adult mice (n=5)  and plated at 
5x104 cells/well in a flat bottomed 96 well plate in the presence of M-CSF (5 ng/ml).  After 
4 weeks in culture M-CSF was removed and MG were primed with 20 U/ml IFN-γ overnight 
before stimulation with LPS (200 ng/ml) with or without IC (106/well).  After four hours, 
purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were added to the MG cultures for 
72 hours.  To stimulated PD-1, 8 µg/ml of PD-L1ch or a control IgGch was added to cultures 
with the stimuli.  IFN-γ (a) and IL-17A (c) levels were measured by ELISA, and CD124 (b) 
expression was measured by flow cytometry.  Shown are the means and SEM of at triplicate 
wells from two combined experiments.   
 
a. b. 
c. 
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6.4 Discussion 
Type II activated MΦ have anti-inflammatory properties as seen by their altered cytokine 
profile and express lower levels of IL-12 and higher levels of IL-10 compared to classically 
activated MΦ (Anderson & Mosser, 2002).  It has also been shown that type II inducing 
treatments have an ability to protect mice from proinflammatory conditions such as EAE and 
sepsis, suggesting type II MΦ can alter an inflammatory environment to provide protection 
(Anderson & Mosser, 2002; Tierney et al., 2009).  It was found that MG are capable of being 
activated to a type II phenotype in vitro, and that this activation state is capable of inducing 
differential activation of T cells.  MG are thought to be very important in controlling the 
immune microenvironment in the CNS.  Activation of MG to an anti-inflammatory or 
regulatory state may thus provide protection against neuroinflammatory conditions such as 
EAE.  The aim of this work was to assess whether MG are capable of type II activation by IC, 
a treatment that has been shown to protect from neuroinflammation during EAE (La Flamme 
et al., 2006).   
 
The phenotype of type II activated MΦ has been well documented with the altered cytokine 
profile being the most commonly associated feature.  MG cultured in similar conditions to 
type II MΦ are also capable of type II activation as demonstrated by the trend towards an 
increase in IL-10 production and the decrease in IL-12.  Non-stimulated MG did not produce 
IL-12, which is consistent with previous reports showing that IFN-γ stimulation was not 
sufficient to induce IL-12 production in the absence of LPS (Aloisi et al., 1997).  Type II MG 
also produce lower levels of IL-6.  In addition, when, M-CSF is removed 3 days prior to 
IFN-γ stimulation type II MΦ produce less TNF-α and MCP-1.  This change may be a 
phenotypic alteration or possibly a result of decreased viability in the absence of M-CSF.  
Whether these changes are retained when M-CSF in left in culture longer, which would 
enhance MG viability, needs to be investigated.   
 
MG appear to die soon after they are removed from culture conditions making the assessment 
of cell surface molecules difficult.  Nevertheless, flow cytometric analysis of cultured MG 
suggested that type II activated MΦ expressed lower levels of PD-L1 compared to classically 
activated MG, and this finding is consistent with type II activation.  While CD40 levels were 
increased on classically and type II activated MG compared to non-activated MG, type II 
activated MG did not express the decreased levels of CD40 as expected from previous MΦ 
studies (Tierney et al., 2009).  Overall, the phenotype of MG under type II activating 
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conditions, while not being completely identical to type II MΦ, is consistent with type II 
activation.  This type II activation of MG represents an immunoregulatory phenotype which, 
if induced in vivo would likely be capable of modulating the CNS microenvironment to 
protect from the inflammation seen in EAE and MS. 
 
One possible draw back with this particular model is that the exact number of MG per well in 
a culture plate cannot be quantified precisely.  Because the MG die soon after they are 
removed from the culture, the reseeding of cells at a specific density is unfeasibly difficult.  
However, because similar numbers of MG are seeded in the original cultures for expansion by 
M-CSF, the number of MG per well in each experiment is relatively similar.  Because ten IC 
are used for every MΦ to induce type II activation and the number of MG per well is not 
exactly known, it is possible that the number of immune complexes added (106/well, the same 
number that would be added to a well containing 105 MΦ) may not be equivalent to the ratio 
used for MΦ activation.  Since it has been documented that the amount of IC used and the 
amount of cross linking of the FcγR has an effect on the production of IL-10 (Gallo et al., 
2010), a variable MG:IC ratio may explain the variable levels of IL-10 produced by type II 
activated MG.  However, it has been shown previously that only 1-2 optimally opsonised IC 
are necessary to induce the switch from classical to type II activation in MΦ (Gallo et al., 
2010).  It is therefore unlikely the variable results stem from too many IC but instead from too 
many MG.  One way to further optimise this protocol may be to quantify the average number 
of MG per well.  This could be achieved by staining the MG in each well with a dye that can 
be measured by optical density or fluorescence and comparing this value to different 
concentrations of MΦ.  This approach could be used to approximate the number of MG that 
grow in each well, and allow for normalisation of the experiment. 
 
IL-12 is one of the most commonly used marker for classical activation of MΦ.  This cytokine 
is important for driving the development of Th1 cells and in this way has a negative impact on 
the development of other cell types including Th2 and Th17 (Komiyama et al., 2006; Zhu et 
al., 2010).  IL-12 is known to be produced by MG in EAE (Krakowski & Owens, 1997).  In 
the earlier phases of the disease, proinflammatory cytokines are very important; indeed 
without the expression of IL-12p40 by resident CNS cells, EAE is less severe and the CNS 
microenvironment is biased towards Th2 (Becher et al., 2003).  Early studies using IL-12p40-
deficient mice or blocking antibodies suggested that IL-12 was an essential cytokine in EAE.  
However later studies showed that IL-23, which shares the p40 subunit of IL-12, was the 
essential cytokine in EAE (Cua et al., 2003).  Nevertheless, studies have shown that Th1 cells, 
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along with Th17 cells, are important in the development of EAE (Domingues et al., 2010; 
O’Connor et al., 2008).  The decrease in the level of IL-12 produced by type II MG suggests 
that they would be less supportive of an inflammatory environment.  If this activation state 
were induced in EAE it may be protective as it would not be supportive of encephalitogenic 
Th1 cells and would potentially support a Th2 environment instead. 
 
IL-10 is essential for protection from EAE (Bettelli et al., 1998).  The effects of IL-10 on the 
course of EAE as a whole can be seen using IL-10-/- mice, which have increased disease 
severity, and IL-10 transgenic mice, which are protected from disease (Bettelli et al., 1998).  
IL-10 is important in regulating pathogenic T cell responses by being able to suppress both 
Th1 and Th17 cells and is a key cytokine produced by the Tregs involved in suppressing EAE 
(Fiorentino, Bond, & Mosmann, 1989; Gu et al., 2008; Zhang et al., 2004).  In addition, IL-10 
delivered directly to the CNS using fibroblasts induced to express IL-10 by retroviruses 
resulted in significant protection from EAE and suggests that local expression of IL-10 can be 
very effective at controlling inflammatory damage (Croxford et al., 2001).  If the production 
of IL-10 could be induced earlier it may promote disease resolution or even prevent the 
development of the inflammatory response.  Therefore, the increased production of IL-10 by 
the type II activated MG could be very beneficial in EAE. 
 
In addition to IL-12/IL-23, IL-6 is essential for the induction of EAE.  IL-6 deficient mice are 
resistant to active EAE induction, and have also been shown to be resistant to EAE induction 
by adoptive transfer using T cells from wild type animals (Mendel, Katz, Kozak, Ben-Nun, & 
Revel, 1998).  The exact role that IL-6 plays in EAE is multifaceted.  While IL-6 is important 
for the development of Th17 cells, adoptive transfer experiments suggest that the expression 
of IL-6 by resident CNS cells is also important (Bettelli et al., 2006; Mendel et al., 1998).  
Experiments using IL-6 deficient mice have demonstrated that in the absence of IL-6 
VCAM-1, which is important for T cell trafficking into the CNS, is not upregulated on the 
endothelium as it is in wild type controls, thus preventing infiltration into the CNS (Eugster, 
Frei, Kopf, Lassmann, & Fontana, 1998).  Furthermore, over expression of IL-6 by astrocytes 
specifically in the cerebellum switched the progression of C57BL/6 EAE from a primarily 
spinal cord based disease to one in the cerebellum (Quintana et al., 2009).  This switch 
suggests that the expression of IL-6 may alter the microenvironment to encourage 
inflammation and immune cell trafficking.  In this study, type II activated MG expressed 
lower levels of IL-6 compared to classical activation.  As IL-6 has such an important role in 
EAE, it is possible that decreased expression of IL-6 by microglia could have a protective 
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effect by reducing the expression of VCAM-1 on the endothelium.  Thus though a reduction 
in IL-6, type II activation of MG may provide a protective phenotype if induced in vivo.  
However, the overall reduction in IL-6 would need to be balanced with production by other 
cells as IL-6 can be produced by other cells including astrocytes (Ma et al., 2010). 
 
MCP-1 (also known as chemokine ligand 2; CCL-2) is a CC type chemokine, and is released 
by both immune and non-immune cells.  In the CNS, astrocytes, microglia and invading 
immune cells have been shown to produce MCP-1 (Hayashi, Luo, Laning, Strieter, & Dorf, 
1995).  MCP-1 is often described as having dual roles.  MCP-1 is a chemotactic protein that is 
involved in the recruitment of immune cells, such as monocytes and T cells, into sites of 
inflammation, thus promoting inflammatory responses.  Conversely, MCP-1 is also important 
in the development of Th2 type responses, which are associated with protection in EAE (Gu 
et al., 2000).   
 
While type II activation of MG did not result in a decrease in MCP-1 when M-CSF was left in 
culture until IFN-γ stimulation, the decrease in MCP-1 when the M-CSF was removed 3 days 
prior to IFN-γ stimulation warrants further investigation.  In EAE, elevated MCP-1 in the 
CNS is associated with increased disease severity in progressive and relapsing disease models 
(Huang, Wang, Kivisakk, Rollins, & Ransohoff, 2001).  In addition, specific deletion of 
MCP-1 from the CNS but not the periphery demonstrated that production of MCP-1 by the 
resident cell is important for the development of disease, and this deletion of MCP-1 in the 
CNS provides protection form EAE (Dogan, Elhofy, & Karpus, 2008).  Due to the well 
established role of MCP-1 in EAE, a decrease in production by MG in vivo, would likely be 
protective. 
 
Similarly to MCP-1, TNF-α was not significantly altered by type II activation when the 
M-CSF was removed at the time of IFN-γ stimulation, but was significantly decreased when 
the M-CSF 3 days prior to IFN-γ stimulation; this interesting finding merits further 
investigation.  TNF-α is a proinflammatory cytokine, which is important in host defence 
against pathogens but also has vital roles in the other conditions such as injury, burns and 
ischemia (Cairns, Panacek, Harken, & Banerjee, 2000).  TNF-α is produced by many cell 
types including MΦ and MG and has been shown to be produced by both these cell types in 
EAE (Renno, Krakowski, Piccirillo, Lin, & Owens, 1995).  In addition to its proinflammatory 
properties, TNF-α is capable of altering the permeability of the vascular endothelium, both in 
the peripheral circulation and in the BBB (Mayhan, 2002; Yang, Gong, Qin, Liu, & Lorris 
Chapter 6- Type II Activation of Adult Microglia 161 
 
Betz, 1999).  A decrease in the effects of TNF-α on the BBB would help to prevent the 
movement of inflammatory cells from the blood into the CNS parenchyma.  Therefore, if type 
II MG are shown to decrease TNF-α, this reduction in TNF-α may be a potential mechanism 
to decrease CNS inflammation in EAE. 
 
CD40 expression in the periphery is essential for the development of EAE; however, 
interruption of the interaction between MG and T cells by specifically deleting CD40 from the 
CNS also results in decreased disease severity in EAE (Becher, Durell, Miga, Hickey, & 
Noelle, 2001), and in addition, ligation of CD40 on human MG is known to induce IL-12 
production (Becher, Blain, & Antel, 2000).  Further reports demonstrated that mice that 
lacked CD40 expression in the CNS had impaired MG activation.  This lack of CD40 was not 
only associated with decreased MG activation, but also with decreased proliferation of T cells 
in the CNS (Ponomarev et al., 2006).  If type II activated MG also showed a similar level of 
CD40 down regulation then it would be conceivable that they may be less responsive to 
CD154 stimulation by activated T cells that migrate into the CNS, which could result in 
lowered disease burden. 
 
Due to the lowered level of CD40 seen on type II activated MΦ (Tierney et al., 2009), it was 
hypothesised that type II activation of MG may produce a similar effect on CD40 levels.  If 
this activation state could be achieved in vivo it could provide a potential pathway for 
protection from disease.  However, despite type II activated MG displaying a cytokine profile 
similar to type II activate MΦ, the expression of CD40 on type II activated MG was 
comparable to classical activation.  This finding suggests that lowered CD40 expression is 
unlikely to be the method by which type II MG could protect from EAE. 
 
PD-1/PD-L1 interactions are involved in peripheral tolerance and have been shown to be 
important in many autoimmune conditions, including EAE.  Both PD-1 and PD-L1 knockout 
mice exhibit an increased severity of EAE compared to wild type strains (Carter et al., 2007; 
Ortler et al., 2008; Salama et al., 2003).  PD-L1 knockout mice have also been shown to have 
increased T cell infiltrates into the CNS at peak disease (Ortler et al., 2008).  In addition the 
expression of PD-L1 is markedly increased on MG in EAE, particularly during late stage of 
disease, suggesting PD-L1 may be important in the regulation of T cell responses in the CNS 
and the resolution of inflammation (Magnus et al., 2005).  T cells cultured with neonatal 
microglia that express higher levels of PD-L1 (in response to high level IFN-γ stimulation) 
produce lower levels of proinflammatory cytokines (Magnus et al., 2005).   
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The results of this study suggest that type II activated MG express lower levels of PD-L1, 
compared to classically activated MG.  Due to the inhibitory nature of PD-L1 and the 
protective role it plays in EAE, the decreased expression of PD-L1 on type II activated MG 
may not be advantageous.  However, it is possible that the decreased expression of PD-L1, in 
combination with the other changes seen in type II MG (such as increased IL-10 and 
decreased IL-12) would create an overall environment that could support the expansion of 
protective T cell responses while inhibiting detrimental proinflammatory T cell responses.  
Thus, it needs to be determined whether MG can be type II activated in vivo in response to IC 
treatment, whether a decrease in PD-L1 also occurs in vivo, and if this change is associated 
with protection from EAE. 
 
A large part of the role MG play in inducing or protecting from disease likely lies in their 
ability to interact with T cells.  Other forms of activated MΦ, such as the alternatively 
activated MΦ, do not efficiently present antigen to T cells and are therefore unable to drive a 
T cell response (Edwards et al., 2006).  Given the inability to induce antigen specific T cell 
responses, were MG activated to an alternatively activated MG should not be effective at 
regulating the T cells directly.  Conversely, type II activated MΦ are capable of presenting to 
and driving the activation of T cells (Anderson & Mosser, 2002).  Therefore, type II 
activation of MG may not simply be able to induce an immunoregulatory environment, but 
may also be capable of interacting with T cells to down regulate pathogenic T cell responses.   
 
In the current study it was found that IFN-γ primed MG were capable of inducing a T cell 
response, inducing T cells to produce large amounts of both IFN-γ and IL-2.  Interestingly, 
MG primed with IFN-γ alone or MG primed with IFN-γ and subsequently stimulated with 
LPS induced similar levels of IFN-γ and IL-2 from T cells.  This increase in IFN-γ production 
in co-cultures occurs despite there being significantly different levels of IL-12, a cytokine 
known to be important in Th1 development (Kaplan et al., 1996), in cultures with LPS 
stimulated and non-stimulated MG cultures.  This finding is contrary to the results seen in 
MΦ co-cultures, where IFN-γ-primed, LPS-stimulated MΦ induced T cells to produce 
significantly more IFN-γ than MΦ primed with IFN-γ but without LPS stimulation.  As with 
MΦ cultures, IFN-γ was removed from the MG culture before the stimuli (e.g. LPS) were 
added.  Therefore, the IFN-γ present in the culture supernatants is due to in vitro production 
not the result of residual IFN-γ left over from the priming process.  This result may suggest 
that MG have an increased ability to activate T cells and, given that the MG vastly increased 
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IFN-γ production under non-biasing conditions, may suggest that MG preferentially bias 
towards Th1.   
 
IFN-γ is used to prime MG in many studies, and it has been found that IFN-γ can induce 
activation of MG and the upregulation of several cell surface molecules such as CD40 (Li et 
al., 2007; Ponomarev et al., 2006).  IFN-γ also stimulates MΦ, and is known to induce 
microbicidal activity (Szabo et al., 2003).  In the current study, relatively low concentrations 
of IFN-γ (20 U/ml) were used to prime both MΦ and MG.  This low level of IFN-γ was 
chosen because IL-10 production by MΦ has been shown to be highest at this concentration, 
and therefore this level of stimulation provides optimal conditions for type II activation of 
MΦ (Tierney et al., 2009).  Although type II activation of MΦ does still occur using higher 
levels of IFN-γ (Gerber & Mosser, 2001; Sutterwala et al., 1998; Tierney et al., 2009).  
Previous reports using neonatal cultures have shown that MG stimulated with 100 U/ml IFN-γ 
are able to stimulate T cell proliferation and IFN-γ production (Li et al., 2007).  In addition, 
IFN-γ doses as low as 10 U/ml have been shown to stimulate MG to become efficient APC to 
pre-activated Th1 and Th2 cell lines (Aloisi, Simone, Columba-Cabezas, Penna, & Adorini, 
2000).  This suggests the low level of IFN-γ used in the current study should be sufficient to 
induce MG to become efficient APC cells, despite the T cells used in this study being naïve, 
not pre-activated.  Unstimulated MG (IFN-γ primed) produce low to undetectable levels of 
IL-12.  Given that it has been shown that IFN-γ in combination with CD40/CD154 
interactions drives IL-12 production (Aloisi, Penna, Polazzi, Minghetti, & Adorini, 1999), one 
could speculate that these MG may be producing low levels of IL-12, which is driving IFN-γ 
production, but as the IL-12 is being taken up by the T cells, it is therefore undetectable in the 
culture supernatant.   
 
Unstimulated, IFN-γ primed MΦ do not drive an adaptive immune response in the same way 
that IFN-γ primed MG do.  Possibly, this difference is because MG are more sensitive to 
IFN-γ and due to MG existing in an immune privileged environment where they would not be 
exposed to IFN-γ.  MΦ in the periphery, which are more commonly exposed to IFN-γ may 
have a higher threshold for IFN-γ stimulation to prevent aberrant activation and collateral 
tissue damage.  However, activation of T cells with MG that have not been primed with IFN-γ 
was not assessed in this study.  IFN-γ priming was employed as early results in this study 
demonstrated that IFN-γ enhanced LPS driven IL-12 production by MG (Chapter 5).  The 
relatively high level of CD124 expression on T cells cultured with unstimulated, IFN-γ-
primed MG compared to those cultured with classically activated MG could suggest that these 
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IFN-γ primed MG, while activating T cells, are not as efficient at biasing the T cell response 
towards a Th1 type response.  
 
MG in the current study were grown for 4 weeks in the presence of M-CSF in order to obtain 
high enough cell numbers for experimentation.  It is possible that the exposure to M-CSF may 
alter the way the MG respond and affect the way in which the MG interact with T cells as MΦ 
were not differentiated using M-CSF in this work.  M-CSF was chosen for the current study 
over other proliferative factors such as GM-CSF due to the fact that GM-CSF induces MG to 
differentiate into a DC like phenotype whereas MG exposed to M-CSF maintain a phenotype 
consistent with resting MG (Ponomarev et al., 2005).  Indeed, treatment of adult MG with 
GM-CSF enhanced Th1 responses in vitro while M-CSF was not reported to have the same 
effect (Aloisi et al., 2000).  Expansion of rat neonatal microglia with M-CSF did not affect 
their response to LPS (Vidyadaran et al., 2009).  Furthermore, culture of adult MG for 4 
weeks has been shown to have a similar phenotype to freshly isolated adult MG cells 
(Ponomarev et al., 2005).  Thus, while it is possible the M-CSF is responsible for the 
differences in the MG responses compared to MΦ, the finding that the M-CSF expanded MG 
are similar to freshly isolated MG, suggests that this M-CSF culture method does not have a 
large effect on MG responses.   
 
Type II activated MG bias the T cell response in a distinct way from type II MΦ, although 
some features are shared.  For example, there is a strong trend towards an increase in CD124 
expression on T cells cultured with type II activated MG compared to those activated by 
classically activated MG.  This increase in CD124 suggests that the T cells may be more 
responsive to IL-4.  This could be potentially protective in EAE as it has been shown that MG 
produce IL-4 during EAE and that disease is more severe if the production of IL-4 is 
prevented (Ponomarev et al., 2007).  In addition, type II activated MG induced production of 
high levels of IL-17A, compared to T cells cultured with classically activated MG.  The exact 
pathway leading to increased IL-17A production by type II activated MG as not been 
elucidated; however, it is possible that some of the potential mechanisms described in chapter 
3 may be involved.  For example, it is possible that these type II MG are producing increased 
levels of TGF-β.  In conjunction with IL-6, which although significantly decreased in type II 
MG is still present in cultures, could potentially drive IL-17A production (Bettelli et al., 
2006).  This particular facet of T cell biasing of type II MG would potentially be detrimental 
in EAE.  Th17 responses are considered pathogenic in EAE and are associated with the 
recruitment of neutrophils that are capable of causing significant tissue damage (Louten et al., 
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2009).  It should be noted that the level of IL-17A production, while significantly increased in 
T cells cultures with type II activated MG compared to other conditions, is relatively low 
compared to IFN-γ, therefore the ability of this cytokine to dominate an adaptive response in 
vivo remains to be determined.   
 
Due to the differential effect that type II and classically activated MG have on T cells, the 
pathways involved in the biasing of the T cell response were investigated.  Flow cytometry 
data suggested that PD-L1 was down regulated on type II MG and has been found on type II 
MΦ, and so this pathway was investigated.  As stated previously, PD-L1 is generally 
considered an inhibitory pathway involved in suppression of T cell responses (Carter et al., 
2002).  In the CNS, PD-L1 is upregulated in late stages of EAE and may be involved in 
resolution of the immune response (Magnus et al., 2005).  However, in the context of type II 
activation, PD-L1 may be involved in the biasing of T cell responses.  Therefore, this 
decrease in PD-L1 may be protective by biasing the T cell response towards less pathogenic 
phenotype.  In the current study, αPD-1 and the PD-L1ch were used to block or stimulate the 
PD-1/PD-L1 pathway to T cells respectively.  Despite the well known role of the PD-1/PD-L1 
pathway in the inhibition of T cell responses (Carter et al., 2002), neither the αPD-1 nor the 
PD-L1ch had any further effect on the activation state of T cells beyond what was induced by 
the different activation states of the MG.  In addition, the alteration in the PD-1/PD-L1 
pathway also did not alter the biasing of the T cell response.  This data is in line with those 
from Chapter 4 which demonstrate that this pathway is also not strongly involved in T cell 
biasing by classically or type II activated MΦ and suggests that the reduced expression of 
PD-L1 on type II MG is not involved in T cell biasing.   
 
It is possible that αPD-1 and the PD-L1 chimera were not used at high enough concentration 
to see an effect.  Due to the limited numbers of MG available per experiment, it was not 
feasible to perform a titration experiment using MG, therefore the αPD-1 and the PD-L1ch 
were used at the same concentrations as in the MΦ:T cell experiments (Chapter 4).  As 
explained Chapter 4, it is likely that these molecules are being used at sufficient concentration 
to elicit a response based on the concentrations from previous studies (Vogt et al., 2006; 
Yamazaki et al., 2005).  As there was no change in any markers, an alternate possibility is that 
the αPD-1 and the PD-L1ch were not active in this system, PD-L1. The PD-1/PD-L1 pathway 
is known to be important in inhibiting proliferation (Carter et al., 2002; Konkel et al., 2010), 
which was not measured in this study, it is possible this could be used as a positive control.  
Additionally, other methods for altering PD-1/PD-L1 interaction may provide further 
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information, such as RNAi experiments.  As the role of PD-L1 in EAE may be to restrain the 
proliferation of encephalitogenic T cells in the CNS, the decreased PD-L1 on type II MG may 
be important in vivo for the inhibition of T cell responses and not the biasing of T cell 
responses in the CNS. 
 
6.5 Summary 
This chapter conclusively demonstrates for the first time that in response to prototypical 
classical (LPS) and type II (LPS+IC) activating conditions, MG develop phenotypes that 
clearly resemble classical and type II activation respectively.  As type II MΦ are 
immunoregulatory, and have been demonstrated to be protective in EAE (Tierney et al., 
2009), these type II activated MG may also be protective in EAE.  Their ability to regulated 
T cell resposnes is particularly importantas these type II activated MG would be acting at the 
site of inflammation to help regulate the local response. 
 
Overall these data suggest that MG do not activate T cells in the same manner as MΦ, despite 
having similar activation profiles.  Of note is that the T cells cultured with unstimulated MG 
have a similar activation state and IFN-γ production compared to T cells cultured with 
classically or type II activated MG.  This finding suggests that the ability of MG to induce 
T cell responses is increased compared MΦ since unstimulated MΦ are poor activators of 
T cell responses.  One of the major features of T cell biasing by type II MΦ (i.e. the decreased 
IFN-γ) is not present in the MG cultures suggesting the MG are not capable of biasing away 
from a Th1 type response.  However, the T cells cultured with type II activated MG produced 
higher levels of IL-17A as well as a tendency towards increased levels of CD124 suggesting 
that some of the features of T cell biasing by type II MΦ and conserved by activation of 
T cells by type II MG.  Finally, this work showed that the PD-1/PD-L1 pathway does not 
appear to have a role in the biasing of T cell responses by classically and type II activated 
MG. 
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7.1 Introduction 
The previous results from this thesis indicate that in vitro stimulation of MG under type II 
activating conditions (LPS+IC) results in a type II activated phenotype similar to that seen 
with MΦ activated under the same conditions.  In addition to this phenotypic similarity, the 
ability of type II activated MG to induce and bias an antigen-specific T cell response in 
co-culture was also similarly modified.  As these results demonstrate that in in vitro cultures 
type II activated MG display a similar phenotype and function as type II activated MΦ, the 
effect of type II activating treatments on the MG phenotype in vivo was assessed.   
 
Initially, for the study of MG activation in vivo it had been intended that the BALB/c model 
of EAE would be used because, although this model is used less frequently than the C57BL/6 
model, it displays a different histopathological phenotype.  Unlike C57BL/6 mice in which 
CNS lesions are primarily located in the spinal cord (Pham et al., 2011), lesions in BALB/c 
mice develop principally in the upper CNS and are more similar to those in MS patients 
(Personal communication, Dr Jacqueline Orian; La Trobe University, Melbourne, Australia; 
manuscript in preparation).  However, despite the protection seen when C57BL/6 mice are 
treated with IC in EAE, the treatment of BALB/c mice did not provide protection (see 
appendix C).  The IC treatment was compared to glatiramer acetate (GA), a common 
treatment for MS which has also been shown to induce a MΦ activation state similar to type II 
activation (Weber et al., 2007).  However, GA provided minimal protection in BALB/c mice 
even at a concentration that provides almost complete protection in C57BL/6 mice (Toker et 
al., 2011; see appendix C).  As IC treatment is not effective in BALB/c mice, C57BL/6 mice 
were used for the assessment of MG in vivo.  MG in the CNS of C57BL/6 mice were 
assessed, thus the changes observed in this study are changes in the activation state of MG 
under inflammatory conditions as a whole, as opposed to a change specifically at the site of 
inflammation.   
 
In the CNS of a naïve mouse, MG can be easily identified on the basis of CD45lo staining as 
they are the only CNS cell type that expresses this marker.  However, in vivo study of MG in 
an inflamed CNS is hampered due to the fact that activated MG take on a phenotype that is 
indistinguishable from peripheral MΦ/monocytes that invade the CNS in EAE (Melchior et 
al., 2006; Ponomarev et al., 2006).  In order to study MG in vivo bone marrow chimeric mice 
were generated.  As described in methods, C57BL/6 mice, which express the CD45.2 allele, 
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were lethally irradiated and their bone marrow was replaced with that from B6.SJL-ptprca 
mice, which express the CD45.1 allele but are otherwise considered genetically identical to 
C57BL/6 mice.  As the CNS is not sensitive to irradiation, the MG do not get ablated in the 
same way the peripheral immune system does.  Therefore, following bone marrow 
reconstitution, the peripheral immune system will express CD45.1 and the MG in the CNS 
will express CD45.2.  Thus under inflammatory conditions, MG can be distinguished from 
invading cells on the basis of CD45.2 expression.   
 
Treatment of mice with IC, which induce type II activation, has been shown to provide 
protection from EAE in C57BL/6 mice (La Flamme et al., 2006).  IC treatment of 
unimmunised mice increased the levels of IL-10 and IL-5 produced by ConA stimulated 
splenocytes, suggesting an overall shift in the immune response towards a Th2 response.  In 
addition protection from disease in immunised mice was associated with increased Th2 
responses in the periphery.  Furthermore, increases in IL-10 and IL-4, and a decrease in IL-12 
was observed in the spinal cords of IC treated immunised mice (La Flamme et al., 2006).  
This study shows that IC treatment in vivo has the ability to alter both the peripheral and the 
CNS immune responses.   
 
In vitro, type II activated MG display a phenotype that is highly likely to be protective in vivo.  
The proinflammatory molecules IL-12 and IL-6 that are detrimental in EAE (Becher, Durell, 
& Noelle, 2003; Quintana et al., 2009) are down regulated by type II activated MG (chapter 
6).  The reduction in these cytokines could potentially help to reduce disease by decreasing 
recruitment of immune cells and altering interactions between MG and T cells.  Previous 
studies have shown that a reduction in pathological CNS inflammation can be induced by 
altering the ability of MG to produce proinflammatory cytokines or interact with T cells 
(Becher, Durell, Miga, Hickey, & Noelle, 2001; Becher et al., 2003). 
 
7.2 Aims 
The aim of this chapter was to optimise a protocol for the creation of bone marrow chimeras 
and to use this protocol to investigate the ability of type II activating treatments to affect the 
activation state of MG in vivo.  In addition, effects of IC treatment on the peripheral immune 
system were investigated to look at any potential correlations between the peripheral immune 
system and the immune response and the CNS. 
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7.2.1 Specific aims 
1. To assess the effects of type II activating treatments on the peripheral immune system, 
based on the changes in T cell cytokines seen in MΦ:T cell co-cultures. 
2. To use flow cytometry to assess invasion of peripheral immune cells as well as the 
phenotype of both peripheral and resident immune cells by assessing cell surface 
expression. 
3. To assess the pattern of MG activation in the CNS by immunohistochemistry. 
4. To optimise a protocol for the generation of bone marrow chimers and the isolation of 
MG cells. 
5. To use bone marrow chimeras to isolate MG from the CNS of naïve mice and mice 
with EAE to assess the effect of IC treatment on the MG by qPCR. 
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7.3 Results 
 
7.3.1 Treatment with IC protects from EAE 
Because the ultimate aim of this work was to determine if and how type II activation in vivo 
affected the resident MG using bone marrow chimeras, the ability of IC to induce protection 
in this model was first verified.  Bone marrow chimeric mice were generated by irradiation of 
C57BL/6 mice and transfer of either B6.SJL-ptprca bone marrow (B6C57) or C57BL/6 
bone marrow (C57C57). The C57C57 group served as a control for the B6C57 group 
and allowed evaluation of any possible effects due to irradiation and reconstitution of the 
bone marrow.  Six-ten weeks following irradiation, the phenotype of peripheral immune cells 
was assessed to determine the extent of reconstitution bone marrow.  As expected, the level of 
CD45.2+ cells in blood samples from B6C57 mice was high with 95.66% ± 0.1897 cells 
positive for CD45.2 (mean ± SEM from 73 mice over 5 experiments) demonstrating high 
levels of reconstitution of the bone marrow.  Treatment of B6C57 mice with IC reduced the 
severity of disease in mice immunised for EAE as seen by reduced disease scores compared to 
untreated mice (Figure 7.1a, c and e).  This reduction in severity reached statistical 
significance in some experiments, however, the severity of the disease course was quite 
variable between experiments.  In contrast, the incidence of disease was more consistently 
decreased in IC-treated mice in these experiments than the disease score (Figure 7.1b, d and 
f), and IC-treated mice tended to have a lower cumulative disease (Figure 7.2).  C57C57 
mice showed similar patterns of disease as B6C57 mice indicating the irradiation and bone 
marrow reconstitution did not affect disease expression (see appendix C).  Together these data 
show that IC treatment has a beneficial effect in EAE by reducing the severity and overall 
incidence of disease and that this chimeric model can be used to explore the involvement of 
the radiation-resistant, resident CNS immune cells (i.e. MG).   
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Figure 7.1.  Treatment of mice with IC reduced the severity and incidence of EAE.  
Seven weeks following irradiation and reconstitution of B6C57 animals, mice were 
pre-treated with 2x106 IC by i.p. injection one week before immunisation and weekly 
thereafter.  Mice were immunised to induce EAE as described in the methods.  Disease scores 
(a, c, e) and incidence (b, d, f) for 3 of 5 experiments are shown (n=5/group).  **p<0.01; 
****p<0.0001 by two way ANOVA with Sidak’s multiple comparison post test. 
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Figure 7.2.  Treatment of mice with IC reduced the cumulative disease in EAE.  Seven 
weeks following irradiation and reconstitution of B6C57 animals, mice were pre treated 
with 2x106 IC by i.p. injection one week before immunisation and weekly thereafter.  Mice 
were immunised to induce EAE as described in the methods. Shown are the means and SEM 
of cumulative disease for individual mice (n=5/group) and calculated as the area under the 
curve or AUC.  Shown are 3 of 5 individual experiments.  **p<0.01 by Mann Whitney U test. 
 
c. 
a. b. 
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7.3.2 IC treatment alters the peripheral immune response 
Previous studies have demonstrated the abilities of both IC and type II MΦ to induce 
protective changes in the peripheral immune responses (La Flamme et al., 2006; Tierney et 
al., 2009).  The peripheral immune responses were assessed using restimulation assays in 
which splenocytes are stimulated with ConA (polyclonal stimulation) and MOG (antigen 
specific stimulation).  In the current study, low levels of IL-4 were detected in supernatants 
from splenocyte cultures at peak disease stimulated with ConA, and there was a trend towards 
increased levels of IL-4 in ConA-stimulated splenocytes from IC-treated mice compared to 
untreated.  This trend was seen in both immunised and unimmunised groups (Figure 7.3b).  
Only very low levels were detected without stimulation or in response to MOG (Figure 7.3b).  
Taken together, the increase in polyclonally-stimulated IL-4 suggests a shift in the overall 
immune environment in the periphery supporting the idea that IC treatment promotes a 
systemic Th2 environment in vivo.   
 
In contrast to IL-4, ConA strongly induced the production of IFN-γ by all treatment groups 
(Figure 7.3a).  In cultures from unimmunised mice, IC treatment resulted in a significant 
reduction in IFN-γ compared to untreated mice (Figure 7.3a).  This effect was not mirrored in 
the cultures from immunised mice, in which equivalent levels of IFN-γ were produced (Figure 
7.3a).  Additionally, IFN-γ production by cultures from untreated immunised mice was 
modestly but significantly lower than that seen in cultures from untreated, unimmunised mice.  
Similar to polyclonal responses, antigen-specific IFN-γ production was equivalent between IC 
and untreated immunised mice suggesting that although immunisation induces antigen 
specific production of IFN-γ, IC treatment does not alter this response (Figure 7.3a).  In 
contrast to IFN-γ, IL-17A production in response to both ConA and MOG was significantly 
higher in immunised mice compared to unimmunised for both treatment groups (Figure 7.3c).  
In addition, while immunisation induced significant production of IL-17A by both treatment 
groups, it was significantly higher in cultures from IC-treated mice compared to untreated 
mice suggesting that as found in in vitro cultures, IC treatment enhances antigen-specific 
IL-17A responses in vivo (Figure 7.3c).   
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Figure 7.3.  Treatment of mice with IC alters the production of cytokines by splenocytes.  
Seven weeks following irradiation and reconstitution of B6C57 animals, mice were pre-
treated with 2x106 IC by i.p. injection one week before immunisation and weekly thereafter.  
Mice were immunised to induce EAE as described in the methods.  At peak disease, 
splenocytes (1x106/well) were isolated and cultured alone or with ConA (3 µg/ml) or MOG 
(27 µg/ml) for 48 hours (ConA) or 72 hours (MOG).  IFN-γ (a), IL-4 (b) and IL-17A (c) 
levels were measured by ELISA.  Data shown are means and SEM of triplicate wells from 
two combined experiments (n=10 mice/group, for immunised and 4-6 mice/group for 
unimmunised).  *p<0.05, **p<0.01, ****p<0.0001 by one way ANOVA with Tukey’s 
multiple comparison post test. 
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7.3.3 IC treatment altered the phenotype of myeloid cells in the brain 
To further investigate the in vivo activation state of MG from mice that had received a type II 
activating stimulus, the brains of C57C57 mice were processed by flow cytometry.  As the 
mice used for flow cytometry are C57C57 and not B6C57, the resident cells cannot be 
identified on the basis of expression of a specific CD45 isotype.  However, given that most 
lesions develop in the lower CNS in this model, it is likely that the majority of the cells 
isolated from the brains of these animals are CNS resident and not a result of peripheral 
infiltration.  Using the haematopoietic marker CD45 and the myeloid marker CD11b (i.e. 
complement receptor 2), 3 distinct populations of CD45+CD11b+ (CD45hiCD11b++, 
CD45intCD11b+, CD45loCD11b+) cells can be found in the brains of C57C57 mice, which 
represent 3 distinct populations of cells (Figure 7.4, see appendix D for gating strategy).  
These 3 different myeloid populations were present at different levels in the brains of 
immunised mice compared to naïve mice.   
 
In immunised mice there is a comparably large population of CD45hiCD11b++ cells (Figure 
7.4a).  This same population is reduced in naïve mice, with only a small number present 
(Figure 7.5b).  This population is composed of peripheral immune cells, which are known to 
be CD45hi (Ponomarev et al., 2006; Sedgwick et al., 1991; Zhang, Li, Ventura, & Rostami, 
2002).  However, it is possible that some activated MG may also be present in the 
CD45hiCD11b++ population, as MG increase CD45 on activation (Ponomarev et al., 2006).  
CD45hiCD11b++ cells are significantly increased in the brains of IC-treated immunised mice 
compared to IC-treated unimmunised mice (Figure 7.4c), and a strong trend towards increased 
CD45hiCD11b++ was seen between immunised and unimmunised mice from the untreated 
groups (Figure 7.4c).  This result suggests that despite the absence of evident lesions in the 
brains of C57BL/6 mice, myeloid cell infiltration into the brain is induced by immunisation in 
this model. 
 
In all treatment groups the most abundant myeloid population within the brain was the 
CD45loCD11b+ population (Figure 7.4e).  This CD45loCD11b+ population represents the 
resident, parenchymal MG cells of the brain.  As MG upregulate expression of CD45 
following activation (Ponomarev et al., 2006; Sedgwick et al., 1991), this population may 
represent MG that are either unactivated or are not highly activated.  Immunisation induced a 
trend towards decreased percentage of CD45loCD11b+ cells in the myeloid compartment of 
the brain, compared to unimmunised mice, and this difference was also significant between 
Chapter 7- Effects of type II inducing treatment in vivo  177 
 
 
 
the IC-treated groups (Figure 7.4e).  However, as both immunised groups also saw an increase 
in CD45hiCD11b+ cells, this proportional decrease could potentially be the result of an 
increase in the infiltrating cells.  Alternatively, immunisation could induce a decrease in 
resting or unactivated MG.   
 
The third population of CD45+CD11b+ cells was CD45intCD11b+ and the proportion of 
myeloid these cells was similar among all treatment groups (Figure 7.4d).  As seen in the flow 
cytometry plots, this population is distinct although the level of CD45 expression on these 
cells overlaps with that of the resident MG population (Figure 7.4a and b).  There is a general 
consensus in the literature that the CD45hiCD11b++ cells are peripheral immune cells and that 
CD45loCD11b+ are resident MG (Melchior et al., 2006; Ponomarev et al., 2006; Sedgwick et 
al., 1991; Zhang et al., 2002).  However, the literature is less clear on the exact cell type 
represented by the CD45intCD11b+ cells.  These cells were found in both immunised and 
unimmunised mice and therefore, they are likely to be resident cells and represent a 
population of CNS-associated MΦ, such as perivascular MΦ (Zhang et al., 2002). 
 
To understand if the activation state of these myeloid cells was altered, the expression of 
MHC class II, CD40, and PD-L1 was assessed.  Immunisation did not alter MHC class II 
expression on resident MG cells (CD45loCD11b+) nor did treatment with IC (Figure 7.6a).  
Similarly, expression of CD40 was consistent among all treatment groups (Figure 7.6c).  
PD-L1 was significantly increased on MG from untreated, immunised mice compared to 
untreated unimmunised mice. A similar trend in PD-L1 expression was seen in the IC-treated 
groups; however, this trend did not reach significance (Figure 7.6b).  Overall, these data 
suggest that MG from immunised mice do not upregulate markers involved in T cell 
activation.  Alternatively, the increase in PD-L1 expression on MG may indicate a switch to a 
suppressive phenotype that may regulate T cell-mediated inflammation in both treatment 
groups. 
 
In contrast to MG (CD45loCD11b+) cells, which did not have altered expression of MHC 
class II, MHC class II expression was upregulated on CNS-associated MΦ from immunised 
mice and this increase was significantly attenuated by IC treatment (Figure 7.5b).  In addition, 
the percentage of MHC class II-positive cells in this CNS associated MΦ population was 
significantly higher in untreated compared to IC-treated, immunised mice. Neither the 
expression of CD40 nor the expression of PD-L1 was altered on CNS-associated MΦ (Figure 
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7.5a and c), and there was no difference in any of these activation markers between the two 
unimmunised groups (Figure 7.5).  The increased expression of MHC class II on CNS-
associated MΦ from untreated compared to IC-treated, immunised mice suggests that the MΦ 
population in the untreated mice may be more capable of presenting antigens and activating 
T cells. 
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Figure 7.4. EAE altered the composition of the myeloid compartment in the brain.  Six-
seven weeks following irradiation and reconstitution of C57C57 animals, mice were pre-
treated with 2x106 IC by i.p. injection one week before immunisation and weekly thereafter.  
Mice were immunised to induce EAE as described in the methods. At peak disease, 
haematopoietic cells were isolated from brains and analysed by flow cytometry.  
CD45+CD11b+ live, single cells were gated as shown in appendix.  Representative plots from 
an immunised (a) or an unimmunised mouse (b) showing the gates: R1 (CD45hiCD11b+), R2 
(CD45intCD11b+), and R3 (CD45loCD11b+).  CD45hiCD11b+ (c), CD45intCD11b+ (d), and 
CD45loCD11b+ (e) are expressed as the percentage of total CD45+CD11b+ cells and shown 
are the means and SEM from two combined experiments (n=10/immunised groups, 6/IC 
treated, unimmunised group, and 4/untreated, unimmunised group).  *p<0.5, **p<0.01, by 
one way ANOVA with Tukey’s multiple comparisons post test.
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Figure 7.5. IC treatment altered the expression of MHC class II on CNS-associated MΦ.  
Six-seven weeks following irradiation and reconstitution of C57C57 animals, mice were 
pre-treated with 2x106 IC by i.p. injection one week before immunisation and weekly 
thereafter.  Mice were immunised to induce EAE as described in the methods. At peak 
disease, haematopoietic cells were isolated from brains and analysed by flow cytometry. 
CD45intCD11b+ live, single cells were gated as shown in Figure 7.5. MHC class II (I-Ab) 
(percent positive, a; geomean, b), PD-L1 (c) and CD40 (d) expression were assessed on CNS 
associated MΦ (CD45intCD11b+) cells.  Shown are the means and SEM from two combined 
experiments (n=10/immunised groups, n=6/IC treated, unimmunised group, and 
n=4/untreated, unimmunised group).  *p<0.5, **p<0.01, by one way ANOVA with Tukey’s 
multiple comparisons post test. 
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Figure 7.6. IC treatment did not significantly alter activation markers on resident 
microglia.  Six-seven weeks following irradiation and reconstitution of C57C57 animals, 
mice were pre-treated with 2x106 IC by i.p. injection one week before immunisation and 
weekly thereafter.  Mice were immunised to induce EAE as described in the methods. At peak 
disease, haematopoietic cells were isolated from brains and analysed by flow cytometry. 
CD45lowCD11b+ live, single cells were gated as shown in Figure 7.5.  MHC class II (I-Ab) (a), 
PD-L1 (b) and CD40 (c) expression were assessed on resident microglia (CD45loCD11b+).  
Shown are the means and SEM from two combined experiments (n=10/immunised groups, 
n=6/IC treated, unimmunised group, and n=4/untreated, unimmunised group).   
 
c. 
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7.3.4 IC treatment altered the expression of the MG-associated marker, Iba1, compared 
to untreated mice during EAE. 
To further investigate phenotypic changes in MG of the brain, the expression of Iba1 was 
observed by immunohistochemistry.  Iba1 is a calcium binding protein that is expressed by 
MG and upregulated by activated MG, including MG in EAE (de Lago, Moreno-Martet, 
Cabranes, Ramos, & Fernández-Ruiz, 2012; Ito, Tanaka, Suzuki, Dembo, & Fukuuchi, 2001; 
Staniland et al., 2010).  The level of Iba1 in these sections was graded on a scale of 0-3, with 
3 being the largest amount of staining.  As this test is subjective, the sections were blinded 
and scored independently by 3 individuals.  Following activation MG undergo a 
morphological change, switching from a ramified to an amoeboid morphology (Melchior et 
al., 2006).  MG in the brains of unimmunised mice stain weakly for Iba1 and have a distinct 
ramified morphology (Figure 7.7, normal).  The MG in the brain of immunised mice (both IC 
and untreated groups) have an increased intensity of Iba1 staining compared to unimmunised 
mice.  Purely from an observational point of view, large numbers of ramified MG are seen in 
these mice, supporting the identification of these cells as parenchymal MG.  The proportions 
of ramified vs. amoeboid cells has not been assessed in this study.   
 
Scoring of Iba1 stained sections show that there is strong trend towards increased Iba1 
staining in cerebellum and hippocampus of untreated immunised mice which was attenuated 
by IC treatment and while these values did not reach significance, a strong trend was evident 
(Figure 7.7).  Minimal change with IC treatment was seen in the olfactory bulb and the brain 
stem (Figure 7.8).  The decrease in staining is characterised by decreased numbers and 
decreased intensity of MG based on visual comparison.  These results suggest that IC 
treatment may be inducing differential activation of MG in vivo.  In C57BL/6 mice lesions are 
thought to occur primarily in the spinal cord, while these data suggest that the local changes 
occurring in the spinal cord may have the ability to affect the overall activation state of the 
CNS as well. 
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Figure 7.7.  IC treatment induced trend towards differential activation of resident MG in the cerebellum and the hippocampus 
during EAE.  Seven weeks following irradiation and reconstitution of B6C57 animals, mice were pre-treated with 2x106 IC by i.p. 
injection one week before immunisation and weekly thereafter.  Mice were immunised to induce EAE as described in the methods. At 
peak disease, isolated brains were fixed in PFA and 30 µm tissue sections were stained for Iba1 expression by immunohistochemistry.  
Sections were counter stained with haematoxylin, and Iba1 expression assessed in the cerebellum and hippocampus. Sections 
(n=5/immunised groups, and n=4/untreated, unimmunised group) were scored blindly as follows: 0 = low, 1 = mildly elevated, 2 = 
moderately elevated, and 3 = high expression.  Shown are representative sections and the means and SEM of averaged scores from 3 
blinded assessors and are from one experiment.  
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Figure 7.8.  IC treatment did not alter Iba1 expression on resident MG in the olfactory bulb and the brain stem during EAE.  
Seven weeks following irradiation and reconstitution of B6C57 animals, mice were pre-treated with 2x106 IC by i.p. injection one 
week before immunisation and weekly thereafter.  Mice were immunised to induce EAE as described in the methods. At peak disease, 
isolated brains were fixed in PFA and 30 µm tissue sections were stained for Iba1 expression by immunohistochemistry.  Sections 
were counter stained with haematoxylin, and Iba1 expression assessed in the cerebellum and hippocampus. Sections (n=5/immunised 
groups, and n=4/untreated, unimmunised group) were scored blindly as follows: 0 = low, 1 = mildly elevated, 2 = moderately elevated, 
and 3 = high expression.  Shown are representative sections and the means and SEM of averaged scores from 3 blinded assessors and 
are from one experiment. 
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7.3.5 Changes in IL-12 expression by MG 
IC treatment during EAE has been shown to alter the immune response that develops in the 
spinal cord; however, this study was not able to distinguish between the contribution of 
resident immune cells in the CNS and infiltrating, peripheral immune cells (La Flamme et al., 
2006).  Therefore B6C57 mice were generated to specifically enable the isolation and 
characterisation of the resident MG during EAE.  B6C57 mice were treated weekly with or 
without IC starting 7 days before immunisation.  At peak disease (day 14-15), the resident, 
radiation-resistant MG (i.e. CD45.2+CD11b+ cells) were sorted by FACS (Figure 7.9), and 
these samples were processed for qPCR as described in methods.  Because only a limited 
number of MG could be sorted from individual mice, the established macrophage-like 
RAW-264.7 cell line was used to generate template mRNA for the purposes of optimising the 
qPCR test parameters and confirmation of primer product size by gel electrophoresis (see 
section 2.5.3 and appendix C).  Following optimisation using RAW-264.7 cells, the 
expression of IL-12p40 was evaluated in MG isolated from the brains of mice, and the melt 
temperature of the products was the same as seen with the RAW-267.4 cells.  However, due 
to the low yield of cells in this experiment, little mRNA was obtained from each individual 
mouse such that in some treatment groups (untreated, immunised and unimmunised), there 
was insufficient RNA for qPCR.  Preliminary results were obtained from the IC-treated 
groups and suggest that IL-12p40 is upregulated in sick mice compared to not sick mice 
(Figure 7.10).  However, this result should be interpreted cautiously due to large variability in 
the unimmunised group, which was used to calculate the ∆(∆Ct) value.  Despite this 
variability, IL-12p40 has previously been shown to be increased in the spinal cords of sick 
mice compared to mice in relapse (Issazadeh, Navikas, Schaub, Sayegh, & Khoury, 1998), 
and therefore the increased expression of IL-12p40 in the CNS of sick mice compared to not 
sick mice in this study is consistent with previous work.  Overall, these preliminary qPCR 
findings support the use of bone marrow chimeras as a useful method to study the effects of 
IC treatment on the resident MG in vivo, and future work using this method can investigate 
the specific effects of IC treatment on other markers and cytokines such as CD40, PD-L1, 
MHC class II, and IL-10. 
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Figure 7.9.  Gating strategy for isolation of MG from B6C57 mice by FACS.  Seven 
weeks following irradiation and reconstitution of B6C57 animals, mice were pre-treated 
with 2x106 IC by i.p. injection one week before immunisation and weekly thereafter.  Mice 
were immunised to induce EAE as described in the methods.  At peak disease brains and 
spinal cords were processed for FACS analysis as described in methods and isolated using the 
gaiting strategy described.  R1, single cells; R2, cells (without debris); R3, live cells (DAPI 
negative); R4, CD45.2+CD11b+.  Shown is data from one immunised mouse. 
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Immunisation 
state 
Treatment Disease 
state 
n 
∆Ct* 
(mean ± 
SEM) 
∆(∆Ct)# 
(mean ± 
SEM) 
Fold 
change 
(2-∆∆Ct) 
Unimmunised IC treated Not sick 2 9.37±2.69 0.0±2.69 3.3±3.14 
Immunised IC treated Not sick 3 7.33±0.32 -2.03±0.32 4.2±0.9 
Immunised IC treated Sick 2 8.9±0.69 -0.47±0.69 1.7±0.71 
*Ct(IL-12p40)-Ct(Cyclophilin A) 
#
∆Ct sample- average ∆Ct of unimmunised (physiological control) 
 
 
Figure 7.10.  Expression of IL-12p40by resident MG after IC treatment.  Seven weeks 
following irradiation and reconstitution of B6C57 animals, mice were pre-treated with 
2x106 IC by i.p. injection one week before immunisation and weekly thereafter.  Mice were 
immunised to induce EAE as described in the methods. At peak disease mice were euthanised 
and MG (CD45.2+CD11b+) were sorted by FACS from individual mice (Figure 7.9).  (a) 
Total mRNA was isolated from MG, cDNA was generated, and IL-12p40 cDNA amplified 
with gene-specific primers using qPCR.  IL-12p40 was normalised to the control gene 
cyclophilin A (∆Ct) and change relative to a physiological control (IC treated, unimmunised 
mice) was calculated (i.e. ∆(∆Ct)).  Fold change relative to control was generated using the 
formula: fold change IL-12p40 = 2-∆(∆Ct).  (b) Shown are the mean ± SEM of expression 
relative to IC treated, unimmunised mice and are from one experiment. 
 
 
b. 
a. 
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7.4 Discussion 
In this study, the role of type II activating treatments on MG was assessed.  This treatment 
involves the intra-peritoneal injection of IC 7 days before the induction of EAE and every 
7 days for the duration of the experiment and has previously been shown to be highly 
effective at suppressing EAE (La Flamme et al., 2006).  The work in this chapter 
demonstrated that IC treatment was protective in EAE and induced an increase in the 
production of IL-17A in the peripheral immune system.  In addition, IC treatment resulted in 
decreased expression of MHC class II expression on CNS associated MΦ and a trend towards 
decreased levels of Iba1 in certain brain regions such as the cerebellum of immunised mice.  
The use of bone marrow chimeras to allow the isolation and characterisation of MG for 
assessment MG activation in vivo was optimised.  Together this work indicates that IC 
treatment not only alters peripheral immune responses but also has distinct effects on the 
phenotype of CNS-associated MΦ and MG. 
 
In the current study IC treatment was protective in EAE, as seen by reduced disease scores 
and decreased incidence of disease.  However, the disease course displayed a high degree of 
variability between experiments, and there are several possibilities that may explain this 
variability.  First, it is possible that the age of the mice affected the disease course since 
previous studies in SJL/J mice have shown that mice under the age of 6 weeks are resistant to 
EAE (Smith, Eller, McFarland, Racke, & Raine, 1999).  In addition, aged BALB/c mice are 
resistant to EAE when immunised at 18 and 24 months (Endoh, Rapoport, & Tabira, 1990) 
suggesting that EAE is not optimally induced in young or old mice.  In the current study the 
age of mice at the time of immunisation was 17.93±0.822 weeks (mean±SEM, from 6 
experiments).  In contrast, C57BL/6 mice are most commonly used for EAE studies between 
8 and 12 weeks.  Because chimeras require 6-8 weeks following irradiation to ensure full 
reconstitution of the bone marrow, the use of older mice could not be avoided.  While the use 
of mice of this age were not resistant to disease, it is likely that the age may be responsible for 
the highly variable disease course.  
 
In a previous study from our laboratory, it was shown that mice treated with IC were resistant 
to EAE and had enhanced basal Th2 responses (La Flamme et al., 2006); however, Th17 and 
IL-17A production, in particular, was not assessed.  Because the results from this thesis 
indicate that IL-17A production by T cells is enhanced by type II activation, the peripheral 
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immune response was investigated in the current study.  While IC treatment showed a trend 
towards increased production of polyclonally stimulated IL-4, there was no augmentation in 
antigen-specific IL-4 production.  Additionally, IC treatment did not alter either antigen 
specific or polyclonally stimulated IFN-γ production by splenocytes isolated from immunised 
mice, and this result is consistent with previous reports (La Flamme et al., 2006).  As 
expected, immunisation of mice led to an increase in both antigen-specific and polyclonal 
production of IL-17A.  However, in agreement with the in vitro co-culture results, antigen 
specific production of IL-17A was increased in the culture supernatant of splenocytes from IC 
treated, immunised mice compared to untreated, immunised mice.  This study is the first to 
report that IL-17A is increased under type II activating conditions in vivo.   
 
The increased production of IL-17A is interesting given that IL-17A is considered highly 
pathogenic in EAE (Bettelli et al., 2006; Domingues et al., 2010; O’Connor et al., 2008), and 
yet this pathogenic cytokine is induced by a treatment that provides protection in this model.  
The phenotype of circulating and CNS infiltrating T cells were not assessed in the current 
study; therefore, it is not known if the IL-17A is being produced by Th17 cells or another cell 
type such as IL-17A expressing Th1 cells.  It has previously been shown that in some 
circumstances Th17 cells are capable of producing both IL-10 and IL-17A, and that the 
production of IL-10 is dependent on IL-6 and TGF-β (Esplugues et al., 2011; McGeachy et 
al., 2007; Xu et al., 2009).  In addition to being synergistic, both IL-6 and TGF-β are capable 
of increasing IL-10 alone (Xu et al., 2009).  Furthermore, these IL-10 producing Th17 cells 
have been shown to have immunosuppressive properties in both EAE and a model of 
intestinal inflammation (Esplugues et al., 2011; McGeachy et al., 2007), and it was 
demonstrated that the protection provided by antigen specific IL-10 producing Th17 cells was 
dependent on the IL-10 production (McGeachy et al., 2007).  Thus, an increase in IL-17A 
does not necessarily correlate with an increase in disease severity.   
 
While IL-10 was not measured in the current in vivo IC treatment study, it has been shown 
previously that IC treatment increases the production of IL-10 by splenocytes and in the 
spinal cord of mice with EAE (La Flamme et al., 2006).  The IL-10 produced in IC-treated 
mice may be derived from many sources including MΦ and T cells, and it is possible that 
some of this cytokine is being produced by IL-10 producing Th17 cells.  Furthermore GA, 
which produces a similar MΦ activation state as IC induces up regulation of TGF-β by 
monocyte/MΦ (Weber et al., 2007).  Therefore, the type II activated MΦ, which also express 
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TGF-β, could induce IL-10 producing Th17 cells.  Therefore, an analysis of the peripheral 
immune cells in IC treated immunised mice, compared to untreated immunised mice will be 
important to further establish the cellular sources of IL-17A and determine if this cell type 
also produces other cytokines, such as IL-10.  The exact mechanism by which IC treatment 
mediates protection, even in the presence of increased IL-17A has not yet been elucidated, but 
is an extremely interesting feature of this treatment. 
 
In this model, where IC is given by intraperitoneal injection, it is highly likely that peripheral 
MΦ/monocytes will come into direct contact with IC.  For the same reasons, it is much less 
likely that MG will be directly activated after an intraperitoneal injection of IC.  Movement of 
IC into the CNS would likely be inhibited by the BBB even considering that the BBB breaks 
down in EAE (Carson et al., 2006).  Moreover, the delivery of the IC by intraperitoneal 
injection would only have limited entry into the blood compared to intravenous injection.  
Given the unlikelihood of MG being directly exposed to IC, it is more probable that IC 
treatment affects MG through an alteration in the peripheral immune response.  For example, 
type II-activated MΦ/monocytes invading into the CNS may expose the MG to suppressive 
cytokines such as IL-10, which through a bystander effect could prevent harmful activation of 
MG in EAE and possibly promote a protective phenotype.  A similar bystander effect was 
reported by Sica et al who showed that MΦ are able to suppress neighbouring cells through 
the production of IL-10 (Sica et al., 2000).  Alternatively, MG activation could be altered by 
humoral factors such as serum cytokines.  Indeed, it has been shown that changes in the 
systemic immune environment can affect MG, for example, induction of peripheral 
inflammation has been shown to increase MG activation in the CNS (Cardona et al., 2006; 
Thompson, Karpus, & Eldik, 2008).  This suggests that a shift in the peripheral immune 
response induced by IC treatment may be a pathway by which resident MG activation could 
be altered. 
 
To further assess the effect that IC treatment has on the activation state of MG in vivo brains 
from C57C57 mice were assessed by flow cytometry.  It was intended that the study of MG 
in vivo would be conducted in BALB/c mice due to the increased number of lesions found in 
the brains of this strain compared to C57BL/6 mice (Personal communication, Dr Jacqueline 
Orian).  Analysis of MG activation in the brain of BALB/c mice would have provided a larger 
pool of MG located at the site of inflammation as well as a more relevant MG population.  
However, it was found that neither IC treatment, nor GA, a common treatment for MS was 
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strongly protective in EAE (see appendix C).  Both GA and IC affect MΦ and promote Th2 
responses (Aharoni, Teitelbaum, Sela, & Arnon, 1997; Anderson & Mosser, 2002; La 
Flamme et al., 2006; Weber et al., 2007).  This suggests that these kinds of treatments have 
lower efficacy in BALB/c mice, therefore the C57BL/6 model was employed instead.  
Although the majority of CNS lesions are found in the spinal cord (Pham et al., 2011, 
Personal communication, Dr Jacqueline Orian) and comparatively fewer infiltrates are seen in 
the brains in the C57BL/6 model of EAE, infiltration and microglial activation still occurs.  
Thus, the brain was chosen for flow cytometric analysis as it is likely that the majority of the 
MG cells isolated for qPCR were from the brain, and MG activation in the brain was assessed 
by immunohistochemical staining.  Moreover, because fewer lesions form in the brains during 
peak disease (d15), the majority of myeloid cells would be expected to be from resident 
populations (MG or CNS-associated MΦ).   
 
In the myeloid compartment of the CNS, 3 distinct populations were identified based upon 
CD45 and CD11b co-expression.  The CD45hiCD11b++ cells are representative of peripheral 
MΦ but may also contain activated MG which are known to upregulate CD45 upon activation 
(Ponomarev et al., 2006; Sedgwick et al., 1991).  The possibility that MG may contribute to 
the CD45hiCD11b++ population is supported by the decrease in the percentage of MG cells in 
the brains of immunised mice.  However, it is possible that this decrease is due to alterations 
in the proportions of cells in the myeloid compartment following infiltration; it is difficult to 
say conclusively which situation has occurred in C57C57 chimeric mice where resident and 
peripheral cells express the same CD45 allele.  The CD45hiCD11++ population contains both a 
Gr1+ and a Gr1- population (see gating strategy in the appendix D).  Gr1 is commonly used to 
identify neutrophils but actually is specific for two markers, Ly-6C on monocytes and Ly-6G 
on neutrophils (Slaney, Toker, La Flamme, Bäckström, & Harper, 2011).  As it is not possible 
to differentiate between neutrophils and monocytes in the current study, and as the presence 
of another population would likely have confounding effects on the analysis of cell surface 
molecules on monocytes, this population was not analysed further. 
 
Unactivated MG have previously been described in the literature as having either a low or 
low-intermediate expression of CD45 (Juedes & Ruddle, 2001; Ponomarev et al., 2006; 
Sedgwick et al., 1991).  In the current study, two resident population were identified; 
CD45intCD11b+ and CD45loCD11b+.  While the CD45loCD11b+ population is certainly a MG 
population, the cells which constitute the CD45intCD11b+ population are less clear in the 
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literature.  A study by de Haas, Boddeke, & Biber, (2008) suggests that MG from different 
CNS regions display different levels of CD45 expression.  This study showed that MG 
isolated from the spinal cord of adult C57BL/6 mice express higher levels of CD45 than MG 
isolated from the hippocampus (de Haas et al., 2008).  It is possible that this different may 
also exist between other parts of the brain (e.g. MG from the cerebellum, cortex and 
hippocampus may have different resting levels of CD45).  This finding raises the possibility 
that the CD45intCD11b+ cells may represent a subset of MG.  If this is the case care must be 
taken when using whole brain analysis as different populations of MG may respond 
differently under inflammatory conditions.   
 
An alternative explanation for the CD45intCD11b+ population is that they represent a 
population of CNS-associated MΦ, such as perivascular MΦ, as opposed to a resident MG 
cell found in the CNS parenchyma (Zhang et al., 2002).  There are several populations of 
CNS-associated MΦ, including perivascular MΦ, and MΦ found in the choroid plexus and the 
meninges.  These sites are located between the CNS parenchyma and the periphery and are all 
considered potential sites for entry of encephalitogenic T cells into the CNS (Ford, Goodsall, 
Hickey, & Sedgwick, 1995; Ransohoff et al., 2003).  It has been shown in rats that these 
CNS-associated MΦ are more efficient at presenting to T cells ex vivo than MG cells (Ford et 
al., 1995).  T cell require reactivation in the CNS for EAE to develop (Kivisäkk et al., 2009).  
As CNS-associated MΦ are found at locations that are associated with CNS infiltration, it is 
possible that they have important roles in antigen presentation and the reactivation of T cells.  
Indeed, MHC class II positive cells have been shown to interact with T cells in the 
leptomeningies and these cells are thought to play an important role in EAE (Kivisäkk et al., 
2009).  Therefore, it is possible that changes to this subset may alter either the invasion or 
reactivation of T cells entering the CNS.   
 
In the current study, CNS-associated MΦ (CD45intCD11b+) from IC-treated, immunised mice 
expressed lower levels of MHC class II, and had fewer MHC class II positive cells compared 
to untreated, immunised mice.  It is possible that this change is associated with the protection 
from EAE provided by type II treatments, as lower MHC class II could potentially reduce 
T cell reactivation and thus disease severity.  The cause of the IC mediated decrease in MHC 
class II is currently unknown, it is possible that IC treatment induces a less inflammatory 
environment, resulting in decreased activation of the CNS-associated MΦ and thus decreased 
MHC class II expression.  Alternatively, the MHC class II molecules may be being actively 
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sequestered by regulatory molecules such as MARCH-1.  MARCH-1 is an E3-ubiquitin ligase 
which is known to be involved in the regulation of cell surface levels of MHC class II 
(Ohmura-Hoshino et al., 2009; Thibodeau et al., 2008).  IL-10 has been shown to decrease 
MHC class II expression on human monocytes via a MARCH-1 dependent mechanism 
(Thibodeau et al., 2008).  As increases in IL-10 have been shown to occur in the spinal cords 
of immunised mice treated with IC (La Flamme et al., 2006), it is possible that a similar 
mechanism may be involved in regulating cell surface levels of MHC class II on CNS-
associated MΦ in IC treated mice.  It has previously been shown that type II MΦ upregulate 
expression of MHC class II compared to classically activated MΦ (Edwards et al., 2006).  
Therefore the phenotype of the CNS-associated MΦ in IC treated immunised mice may not 
mirror type II activation completely.  As MΦ activation occurs in a spectrum, these different 
populations of MΦ may share some immunoregulatory properties while maintaining some 
distinct characteristics. 
 
In the current study, the CD45loCD11b+ resident MG cells did not alter their expression of 
CD40 or MHC class II molecules.  However, in both immunised groups there was a strong 
trend towards increased expression of PD-L1 compared to immunised mice, and this 
difference was significant between the IC treatment groups.  It has previously been shown that 
PD-L1, which is inhibitory to T cells, is upregulated on MG at peak disease (Carter et al., 
2002; Ortler et al., 2008).  As the samples in this study were isolated at peak disease, these 
data are consistent with previous results.  Although other important co-stimulatory molecules 
such as CD80 were not assessed, the absence of an increase in CD40 and MHC class II, 
together with the increase in PD-L1 suggest that the MG have been induced to a state that 
may be suppressive to T cells.  Since both immunised groups expressed the same overall 
pattern on MG cells, it is unlikely that these changes are associated with the mechanism by 
which IC protect from EAE. 
 
It has previously been demonstrated that the expression of CD40 on MG is important for the 
development of EAE (Becher et al., 2001).  Based upon this study it was expected that MG 
cells would up regulate CD40 to induce disease, however no change in CD40 expression was 
seen in our study when unimmunised and immunised mice were compared.  One possible 
explanation is that the MG cells may not express the same phenotype throughout the course of 
disease.  As the previous study suggests a role of CD40 in the initial stages of EAE (Becher et 
al., 2001), peak disease may be too late a time point to pick up changes in CD40 expression.  
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Additionally, MG have been shown to up-regulate expression of CD45 following activation 
(Melchior et al., 2006; Ponomarev et al., 2006; Sedgwick et al., 1991), and therefore it may be 
that the CD45loCD11b+ cell population is composed primarily of unactivated or not fully 
activated MG, which would not have altered CD40 expression. 
 
Although flow cytometry data did not show that IC treatment altered the expression of 
common immune activation markers on resident MG in the CNS, immunohistochemical 
analysis demonstrated that in at least some areas of the brain, such as the cerebellum and the 
hippocampus there was a trend towards increased Iba1 staining, suggesting differential 
activation of MG occurred between the IC treated and the untreated immunised groups.  
These MG have a ramified phenotype, suggesting they are parenchymal MG, and the level of 
Iba1 staining in the cerebellum showed a strong trend towards decreased staining in 
immunised mice with IC treatment.  Because the cerebellum is a commonly affected area in 
MS, this finding may be particularly relevant to disease (Frohman et al., 2006; Lassmann, 
Brück, & Lucchinetti, 2007).  It is likely that the discordance between the flow cytometry data 
and the immunohistochmistry data is due to the exact markers investigated.  The change in 
Iba1 expression on resident MG cells between the two immunised groups is most marked in 
the cerebellum, and a trend towards altered expression in the hippocampus was also apparent.  
However, these region specific changes suggest that the MG in all parts of the brain may not 
express the same level of certain markers and so the effect of a reduction in only one or two 
brain regions may be lost when looking at MG isolated from the whole brain (de Haas et al., 
2008).  Furthermore, the region specific changes in Iba1 may also suggest that different parts 
of the brain are exposed to different levels of stimulation in EAE.  Taken together, these data 
suggest that a differential activation state of MG exists in IC treated immunised mice although 
the functional consequence of this change is not yet known. 
 
Bone marrow chimeric mice were generated so that MG could be isolated from the brains of 
mice with EAE, without the infiltrating cells interfering with the purity of the MG sample.  
This technique is commonly used for the study of MG; however, as it had not been used 
previously in our laboratory, the method required optimisation.  While irradiation and 
reconstitution of mice with bone marrow from a congenic mouse strain consistently worked 
well, several other technical aspects including the FACS sorting and the RNA isolation 
required more intensive optimisation.  In particular, although the CD45.2+MG were easily 
detected on the FACS Canto II, they were difficult to identify using the FACS Vantage DiVa 
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cell sorter on the basis of CD45.2 expression alone.  However, the addition of CD11b staining 
aided the identification of MG on this machine, and MG were isolated with this method. 
 
To isolate the RNA from the purified CD45.2+ MG Trizol® was initially used but the 
resulting RNA was too dilute to be useful for qPCR and so the Dynabeads mRNA DIRECT 
Micro kit was utilised with greater success for the last experiment.  Thus, the results for the 
level of IL-12p40 transcript were obtained from a single experiment, they provide support for 
the use of this model to answer questions about how MG change during neuroinflammation.  
Additionally, while these data are preliminary, they show that the level of IL-12p40 increased 
in mice that had established disease compared to mice that had been immunised but had no 
overt disease expression.  This finding is consistent with reports that show increased IL-12 in 
the CNS of mice that have EAE (Issazadeh et al., 1998; La Flamme et al., 2006).  Finally, as 
IL-12p40 is the common subunit of both IL-12 and IL-23 (Cua et al., 2003), the possibility 
that the elevated IL-12p40 represents an increase in IL-23 as opposed to IL-12 must be 
considered.   
 
7.5 Summary 
The overall aim of the current chapter was to assess the effect IC treatment had on MG in 
vivo, and to determine if any changes in the peripheral immune environment correlated with 
that seen in the MG.  Although the disease course was variable between experiments, IC 
treatment was shown to provide protection from EAE.  The protection afforded by IC 
treatment was not associated with an alteration in IFN-γ but instead with an increase in 
antigen specific IL-17A.  Because GA, which induces a similar MΦ activation state as IC, 
leads to an increase in TGF-β, future research should assess the involvement of IL-10 and 
TGF-β in protection as well as the possibility that an IL-10/IL-17A Treg population may be 
induced.   
 
Immunohistochemical analysis of brain sections suggested that MG from IC treated mice are 
differentially activated in EAE, and although a change in this population was not seen by flow 
cytometry, only a small pool of markers was assessed.  These markers were chosen as they 
are relevant to type II MΦ activation, yet it is possible there were changes in expression 
markers that were not assessed.  A significant change in the expression of MHC class II on 
CNS associated MΦ was seen by flow cytometry.  As these MΦ are located at sites associated 
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with CNS infiltration, it is possible that these cells are involved in re-activation of T cells.  
The decrease in MHC class II may therefore reduce the interaction of T cells and CNS 
associated MΦ, and provide a potential pathway for protection from disease.  Finally, to more 
comprehensively assess the effect of type II activation by IC treatment on CNS resident MG, 
a bone marrow chimera model was successfully established and validated for future work. 
 
 
  
 
 
 
 
 
Chapter 8:  
General Discussion 
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8.1 Overview 
MS is an immune-mediated disease of the CNS, in which the myelin sheath and the neuronal 
axons which they surround, are damaged leading to a variety of disabilities in MS patients 
(Sospedra & Martin, 2005).  The pathology of both MS and EAE, one of the animal models of 
MS, involve proinflammatory processes (Baxter, 2007; Sospedra & Martin, 2005), and it has 
been shown that treatments which induce deviation of the immune response, such as GA, are 
protective in MS and EAE (Khan et al., 2001; La Flamme et al., 2006; Tierney et al, 2009; 
Weber et al., 2007).  The administration of IC is another such immunomodulatory treatment, 
which has been shown to be protective in EAE (La Flamme et al., 2006; Tierney et al., 2009).  
IC (in conjunction with LPS) generate immunoregulatory type II MΦ, which have the 
capacity to bias the T cell response in an antigen-specific manner (Anderson & Mosser, 
2002).  Thus the cellular pathways by which IC and type II MΦ modulate T cell responses 
and protect during EAE were investigated in depth. 
 
Classically activated MΦ have been shown to bias the T cell response towards a Th1 
response, and type II MΦ towards a Th2 response (Anderson & Mosser, 2002; Edwards, 
Zhang, Frauwirth, & Mosser, 2006).  However, the effects these activation states have on 
other Th subsets had not previously been assessed.  Chapter 3 investigated further the effects 
of type II MΦ on T cells.  Consistent with previous studies, T cells cultured with type II 
activated MΦ produce decreased levels of IFN-γ compared to those cultured with classically 
activated MΦ (Anderson & Mosser, 2002).  T cells cultured with type II MΦ also expressed 
increased levels of CD124, suggesting an increased ability to respond to IL-4.  While IL-4 
could not be measured in this study, possibly due to its rapid uptake following production, 
CD124 was used as a surrogate for IL-4 production.  The change in CD124, together with the 
decrease in IFN-γ is consistent with a switch from a Th1 to a Th2 response.  However, it was 
also found that T cells cultured with type II MΦ also produce increased levels of IL-17A, 
compared to those cultured with classically activated MΦ.  The increase in both CD124 and 
IL-17A suggests the presence of a mixed Th2/Th17 phenotype, and is a novel finding of this 
study.  Investigations into possible pathways involved in T cell biasing by MΦ (Chapter 4) 
revealed that IL-10 and IL-12, which have significantly altered profiles between classical and 
type II MΦ, are important in regulating IFN-γ production but do not have a significant role in 
regulating CD124 or IL-17A levels.  Additionally, results suggest that the effect of IL-10 is 
primarily on the MΦ itself while the effect of IL-12 is primarily on the T cell.  This is 
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consistent with previous reports that IL-10 and IL-12 are known to have strong effects on MΦ 
and T cells respectively (Kaplan et al., 1996; Kobayashi et al., 2012).   
 
Further investigation into the pathways involved in T cell biasing by type II activated MΦ 
investigated the roles of PD-L1 and CD40, which have decreased expression on the surface of 
type II MΦ.  These studies suggested that these individual pathways do not have a strong 
individual role in T cell biasing in this system although the possibility remains that a 
combined alteration in these two pathways may induce a much greater effect than each 
pathway alone.  Further experiments into these markers are required to fully understand any 
role they may play as the absence of any effect could be due to the αPD-1 and the PD-L1ch 
being in active.  In order to address this, and also remove the potentially confounding effects 
of the control antibodies/proteins, other approaches could be used, such as using genetically 
deficient mice or RNAi to block pathways. 
 
As type II MΦ express lower levels of PD-L1 (Tierney et al., 2009), it was hypothesised that 
T cells cultured with these MΦ would have higher rates of proliferation, compared to those 
cultured with classical MΦ, due to a decrease in inhibitory factors.  However, results for 
Chapter 3 demonstrated that, while type II and classically activated MΦ did activate T cells, 
neither of these MΦ activation states were able to induce T cell proliferation.  Both classically 
activated and type II MΦ produce high levels of NO and inhibition of NO synthesis using AG 
restored the ability of MΦ to induced T cell proliferation, however, no significant difference 
in proliferation was seen between T cells cultured with classically or type II activated MΦ.  
Proliferation is the hallmark of antigen specific response, however, as classically and type II 
MΦ do not typically induce T cell proliferation in this study, proliferation was not routinely 
used as a readout of T cell activation.   
 
As MG are the MΦ like cell of the CNS and are considered an important cell type in 
regulating immune responses in the CNS, the ability of MG to be type II activated was 
investigated.  In chapter 6, the activation state of adult MG was assessed under type II and 
classical activating conditions in vitro.  It was found that MG were capable of a type II like 
activation state, producing increased levels of IL-10 and decreased levels of IL-12 compared 
to classically activating conditions.  In addition, type II MG produced decreased levels of 
IL-6.  Like type II MΦ, these type II MG were able to bias T cell response, yet, the biasing by 
MG did not result in the same T cell phenotypes as those induced by MΦ.  For example, MG 
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were able to stimulate T cells to produce IL-2 regardless of the stimuli they were given while 
MΦ required activation (with LPS or LPS+IC) to be able to stimulate IL-2 production by T 
cells.  This result suggests that a fundamental difference in the way MG and MΦ interact with 
T cells may exist.  Some features of type II MΦ:T cell interactions were similar in MG:T cell 
co-cultures, namely T cells cultured with type II MG produce higher levels of IL-17A and 
CD124.  It is therefore difficult to predict how type II MG would affect T cell responses in 
vivo.  However, the reduction in the levels of proinflammatory cytokines produced by type II 
activated MG, such as IL-6 and IL-12, suggests that type II activation of MG may be 
beneficial in neuroinflammatory conditions. 
 
The role of type II inducing treatments in vivo was investigated using B6C57 and 
C57C57 chimeric mice.  IC treatment has previously been shown to be protective in EAE 
and the results of the current study are consistent with previous data (La Flamme et al., 2006).  
Analysis of peripheral immune responses demonstrated that IC treated immunised mice have 
higher levels of antigen specific IL-17A, which is consistent with in vitro results where type II 
MΦ and MG also induced IL-17A production when in co-culture with T cells.  It is interesting 
that an increase in IL-17A has been seen consistently throughout this thesis, under conditions 
that are considered to be anti-inflammatory or regulatory. Therefore, it is likely that the same 
mechanism is inducing the increase in IL-17A in all of these different type II activating 
situations.  The increase in antigen specific IL-17A is seen in IC treated mice, which are 
protected from EAE; this suggests the increase in IL-17A may not be pathogenic, despite the 
well-known detrimental effect IL-17A can have in EAE (Bettelli et al., 2006; Kurschus et al., 
2010; McGeachy et al., 2007; O’Connor et al., 2008).  There is a subset of Th17 cells, 
sometimes referred to as “regulatory Th17 cells” which produce both IL-10 and IL-17A and 
have been shown to have immunoregulatory effects in EAE and a model of inflammatory 
bowel disease (Esplugues et al., 2011; McGeachy et al., 2007).  It is possible that IC treatment 
and type II MΦ/MG are capable of inducing these “regulatory Th17 cells”, and this possibility 
merits further investigation. 
 
Further in vivo data demonstrated an alteration in the phenotype of resident cells in the CNS 
of IC-treated, immunised mice compared to untreated immunised mice.  These included 
decreased levels of Iba1 staining on parenchymal MG, which suggest differential activation 
state of MG from IC-treated, immunised mice compared to untreated, immunised mice.  
Furthermore, resident CNS-associated MΦ (CD45intCD11b+) from IC-treated, immunised 
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mice expressed decreased levels of MHC class II, suggesting that these cells, which are likely 
located in areas associated with T cell infiltration into the CNS, may have a decreased ability 
to interact with and re-activate encephalitogenic T cells.  At this point the current data does 
not demonstrate that MG from IC-treated mice take on a phenotype that is identical to the 
type II MΦ activation state in vitro; however, there is evidence to suggest that resident CNS 
cells may be activated to a regulatory phenotype in vivo.  As MΦ activation occurs on a 
spectrum, it is possible that the CNS resident cells from IC-treated, immunised mice may 
share some characteristics of type II activation. 
 
8.2 Use of animal models for the study of MS 
MS is an inflammatory disease of the CNS in which demyelination occurs around the 
neuronal axons.  MS has many forms, including the relapsing-remitting and the progressive 
forms; and it is possible that MS is a group of related disorders that share symptoms and 
pathophysiological characteristics, rather than a single disease (Heard, 2007).  Furthermore, 
even amongst a particular disease form such as relapsing-remitting, there is wide variability in 
primary symptoms, disease progression, relapse rate, and even response to the current 
treatment options (e.g. IFN-β) (Axtell et al., 2010; Heard, 2007).  The heterogeneous nature of 
the MS thus complicates investigations into its nature as well as potential treatments (Weiner, 
2009).  Finally, because MS is a disease of the CNS, a detailed, molecular study of this 
disease is difficult, with many studies relying on access to brain sections from autopsy or 
biopsy.  Therefore, a suitable animal model that will allow a mechanistic dissection of the 
pathogenesis of MS is extremely desirable, and the current animal models of MS have been 
useful for developing treatments for MS as well as better understanding the underlying 
disease mechanisms. 
 
EAE is the most commonly used animal model of MS.  EAE has been induced in a wide 
variety of animals, ranging from mice to non-human primates (Baxter, 2007).  The disease 
(EAE) which develops is not identical between species and varies dependent on the species as 
well as strain used.  Different models of EAE model different aspects of MS pathology, for 
example, the BALB/c mouse model produce a more faithful model of human CNS lesions 
compared to other mouse strains, while the SJL/J mouse model has a relapsing remitting 
disease course.  EAE has been used successfully to develop three treatments for MS: 
glatiramer acetate, natalizumab, and mitoxantrone (Baxter, 2007; Steinman & Zamvil, 2006; 
personal communication Dr Jacqueline Orian).  
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In addition to roles in developing treatments, EAE also has other uses.  EAE studies can be 
employed to understand the roles molecules and pathways that have been identified in studies 
on MS patients, and which of these molecules may be potential therapeutic targets (Steinman 
& Zamvil, 2006).  For example, IL-6 and IL-17A (both important in the Th17 response) were 
identified in MS lesions; studies in EAE later identified Th17 cells as an important cell type in 
EAE, and EAE was used to investigate this pathway (Bettelli et al., 2006; Lock et al., 2002).  
Additionally, osteopontin was identified in MS lesions, following this discovery osteopontin 
deficient mice were then found to have decreased EAE severity (Steinman & Zamvil, 2006).  
Serum levels of ostepontin is being investigated as a potential biomarker for MS (Shimizu et 
al., 2013).  EAE has also been used to better understand the mode of action of current 
treatments such as GA (Weber et al., 2007). 
 
In recent years EAE has been criticised due to its inability to predict possible side effects, and 
also because EAE has not produced many new treatments for MS in recent years.  
Additionally the current treatments are not viewed as effective enough and not all patients are 
responsive to the current treatments.  PML is the most notable example of preclinical studies 
in EAE failing to predict a potentially life threatening side effects.  Due to species barriers, 
the possibility of PML occurring could not have been tested (Steinman & Zamvil, 2006).  
Like many animal models, EAE has limitations in the area of opportunistic infections 
following treatment, particularly where species barriers are involved. 
 
Part of the inefficacy of the current treatments may be related to the heterogeneity of MS.  For 
the development of further MS treatments, it will be important to understand these inter-
patient differences, and for this patient studies will be a vital source of information.  However, 
EAE is also proving useful in understanding how patient differences can lead to different 
treatment outcomes, as it can be used to ask functional questions based on patient data.  For 
example, current studies in EAE, that have been based on patient data, suggest that relapsing 
remitting patients with a Th17 dominate Th cell response are much less susceptible to IFN-β 
treatment than those with a Th1 dominant response (Axtell et al., 2010).  Additionally, 
employing multiple animal models, which model different disease aspects, may help to 
address the patient heterogeneity and provide a better idea of which treatments are likely to 
translate into effective treatments for MS. 
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It is likely that the mechanisms are different between relapsing-remitting and progressive 
forms of the disease (’t Hart, Gran, & Weissert, 2011; Weiner, 2009).  As such, different 
models may need to be employed to study the different disease subsets.  EAE has been useful 
for studying relapsing remitting MS, but is not a good model for progressive forms of MS, 
however there are other models (Ransohoff, 2012).  An example of a toxin based model of 
MS is cuprizone (a copper chelator given in chow), which induces ogliodendrocyte death 
(demyelination) and may prove to be an effective model of progressive disease (Ransohoff, 
2012).  Cuprizones mode of action is independent of T and B cells (Hiremath, Chen, Suzuki, 
Ting, & Matsushima, 2008), allowing the processes of demyelination and remyelination to be 
examined independent of adaptive immune involvement.  MS involves multiple processes, 
while treatment strategies to prevent further disease development are important, it is also 
important to investigated ways to reverse the damage in the CNS to aid recovery (Weiner, 
2009).  After removal of cuprizone from the diet remyelination occurs thus the cuprizone 
model may be applied, not only to progressive disease, but also to study remyelination, and 
potentially develop treatments to increase remyelination, which may aid patient recovery and 
complement disease modifying therapies (Ransohoff, 2012; Weiner, 2009). 
 
Both EAE and the cuprizone models have limitations (as all animal models do).  EAE has 
proved effective in the development of treatments for MS, and is likely to be capable of 
producing more.  Further refinement of the way EAE is used; applying the different models to 
answer different questions may improve its efficiency.  In addition, the combination of studies 
in humans with studies in EAE has real potential to further the understanding of how MS 
works and may provide new treatment strategies.   
8.3 Clinical applications 
While there are several drugs available for the treatment of MS only two, GA and IFN-β, are 
considered first line drugs based on their safety profiles (Morris & Yiannikas, 2012).  The 
second line treatments such as natalizumab and mitoxantrone have more limited use due to 
their potential side effects (Morris & Yiannikas, 2012).  However, GA and IFN-β have 
limited efficacy, and are only capable of reducing the relapse rate of relapsing remitting MS 
by approximately 30% (Khan et al., 2001).  Therefore, there is a need for both safer and more 
effective treatments for MS patients.  While there are a range of new MS treatments that have 
recently become available to treat relapsing-remitting MS such as Gilenya (Fingolimod or 
FTY720) and Lemtrada (Alemtuzmab), the full impact of these treatments on disease and 
their side-effect profiles still need to be fully confirmed (Morris & Yiannikas, 2012). 
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GA, a common drug for the treatment of MS induces a change in the phenotype of 
MΦ/monocytes that is similar to type II activation, with GA-treated monocytes expressing a 
similar altered cytokine profile and an ability to bias T cells towards both Th2 and Treg 
responses (Weber et al., 2007).  This study suggests that this type II activation of MΦ may be 
responsible for the protection mediated by GA and supports the idea that this approach is a 
viable one for MS therapies.  However, IC treatment and GA treatment, while inducing 
similar MΦ activation states, may work through different mechanisms to protect from EAE.  
For example, in the current study, IC treatment was shown to consistently cause an increase in 
IL-17A in both in vivo and in vitro experiments.  However, to our knowledge, GA has never 
been shown to upregulate IL-17A, and has been reported to decrease the production of 
IL-17A, in the periphery and in the CNS of mice with EAE (Rina Aharoni et al., 2010; Weber 
et al., 2007).  Additionally, preliminary work in our lab has shown that in the same MΦ:T cell 
co-culture system, T cells co-cultured with GA treated MΦ did not produce IL-17A (see 
appendix C).  Thus, while similar to GA, IC does not appear to completely mimic the effects 
of GA in vivo and therefore may represent an alternate treatment option.   
 
IFN-β is one of the most commonly used drugs for the treatment of MS.  However, in 
addition to only reducing the relapse rate by 30%, it is not successful in all patients and up to 
30% of patients on IFN-β treatments generate neutralising antibodies which render the 
treatment ineffective (Bertolotto et al., 2002; Capobianco et al., 2008; Khan et al., 2001).  
Therefore, IC treatment could potentially provide a treatment for patients who do not respond 
or GA or IFN-β.  In addition, work performed in our laboratory on human monocytes 
suggests that using IC in conjunction with GA may provide further benefit, raising the 
possibility of combined GA+IC therapy for the treatment of MS (Personal communication, Dr 
Delgertsetseg Chuluundorj, M.D. PhD; Victoria University of Wellington; manuscript in 
preparation).  In addition to increasing the efficacy of treatment, using combined therapies 
may also allow the doses of the individual drugs to be reduced, which could potentially result 
in a reduction in side effects without a reduction in the efficacy of the treatments. 
 
Intravenous immunoglobulin (IVIG), which is generated from pooled IgG serum from a large 
number of donors, was originally used to treat hypogammaglobulinaemia but has since been 
used for several other conditions including Guillain–Barré syndrome, rheumatoid arthritis, 
and MS (Schwab & Nimmerjahn, 2013).  In clinical trials, IVIG has been found to be 
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effective in RRMS.  These trials showed that IVIG treatment reduced relapse rate and had a 
beneficial effect on patient disability (Sorensen, Fazekas, & Lee, 2002).  In EAE, IVIG 
treatment has been shown to protect from disease when given prophylactically, and protection 
is associated with induction of Treg cells (Ephrem et al., 2008; Humle Jorgensen & Sorensen, 
2005).   
 
The mechanism of action of IVIG is unclear and likely to involve many processes (Schwab & 
Nimmerjahn, 2013).  As IC consist of an antibody-coated cell or molecule, it is possible that 
IVIG and IC may share some overlapping pathways.  IC are not likely to perform some of the 
proposed functions such as cytokine and autoantibody neutralisation, nor are they likely to act 
through the inhibitory FcR, FcγRII, which is a proposed pathway for IVIG but is not involved 
in type II activation of MΦ (Schwab & Nimmerjahn, 2013; Sutterwala et al., 1998).  It has 
been suggested that some of the effects of IVIG are due to effects on innate cells such as DC, 
as when DC are treated with the IVIG in vitro and then transferred to mice they are protected 
from immune thrombocytopenic purpura (Siragam et al., 2006).  IC treatments are thought to 
act mainly on innate immune cells, and as IC have many antibodies bound to them, they are 
able to induce cross linking of receptors, which can potentially provide a stronger signal than 
individual antibodies, suggesting IC may act more strongly through these pathways (Gallo et 
al., 2010).  The potential overlapping pathways between IVIG and IC support the idea that IC 
may provide a potential treatment for MS. 
 
8.4 Future Directions 
The work in this thesis further investigated the biasing of the T cell response by type II MΦ as 
well as the effect that a type II activating treatment, IC, had on EAE.  Furthermore, the ability 
of MG to achieve type II activation and to induce biasing of the T cell response was 
investigated.  While this work produced several interesting findings, it has also raised several 
more questions, particularly surrounding the biasing of the T cell and the effects of IC 
treatment in vivo.   
 
Consistent with previous studies, MΦ:T cell co-cultures with type II activated MΦ have been 
shown to induce Th2 responses and while IL-4 was not detected in the current study, the 
decreased production of IFN-γ and the increased expression of CD124 do suggest a shift 
towards a Th2 type phenotype.  However, a novel finding of this study is the increased 
production of IL-17A in these cultures, which was consistently increased throughout much of 
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the in vitro and in vivo work involved in this thesis.  Further studies should investigate the 
phenotype of the cells producing the IL-17A as it seems counterintuitive given the protective 
and pathogenic roles type II MΦ and IL-17A have in EAE, respectively (Bettelli et al., 2006; 
Tierney et al., 2009).   
 
To further investigate the phenotype of these IL-17A producing cells, a more in-depth 
characterisation of T cells cultured with classically and type II activated MΦ would be 
recommended.  This study should include intracellular staining of cytokines to determine not 
only the proportions of T cells producing specific cytokines but also determine of populations 
of cells that are double positive for specific cytokines such as IL-17A and IL-10.  This method 
would also allow for detection of IL-4-producing cells as IL-4 can be difficult to detect due to 
its rapid uptake.  Furthermore verifying the T cell subsets by assessing the expression of 
transcription factors associated with specific lineages, including GATA-3, T-bet and RORγt 
would aid phenotypic analysis of T cells co-cultured with type II activated MΦ.  
Restimulation assays of T cells cultured with type II or classically activated MΦ could also be 
used to determine if the IL-17A population in these cultures represents a transient population 
of T cells that may further differentiate into another cell type.  Once the phenotype of the 
T cells in culture with MΦ has been fully characterised, it should be investigated in MG:T cell 
cultures and also in vivo, as in both of these systems, consistent increases in IL-17A in the 
presence of IC was seen. 
 
This thesis aimed to determine the pathways involved in the biasing of T cell responses by 
type II and classical MΦ.  While this study strongly supports a role for the altered levels of 
IL-10 and IL-12 produced by type II and classically activated MΦ in biasing T cell responses, 
the data particularly implicates these cytokines as being involved in the regulation of IFN-γ 
levels.  Some of this data, particularly the data involving increasing the level of IL-12 in 
culture requires further verification.  In addition, none of the pathways investigated provided a 
potential mechanism for the increased IL-17A and CD124 in T cells cultured with type II 
activated MΦ.  However, further pathways remain to be investigated, for example, type II MΦ 
have recently been shown to produce IL-4 which could be investigated as a possible 
mechanism involved in T cell biasing (La Flamme et al., 2012), and it has also been reported 
that type II MΦ have altered levels of cells surface receptors such as MHC class II, CD80 and 
CD86 (Edwards et al., 2006; Tierney et al., 2009).  These pathways could be investigated for 
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potential roles in T cell biasing with the use of blocking antibodies, knockout mice, or 
potentially RNA interference.   
 
Studies in MG in vitro demonstrated that MG are capable of achieving a regulatory activation 
state that strongly resembles, but is not identical to type II activated MΦ.  For example, type 
II MG produced decreased levels of IL-6, whereas type II MΦ do not (Kharkrang, 2010).  
Furthermore MG appear to have an increased ability to activate T cells, this ability is 
particularly evident in the equivalent production of IFN-γ and IL-2 in all cultures containing 
IFN-γ primed MG, regardless of further stimuli provided to the MG.  Further studies to 
investigate the inherent ability of MG to stimulate T cells could be performed.  For example, 
the ability of MG that have or have not been primed with IFN-γ to stimulate T cells could be 
assessed.  Also, the phenotype of MΦ and MG in the presence or absence of IFN-γ could be 
compared to assess pathways involved in T cell activation, such as co-stimulatory 
mechanisms, which have the potential be differentially expressed between MΦ and MG. 
 
In addition to the interesting finding that IC treatment results in increased antigen specific 
IL-17A production in immunised mice, effects of IC treatment on CNS cells was also 
investigated.  Although chimeric mice were generated to study the effects of IC treatment on 
resident MG, this protocol required extensive optimization and thus while the method is now 
established and validated, few experimental results were obtained.  It was shown using qPCR 
that MG from IC-treated mice produced higher levels of IL-12 in sick mice compared to not 
sick mice.  This result is consistent with previous reports and supports these chimeras as a 
method to study the effects of IC treatment on MG.  However, due to the low yield of cells, 
the differences in MG activation between IC-treated and untreated mice were not able to be 
assessed.  These experiments should be repeated to fully explore the effects of IC treatment 
on MG in vivo.   
 
Further data suggested that IC treatment in vivo alters the phenotype of resident CNS 
associated MΦ in EAE.  Further work to determine the location of these CD45intCD11b+ cells 
in the brain using immunohistochemistry to observe the cells in situ should be undertaken.  It 
is likely that this cell type is a CNS-associated MΦ population located at perivascular 
locations, and in the meninges and choroid plexus.  As the CD45intCD11b+ cells from normal 
mice but not IC treated mice showed increase expression of MHC II, it may be possible to 
assess MHC class II staining of CNS-associated MΦ by immunohistochemistry, to determine 
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if it is upregulated on CNS-associated MΦ in untreated immunised mice compared to 
immunised mice, and how IC treatment also affects the expression.  
 
Overall these data form an interesting picture of how IC and type II activated MΦ regulate 
T cell responses and EAE, with regulatory mechanisms in EAE possibly involving both 
changes to the T cell response and the CNS environment.  Further studies into the pathways 
involved will allow an even more comprehensive understanding of the type II MΦ phenotype 
and may support IC-mediated type II activation as a potential pathway for treatment of MS. 
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A- Recipes 
 
Phosphate buffered saline (PBS) 
10xPBS 
NaCl        170 g 
Na2HPO4.12H2O     62.32 g 
NaH2PO4.2H2O     4.04 g 
2 litres ddH2O 
1xPBS 
Dilute 10:1 ddH2O for working solution of 1X PBS. 
 
Percoll Diluent (v) 
10X PBS      45 ml 
0.6M HCl      3 ml 
ddH2O       132ml 
Sterilise with a syringe filter 
 
70% Percoll (v/v) 
Percoll (stock)      63% 
Percoll diluent      37% 
37% Percoll (v/v) 
Percoll (70%)      53% 
1xPBS       47% 
 
30% Percoll (v/v) 
Percoll (70%)      43% 
1xPBS       57% 
 
FACs buffer (v/v) 
FCS       2% 
Sodium azide (1 M)     0.1% 
1xPBS       97.9% 
 
Pertussis toxin buffer 
Tris       15mM  
Sodium chloride      0.5M  
Triton X-100       0.017% (v/v)  
In ddH2O, filter sterilised using 0.22µm syringe filter 
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Complete T cell media (CTCM) (v/v) 
Dulbecco’s Modified Eagle Medium   85.9%  
FCS       10%  
L-glutamate (200 mM)     1%  
Penicillin/Streptomycin (100 U/ml/10 mg/ml) 1%  
HEPES buffer (1 M)      1%  
β-Mecaptoethanol (55 mM)    0.1%  
Non-essential amino acids (10nM)    1% 
 
Wash buffer (v/v) 
Dulbecco’s Modified Eagle Medium   96% 
HEPES buffer (1M)     3% 
Penicillin/Streptomycin (100 U/ml/10 mg/ml) 1% 
 
DFP media (v/v) 
Dulbecco’s Modified Eagle Medium   83%  
FCS       15% 
L-glutamate (200 mM)     1% 
Penicillin/Streptomycin (100 U/ml/10 mg/ml) 1% 
 
MG media (v/v) 
Dulbecco’s Modified Eagle Medium   87.9%  
FCS       10% 
L-glutamate (200 mM)     1% 
Penicillin/Streptomycin (100 U/ml/10 mg/ml) 1% 
β-Mecaptoethanol (55 mM)    0.09%  
 
ELISA capture buffer 
Na2HPO4      0.1M  
In ddH2O, adjusted to pH 9.  
 
ELISA stop solution 
H2SO4        0.18M  
In ddH2O 
 
Dynabead isolation buffer (v/v) 
FCS       2% 
EDTA (0.5 mM)     0.004% 
1xdPBS      47.006% 
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IHC block 
Donkey serum (Sigma, USA)    4% 
1xPBS 
 
Griess solution A (w/v) 
Sulphanilamide     1%  
In 2.5% Phosphoric acid  
 
Griess solution B (w/v) 
N-(1-napthyl) ethylenediamine    1%  
In 2.5% Phosphoric acid  
 
Peroxidase quenching solution (v/v) 
Methanol      50% 
H2O2       1% 
ddH2O       49% 
 
Acid alcohol (v/v) 
HCl       0.3% 
Ethanol      70% 
ddH2O       29.7% 
 
0.01% Lithium Carbonate (w/v) 
Lithium Carbonate     0.01% 
ddH2O       99.99 
 
4% Paraformaldehyde (w/v) 
Paraformaldehyde     4% 
1xPBS       96% 
ph adjusted to 7.4 
 
TPBS (v/v) 
TritonX-100      0.2% 
1xPBS       99.8% 
 
PBST (v/v) 
Tween 20      0.05% 
1xPBS       99.5% 
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30% Sucrose 
Sucrose (w/v)      30% 
Sodium Azide (1 M) (v/v)    0.1% 
ddH2O       69.9% 
 
TAE buffer 
50x TAE buffer 
Tris base      242g 
EDTA (0.5M stock)     100ml 
Glacial acetic acid     5.71 ml 
In 1 litre of ddH2O  
 
1xTAE buffer 
Dilute 50:1 with ddH2O for working solution of 1x TAE. 
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B- Antibodies and proteins 
 
B-1.1 Flow cytometry antibodies 
Specificity Label Species and 
Isotype 
Manufacturer  Optimal dilution 
B220 FITC Rat IgG2a BD (PharMingen) 1:1000 
CD4 V500 Rat IgG2a BD (PharMingen) 1:1000 
CD8 PerCP-Cy5.5 Rat IgG2a eBioscience 1:400 
CD11b (MAC-1) FITC Rat IgG2b BD (PharMingen) 1:1000 
PE Rat IgG2b eBioscience 1:2000 
CD25 APC Rat IgG1 BD (PharMingen) 1:600 
CD40 PE Rat IgG2a BD (PharMingen) 1:200 
CD44 PE Rat IgG2a eBioscience 1:2000 
CD45 Cyc Rat IgG2b BD (PharMingen) 1:500 
CD45.1 PE Mouse IgG2a Biolegend 1:400 
CD45.2 APC Mouse IgG2, k BD (PharMingen) 1:200 (blood) 
1:100 (CNS) 
CD62L APC Rat IgG2a BD (PharMingen) 1:3000 
CD124 (IL-4Rα) PE Rat IgG2a BD (PharMingen) 1:400 
F4/80 Biotin Rat IgG Serotec 1:2000 
Gr-1 PE Rat IgG2b BD (PharMingen) 1:2000 
APC-Cy7 Rat IgG2b BD (PharMingen) 1:800 
I-Ab PE Rat IgG2a BD (PharMingen) 1:800 
PD-L1 PE Rat IgG2a eBioscience 1:1500 
Vα3.2 FITC Rat IgG2b, k BD (PharMingen) 1:400 
Vβ11 PE Rat IgG2b BD (PharMingen) 1:400 
Isotype controls FITC Rat IgG2a BD (PharMingen) 1:800 
PE Rat IgG1 BD (PharMingen) 1:800 
Rat IgG2a BD (PharMingen) 1:800 
CyC Rat IgG2a BD (PharMingen) 1:800 
APC Rat IgG2a BD (PharMingen) 1:800 
APC-Cy7 Rat IgG2b BD (PharMingen) 1:800 
V500 Rat IgG2a BD (PharMingen) 1:800 
 
B-1.2 Secondary reagents for flow cytometry 
Label Manufacturer Optimal dilution 
FITC BD (PharMingen) 1:2000 
PE BD (PharMingen) 1:2000 
PE-Cy5 BD (PharMingen) 1:2000 
APC BD (PharMingen) 1:800 
APC-Cy7 BD (PharMingen) 1:400 
V450 BD (PharMingen) 1:2000 
V500 BD (PharMingen) 1:2000 
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B-1.3. ELISA Antibodies 
 
All standard curves were generated by 2-fold serial dilutions and contained 2 blank wells. 
 
IL-12p40 (BD Biosciences) 
Reagent  Concentration/Dilution Diluent 
Capture 1:1000  0.1 M Na2HPO4, pH=9.0 
Blocking solution 10% FCS 1x PBS pH=7.4 
Top standard 4 ng/ml 5% FCS in 1x PBS pH=7.4 
Detection 1:1000 5% FCS in 1x PBS pH=7.4 
Streptavidin horseradish peroxidase 1:2000 5% FCS in 1x PBS pH=7.4 
 
IL-10 (BD Biosciences) 
Reagent  Concentration/Dilution Diluent 
Capture 1:500 0.1 M Na2HPO4, pH=9.0 
Blocking solution 10% FCS 1x PBS pH=7.4 
Top standard 25 ng/ml 10% FCS in 1x PBS pH=7.4 
Detection 1:2500 10% FCS in 1x PBS pH=7.4 
Streptavidin horseradish peroxidase 1:1000 10% FCS in 1x PBS pH=7.4 
 
IFN-γ (BD Biosciences) 
Reagent  Concentration/Dilution Diluent 
Capture 1:1000 0.1 M Na2HPO4, pH=9.0 
Blocking solution 5% FCS 1x PBS pH=7.4 
Top standard 4 ng/ml 5% FCS in 1x PBS pH=7.4 
Detection 1:4000 5% FCS in 1x PBS pH=7.4 
Streptavidin horseradish peroxidase 1:2000 5% FCS in 1x PBS pH=7.4 
 
IL-2 (BD Biosciences) 
Reagent  Concentration/Dilution Diluent 
Capture 1:1000 0.1 M Na2HPO4, pH=9.0 
Blocking solution 5% FCS 1x PBS pH=7.4 
Top standard 500 pg/ml 5% FCS in 1x PBS pH=7.4 
Detection 1:1000 5% FCS in 1x PBS pH=7.4 
Streptavidin horseradish peroxidase 1:2000 5% FCS in 1x PBS pH=7.4 
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IL-17A (BD Biosciences) 
Reagent  Concentration/Dilution Diluent 
Capture 1:500 0.1 M Na2HPO4, pH=9.0 
Blocking solution 10% FCS 1x PBS pH=7.4 
Top standard 1 ng/ml 5% FCS in 1x PBS pH=7.4 
Detection 1:500 5% FCS in 1x PBS pH=7.4 
Streptavidin horseradish peroxidase 1:1000 5% FCS in 1x PBS pH=7.4 
 
IL-4 (BD Biosciences) 
Reagent  Concentration/Dilution Diluent 
Capture 1:2000 1x PBS pH=7.4 
Blocking solution 5% FCS 1x PBS pH=7.4 
Top standard 2350 pg/ml 5% FCS in 1x PBS pH=7.4 
Detection 1:4000 5% FCS in 1x PBS pH=7.4 
Streptavidin horseradish peroxidase 1:2000 5% FCS in 1x PBS pH=7.4 
 
 
B-1.4. Antibodies and proteins for MΦ/MG:T cell co-culture 
Antibodies 
Specificity Species and Isotype Clone Company 
αIL-12p40 Rat IgG1 C15.6 BD Bioscience 
αIL-10 Rat IgG1, κ JES5-2A5 BD Bioscience 
αPD-1/CD279 Rat IgG2a, κ RMP1-14 Biolegend 
αCD40L/CD154 Ar Ham IgG3, κ MR1 BD Bioscience 
Isotype Ar Ham IgG3, κ E36-239 BD Bioscience 
Rat IgG2a, κ R35-95 BD Bioscience 
 
Protein 
Protein Protein type Company 
IL-12p70 Recombinant 
cytokine 
BD Bioscience 
IL-10 Recombinant 
cytokine 
BD Bioscience 
Recombinant mouse B7-H1/PD-L1 Fc 
chimera 
Chimeric protein R&D systems 
Recombinant human IgG1 Fc Chimeric protein R&D systems 
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C. Supplementary Figures 
C-1 Supplementary figures for chapter 4 
C-1.1 Titration of the αCD40L antibody 
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Figure C1.  T cells cultured with classically activated MΦ in the presence of αCD40L 
maintained cytokine production and expression of cell surface markers.  BMMΦ were 
stimulated with IFN-γ (20 U/ml) overnight and then cultured alone or with LPS (200 ng/ml) 
with or without IC (10 per MΦ).  After four hours, purified CD4+2D2 T cells and MOG35-55 
(25 µg/ml) were added to the MΦ cultures for 72 hours.  αCD40L (MR1; 0.5-8 µg/ml) or 
hamster isotype control antibody (IgG1) was added to the cultures.  IL-10 (a) and IL-12 (b), 
was measured by ELISA, IFN-γ (c), IL-17A (d), and IL-2 (e) were measured in the culture 
supernatant by CBA, CD44 (f), CD62L (g), CD25 (h), and CD124 (i) expression was 
measured by flow cytometry.  Shown are the means and SEM of triplicate wells from one of 
two experiments (IL-10, IL-12 IFN-γ, IL-17A, and IL-2) and data from one of two 
experiments (CD44, CD62L, CD25, and CD124).  *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001 by two-way ANOVA with Sidak’s post test.   
 
 
i. 
Appendix C- Supplementary Figures   259 
 
 
 
C-1.2 Titration of the αPD-1 antibody 
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Figure C2.  Blocking the PD-1/PD-L1 pathway had only a small effect of T cells and 
MΦ.  BMMΦ were stimulated with IFN-γ (20 U/ml) overnight and then cultured alone or 
with LPS (200 ng/ml) with or without IC (10 per MΦ).  After four hours, purified CD4+2D2 T 
cells and MOG35-55 (25 µg/ml) were added to the MΦ cultures for 72 hours.  Various 
concentrations of αPD-1 (0.5-4 µg/ml) were added to cultures with the T cells.  .  IL-10 (a), 
IL-12 (b), IFN-γ (c), IL-17A (d), and IL-2 (e) was measured by ELISA, CD44 (f), CD62L (g), 
CD25 (h), and CD124 (i) expression was measured by flow cytometry.  Shown are the means 
and SEM of triplicate wells from one of two experiments (IL-10, IL-12 IFN-γ, IL-17A and 
IL-2) and data from one of two experiments (CD44, CD62L, CD25 and CD124). 
 
 
h. 
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C-1.3 Titration of the PD-L1 chimera 
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Figure C3.  Stimulating the PD-1/PD-L1 pathway may decrease the activation of T cells 
slightly, but has no effect on IL-12 production by MΦ.  BMMΦ were stimulated with 
IFN-γ (20 U/ml)overnight and then cultured alone or with LPS (200 ng/ml) with or without IC 
(10 per MΦ).  After four hours, purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were 
added to the MΦ cultures for 72 hours.  Various concentrations of PD-L1ch (0.5-8 µg/ml) 
were added to cultures with the T cells.  IL-12 (a), IFN-γ (b), IL-17A c), and IL-2 (d) was 
measured by ELISA, CD44 (e), CD62L (f), CD25 (g) and CD124 (h) expression was 
measured by flow cytometry.  Shown are the means and SEM of triplicate wells from one of 
two experiments (IL-12, IFN-γ IL-17A, and IL-2) and data from one of two experiments 
(CD44, CD62L, CD25 and CD124). 
b. a. 
c. d. 
e. f. 
g. h. 
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C-1.4 Supplementary figures for IL-10, IL-12, PD-1/PDL-1 and CD154 pathways 
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Figure C4.  Altering IL-10 levels in BMMΦ:T cell co-cultures did not significantly affect 
expression of markers of activation on T cells.  BMMΦ were stimulated with IFN-γ (20 
U/ml) overnight and then cultured with LPS (200 ng/ml) with or without IC (10 per MΦ).  
After four hours, purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were added to the MΦ 
cultures for 72 hours.  rIL-10 (5 ng/ml), αIL-10 (JES5-2A5, 2 µg/ml) or rat isotype (IgG1, 
2 µg/ml) was added to cultures either with the stimuli (0 hour) or with the T cells (4 hour).  
CD44 (a) CA62L (b), and CD25 (c) expression was measured by flow cytometry, IL-2 (d) 
was measured in the culture supernatant by ELISA.  Shown are the means and SEM of 
triplicate wells from three or more experiments. 
 
b. 
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c. 
d. 
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Figure C5.  Altering IL-12 levels in BMMΦ:T cell co-cultures did not significantly affect 
expression of markers of activation on T cells.  BMMΦ were stimulated with IFN-γ (20 
U/ml) overnight and then cultured with LPS (200 ng/ml) with or without IC (10 per MΦ).  
After four hours, purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were added to the MΦ 
cultures for 72 hours.  rIL-12p70 (5 ng/ml), αIL-12 (C15.6, 2 µg/ml) or rat isotype (IgG1, 2 
µg/ml) was added to cultures either with the stimuli (0 hour) or with the T cells (4 hour).  
CD44 (a) CA62L (b), and CD25 (c) expression was measured by flow cytometry, IL-2 (d) 
was measured in the culture supernatant by ELISA.  Shown are the means and SEM of 
triplicate wells from three or more experiments.   
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Figure C6.  Blocking or stimulating the PD-1/PD-L1 pathway did not affect expression 
of cell surface activation markers on T cells.  BMMΦ were stimulated with IFN-γ (20 
U/ml) overnight and then cultured with LPS (200 ng/ml) with or without IC (10 per MΦ).  
After four hours, purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were added to the MΦ 
cultures for 72 hours.  αPD-1 (2 µg/ml, RMP1-14), rat isotype (2 µg/ml, IgG2a), PD-L1ch (8 
µg/ml) or control protein (8 µg/ml) was added.  CD44 (a), CD62L (b) and CD25 (c) 
expression was measured by flow cytometry.  Shown are the means and SEM of triplicate 
wells from one-five combined experiments.   
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Figure C7.  Blocking the CD40/CD40L pathway did not significantly affect expression of 
cell surface activation markers on T cells.  BMMΦ were stimulated with IFN-γ (20 U/ml) 
overnight and then cultured with LPS (200 ng/ml) with or without IC (10 per MΦ).  After 
four hours, purified CD4+2D2 T cells and MOG35-55 (25 µg/ml) were added to the MΦ 
cultures for 72 hours.  4 µg/ml of αCD40L or hamster isotype control antibody (IgG1) was 
added.  CD44 (a), CD62L and CD25 (c) expression was measured by flow cytometry.  Shown 
is data from one of two experiments.   
b. a. 
c. 
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C-2. Supplementary figures for chapter 6 
 
 
Figure C8.  MG cultured with LPS+IC produce less inflammatory cytokines and 
chemokines compared to LPS alone when M-CSF is removed 3 days before IFN-γ 
stimulation.  MG were isolated from the CNS of adult mice (n=5) and plated at 5x104 
cells/well in a flat bottomed 96 well plate in the presence of M-CSF (5 ng/ml).  After 4 weeks 
in culture M-CSF was removed 3 days before MG were primed with 20 U/ml IFN-γ overnight 
followed by stimulation with LPS (200 ng/ml) with or without IC (106/well) for 24 hours.  
IL-12 (a) levels were measured by ELISA and IL-6 (b), MCP-1 (c) and TNF-α (d) levels were 
measured by CBA.  Shown are the means and SEM of at least duplicate wells from four 
combined experiments.  Raw data was subjected to the ROUT test which removed outliers, 
before statistics were calculated. **p<0.01, ***p<0.001, ****p<0.0001 by one way ANOVA 
with a Tukey’s multiple comparison post test. 
 
 
c. d. 
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C-3 Supplementary figures for chapter 7 
 
C-3.1 Disease course of BALB/c mice treated with IC or GA 
 
 
Figure C9.  Neither GA or IC treatment is strongly protective in a BALB/c model of 
EAE.  8-16 week old BALB/c mice were pre-treated with 2x106 IC by i.p. injection, this 
treatment was repeated every 7 days during the course of the disease.  Mice were immunised 
for EAE seven days after the first IC treatment as described in methods (a).  GA treatment 
was 500 µg/ml in the EAE emulation, and was thus given once at the time of immunisation 
(b).  Disease scores presented in each graph are representative of five (a) or two (b) combined 
experiments. 
 
 
a. b. 
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C-3.2 C57C57 control treatments for experiments shown in Figure 7.1 
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Figure C10.  Treatment of mice with IC reduces the severity and incidence of EAE in 
C57C57 control chimers to a similar extent as B6C57, graphs are controls for 
Figure 6.1.  Seven weeks following irradiation and reconstitution of C57 animals, mice 
were pre-treated with 2x106 IC by i.p. injection one week before immunisation and weekly 
thereafter.  Mice were immunised to induce EAE as described in the methods.  Disease scores 
(a, c, e) and disease burden (b, d, f) for 3 of 5 experiments are shown, number of 
mice/treatment group= 2 (untreated) and 3 (IC treated) (a and b); 4 (c and d) or 5 (e and f). 
***p<0.001 by two way ANOVA with Sidak’s post test.   
 
c. d. 
a. b. 
e. f. 
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C-3.3 Agarose gel of RAW-264.7 qPCR products 
 
 
Lane Sample type (top section) Sample type (bottom section) 
1 1 Kb plus ladder 1 Kb plus ladder 
2 IL-12, unstimulated RAW cells IL-10, no template 
3 IL-12, unstimulated RAW cells IL-10, no template 
4 IL-12, LPS stimulated RAW cells IL-10, no reverse transcription 
5 IL-12, LPS stimulated RAW cells IL-10, no reverse transcription 
6 IL-12, no template Cyclophilian A, unstimulated RAW cells 
7 IL-12, no template Cyclophilian A, unstimulated RAW cells 
8 IL-12, no reverse transcription Cyclophilian A, LPS stimulated RAW cells 
9 IL-12, no reverse transcription Cyclophilian A, LPS stimulated RAW cells 
10 IL-10, unstimulated RAW cells Cyclophilian A, no template 
11 IL-10, unstimulated RAW cells Cyclophilian A, no template 
12 IL-10, LPS stimulated RAW cells Cyclophilian A, no reverse transcription 
13 IL-10, LPS stimulated RAW cells Cyclophilian A, no reverse transcription 
14 1 Kb plus ladder 1 Kb plus ladder 
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Figure C11. Primers specific for IL-12 and Cyclophilin A amplify products of the 
expected size.RAW-264.7 cells were cultured alone or stimulated with 200 ng/ml LPS for 24 
hours and total RNA was isolated.  cDNA was generated and IL-12p40, IL-10and Cyclophilin 
A cDNA were amplified with gene specific primers using SYBR green to detect 
amplification.  The size of the PCR products was assessed by gel electrophoresis using a 2% 
agarose gel and were found to be of the correct size (IL-12p40, 255 base pairs and 
Cyclophilin A, 98 base pairs).  Data shown is from one experiment. 
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Type II activation using GA 
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Figure C12.  GA induces a type II like phenotype in BMMΦ (a and b), which have a 
different effect on T cell biasing (c and d).  BMMΦ were stimulated with 20 U/ml IFN-γ 
overnight and then cultured with LPS (200 ng/ml) alone or with IC (10 per MΦ) or GA (100 
µg/ml).  (a and b) Supernatants were harvested after 24 hours, IL-10 (a) and IL-12p40 (b) 
levels were measured by ELISA.  (c and d) Four hours following stimulation, purified 
CD4+2D2 T cells and MOG (25 µg/ml) were added to the cultures and cultured for 72 hours.  
IFN-γ (c) and IL-17A (d) were measured by CBA.  Shown are the means and SEM of 
triplicate wells from one experiment. 
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D1 Gating strategy for flow cytometric analysis of brains 
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Figure D1.  Gating strategy for flow cytometry on brains from C57C57 mice.  Seven weeks following irradiation and reconstitution of 
C57C57 mice were pre-treated with 2x106 IC by i.p. injection, this treatment was repeated every 7 days during the course of the disease.  Mice 
were immunised for EAE 7 days after the first IC treatment as described in methods.  At peak disease mice were euthanised, and brains were 
analysed by flow cytometry.  CD45+CD11b+ were selected as shown.  R1, CD45+ cells; R2, single cells; R3, cells (without debris); R4, CD11b+ 
cells; R5, CD45hiCD11b+; R6, CD45intCD11b+; R7, CD45loCD11b+; R8, CD45hiCD11b+Gr1-; R8, CD45hiCD11b+Gr1+.  Shown are 
representative plots from one immunised mouse 
